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1. Introduction 
1.1. Epigenetics history 
 
The ancient world was already highly interested in development and 
inheritance mechanisms. Philosophers as Anaxagoras or Hippocrates hold 
the preformation theory and preached the homunculus (Latin for little human) 
as origin of all life. One hundred years later, Aristoteles challenged this maxim 
with his thesis of epigenesis (Greek for subsequent development). He thought 
that embryonic development was characterized by permanent formation of 
new structures. This idea was revived by Wiliam Harvey in 1651 and proved 
by Caspar Friederich in 1796 (Wolff 1759). Both showed that the human being 
is developed from one fertilized egg cell. This discovery motivated 
embryologists as well as developmental biologists to decrypt developmental 
embryonic processes with microsurgical and chemical methods. Remarkably, 
genetics was ignored until rediscovery of Mendel’s laws in the 20th century. 
However, at that time, genetic knowledge was insufficient to explain the link 
between genotype and phenotype since the main focus was on genes 
behavior (Hortshemke 2005). 
The British scientist Conrad Hal Waddington brought about a rebound by 
accentuating the importance of genetics in all domains of biological research 
and thus juggling genetics and developmental biology (Waddington 1942). He 
described inheritance and development as a discussion between the genetic 
information and environment. According to him, the one-dimensional 
interpretation of genes was insufficient to explain development. Thus, it must 
exist something ‘epi’, over or upon genes (genea, greek for descent, race). 
From his point of view, the zygote possesses preformed characteristics that 
interact during early development to form through epigenesis an adult life form 
(Haig 2004). Therefore, Waddington joined the terms epigenesis and genetic 
to coin epigenetic. Hence, he defined for the first time the department of 
science that analyses the causal interaction between genes (genotype) and 
their products (phenotype) (Waddington 1942; Moch 2004). Attention should 
be paid to the fact that Waddington established this revolutionary idea without 
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the knowledge that genes encode proteins. Not until three years later, the 
paradigm of one gene-one enzyme was published (Beadle and Tatum 1941). 
To illustrate his concept of epigenetics, Waddington published in 1957 
the famous epigenetic map, showing a ball rolling down a plain. This ball 
represents an embryonic cell, curling irrevocably down the slope of 
development. The different channels, present on the surface, mark different 
developmental fates (Figure 1) (Burbano 2006). 
 
 
Figure 1: Conrad Hal Waddington’s classical epigenetic landscape. 
The ball is a metaphor for an embryonic cell in the process of differentiation. The 
inclined plan represents the different possible developmental possibilities, whereas 
canalizations stand for irrepealably developmental decisions, which were taken by 
the cell (Goldberg, Allis et al. 2007). 
 
The term of DNA methylation was first mentioned in 1969 in a 
publication about long-term memory (Griffith and Mahler 1969). The 
association between DNA methylation, gene regulation and X-chromosome 
inactivation was established in 1975 (Holliday and Pugh 1975; Riggs 1975; 
Sager and Kitchin 1975). However, the word “epigenetic” did not appear in 
any of these publications (Haig 2004).  
At the beginning of the nineties, epigenetic was defined as the study of 
modifications in gene expression occurring in differentiated cells, as well as 
the mitotic inheritance of this expression pattern. Then, it was referred to 
nucleus-mediated and DNA sequence-independent inheritance. Both 
definitions were not complete but complement each other (Holliday 2006). 
Afterwards, the scientist Hall combined both definitions and defined epigenetic 
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as the sum of genetic and not genetic factors that control gene expression 
and therefore, the phenotypic complexity during development (Hall 1992). 
Medawar and Medawar formulated epigenetic in 1988 as “Genetics proposes, 
epigenetics disposes”. Nowadays, molecular biologists define epigenetic as 
the study of mitotically and/or meiotically heritable changes that occur without 
DNA sequence changes (Berger, Kouzarides et al. 2009). In contrast, 
functional morphologists define epigenetic as a general series of interactions 
among cells and their products, resulting in differentiation and morphogenesis 
(Haig 2004). 
 
1.2. Epigenetics  
 
Epigenetic events are crucial in the control of both normal and defective 
(e.g. cancer-associated) cellular processes (Vaissiere, Sawan et al. 2008). 
The flexible and heritable epigenetic events include, at protein level, a 
bewildering array of post-translational modifications (PTMs) of histone 
proteins, at DNA level, a process in which enzymes add methyl groups onto 
cytosines (DNA methylation) or, at RNA level, an RNA-mediated gene 
silencing in form of RNA interference. To cope with their tasks such as gene 
regulation or transposon silencing, epigenetic mechanisms are interconnected 
and act in self-reinforcement.  
 
1.2.1. Histone modifications 
 
In the nucleus, eukaryotic genome is packed as chromatin, present 
under various levels of condensation from the lightly condensed and actively 
transcribed euchromatin to the compact and silenced heterochromatin. The 
nucleosome core particle forms the ‘heart’ of the chromatin structure. This 
nucleoprotein complex is composed of a histone octamer, consisting of two 
copies of each highly conserved core histone proteins H2A, H2B, H3, and H4 
around which 146bp DNA are wrapped to form a superhelix (Figure 2) 
(Kornberg and Lorch 1999). Together these proteins form a globular domain 
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whereby their unstructured amino termini protrude flexibly on the surface of 
the chromatin polymer. Initially thought as a static and non-participating 
structural chromatin element, it became clear that histones are a dynamic and 
indispensable component of the gene regulation machinery.  
The N-terminal histone tails comprise 25-30% of the mass of individual 
histones and are the sites of numerous PTMs (Figure 2) (Allfrey and Mirsky 
1964; Wolffe and Hayes 1999).  
 
 
Figure 2: Schematic representation of post-translational modifications within 
N-terminal tail domains of the core histone octamer. 
Colored dots over modified amino acids (K: lysine, R: arginine, S: serine) indicate the 
nature of post-translational modifications (i.e. acetylation, methylation, 
phosphorylation or ubiquitylation). Numbers refer to the positions on histone proteins 
(Strahl, Grant et al. 2002).  
 
The panel of histone PTMs including acetylation, methylation, 
phosphorylation, ubiquitylation, deamination, proline isomerization, 
sumoylation or ADP-ribosylation codes for epigenetically relevant information 
at defined genetic loci (Figure 2) (Neff and Armstrong 2009). Indeed, one type 
of PTM can be applied on several amino acids in different histone tail 
positions and interacts with other PTMs. Moreover, in the case of methylation, 
lysine and arginine residues can be mono, di- or tri-methylated, adding 
another layer of complexity to the histone code. Hence, spatial distribution of 
  Introduction 
 5 
histone modifications allows to affect synergistically chromatin-interacting 
enzymes (Kurdistani, Tavazoie et al. 2004).  
Functional consequences of histone modifications may be first the 
establishment of a specific global chromatin environment and second the 
orchestration of DNA-based biological tasks (Kouzarides 2007). Considering 
only electrostatic requirements for the chromatin polymer folding, histone 
acetylation and phosphorylation could synergistically unravel the negatively 
charged chromatin fiber by neutralizing positive and adding negative charges, 
respectively (Kouzarides 2007). However, effects of the myriad of histone 
PTMs are more complex, affecting the interaction of histones, DNA and the 
adjacent nucleosomes as well as the inter-nucleosomal contacts. Accordingly, 
gene promoter accessibility is changed and gene expression activated or 
silenced (Leone, D'Alo et al. 2008). The remarkable diversity and biological 
specificity of histone modifications coupled with distinct patterns of covalent 
histone marks let assume that a histone ‘language’ which may be encoded on 
these tail domains is far more complex than the genetic code. 
For example, acetylation (ac) of specific lysines (K) in the N-terminal tail 
of the core histones H3 and H4 (e.g. H3K9ac, H3K4ac or H4K12ac) is a well-
known histone modification, which plays a fundamental role in transcriptional 
activation (Figure 2) (Lennartsson and Ekwall 2009). In addition to their role in 
regulation of gene expression, histone PTMs partition genome into different 
distinct domains, associated with very local functions such as gene 
transcription and DNA repair, or to more genome-wide functions including 
DNA replication or chromosome condensation. For instance, during 
replication, histones are rapidly synthesized and assembled into newly 
synthesized DNA. In this process, pre-acetylated H3 and H4 are brought to 
replicating chromatin and become erased after complete replication and 
chromatin maturation (Turner and O'Neill 1995). Furthermore, phosphorylation 
of histone H3 on serine 10 (H3S10P) and the presence of the linker histone 
H1 have long been implicated in chromosome condensation during mitosis 
(Bradbury 1992; Koshland and Strunnikov 1996). Moreover, H3S10P 
correlates with the induction of early immediate response genes such as c-
jun, c-fos and c-myc (Zippo, Serafini et al. 2009). Regarding lysine 
methylation, consequences depend on the position within histone tails. For 
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example, di- and tri-methylation of H3K4 and H3K26 are associated with open 
transcriptional active chromatin. In contrast, trimethylation of H3K9, H3K27 or 
H4K20 appears to be largely localized on promoters of repressed genes (Pan, 
Tian et al. 2007). In any case, these generalizations must be treated with 
care, since some modifications can exert different transcriptional outcomes 
depending on the surrounding microenvironment, the specific time point and 
the combination with other PTMs (Bernstein, Mikkelsen et al. 2006; Guenther, 
Levine et al. 2007). 
Non-histone protein complexes with unique biological properties are in 
charge of reading histone modification patterns to mediate the recruitment of 
further docking proteins or complexes (e.g. NuRD, SIN3) leading to 
transcriptional activation or repression. For example, the repressive chromatin 
mark H3K9me3 is bound by the non-histone heterochromatin protein (HP) 1, 
forming a recruitment platform for histone methyltransferases (e.g. Suv familly 
proteins), which is involved in chromatin condensation (Campos and Reinberg 
2009). In addition, non-histone multiprotein complexes are composed of 
proteins involved in chromatin remodeling and formation of repressed 
chromatin structure such as histone deacetylases (HDACs), histone-binding 
proteins (e.g. RbAp48) as well as methylation-binding (MBDs) proteins and 
DNA methyltransferases (DNMTs) (Ahringer 2000). The dynamic modulation 
of chromatin structure is mainly realized by remodeling enzymes, i.e. histone 
methyltransferases (HMTs), histone acetyltransferases (HATs) and HDACs. 
HMTs and HATs generate particular arrays of methylation and acetylation 
marks on histones, respectively (Vaissiere, Sawan et al. 2008). Histone 
deacetylation is catalyzed by HDACs, which are classified in 4 classes 
depending on their sequence similarity, cellular localization, substrate 
specificity and zinc or NAD+ dependency (Minucci and Pelicci 2006; Ouaissi 
and Ouaissi 2006). Acetylation of histones is catalyzed by HATs, which are 
classified in three major families: general control non-derepressible 5 (Gcn5)-
related N-acetyltransferase, p300/ CREB binding protein (CBP) and MYST 
proteins (Yang and Seto 2007). Furthermore, HATs and HDACs affect 
indirectly gene expression by modifying a growing list of non-histone 
substrates (Minucci and Pelicci 2006). Indeed, acetylation of specific lysine 
residues on transcription factors (e.g. p53 or STAT) affects their cellular 
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localization, stability, DNA binding activity and protein-protein interactions 
(Bruserud, Stapnes et al. 2006).  
HMTs can be classified by their target specificity (Suv39h1 (H3K9), 
SET8 (H4K20), MLL1 (H3K4)) into three main groups that catalyze the 
transfer of a methylgroup from the methyl donor S-adenosylmethionine (SAM) 
to the !-nitrogen in lysine or the guanidinium nitrogen in arginine. HMTs form 
large, multiprotein complexes that typically contain other histone modifier 
enzymes (HATs, HDACs), DNMTs, chromatin-binding subunits (chromo-like 
domains) or transcription factors recruiting epigenetic machinery to specific 
target promoters (Esteller 2006).  
Similarly to protein kinases and phosphatases, short preferred 
consensus motifs are likely to exist, leading individual HATs and HDACs to 
their targets and thus helping to establish the final histone code (Kimura and 
Horikoshi 1998). Moreover, these histone modifying enzymes are tethered to 
their targets by cell-specific transcription factors, MBDs, chromatin-binding 
subunits or can even bind directly to DNA (e.g. activating transcription factor 
2) and work in large multiprotein complexes (Cress and Seto 2000; Kawasaki, 
Schiltz et al. 2000). 
 
1.2.2. DNA modifications 
 
Enzymatic methylation of the cytosine base is an essential component of 
mammalian genome that neither influences the Watson-Crick base pairing nor 
the DNA polymerase processing during replication. Hence, DNA methylation 
has no impact on DNA sequence and the pattern is stably propagated during 
mitosis from the parent to daughter cells (Jeltsch 2002). 
In eukaryotic cells, DNA methylation usually occurs within the context of 
the palindromic CpG dinucleotide at the fifth carbon atom of the cytosine ring, 
resulting in gene silencing (Gardiner-Garden and Frommer 1987; Hopkins, 
Burns et al. 2007). Over evolutionary time scale, spontaneous hydrolytic 
deamination of methylated cytosines has been responsible for cytosine to 
thymine transitional mutation. This genetic alteration leads to the under-
representation of CpG dinucleotides with only about one quarter of the 
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expected general frequency in the human genome (Schulz and Goering 
2011). Remaining CpGs are unequally distributed across the genome with 
long CpG-free or -poor DNA stretches separated by short CpG-rich regions. 
CpG islands (CGis) are clusters that contain high frequency of CpG 
dinucleotides and overlap with 76% of putative human promoter regions. 
Marino-Ramirez et al. defined typical CGis as a 500-bp long sequence with a 
GC percentage of over 50% and a ratio of CpG observed/expected that is 
greater than or equal to 0.6 (Marino-Ramirez, Spouge et al. 2004). Although 
many of the approximately 30000 CGis are located in the 5’-untranslated 
region, spanning the transcription start site (TSS) and the first exon of genes, 
certain CGis may occasionally be found within the coding sequence or the 3’ 
region of a gene (Ball, Li et al. 2009). CGis in these “atypical” coding 
sequence locations are more prone to methylation; however, the RNA 
transcription machinery can pass over without any interference (Jones 1999; 
Nguyen, Liang et al. 2001). Furthermore, some publications revealed the 
presence of extensive DNA methylation at CGi ‘shores’, which are regions of 
relatively low CpG density located close to CGis (Meissner, Mikkelsen et al. 
2008; Doi, Park et al. 2009). Recently, the existence of 5-
hydroxymethylcytosine (5-hmc) was described in embryonic stem cells and 
Purkinje neurons. 5-methylcytosine can be converted into 5-hmc by the 
oxoglutarate- and Fe (II)-dependent oxygenases TET1, TET2 and TET3. 
These enzymes are probably involved in the active demethylation associated 
with embryonic epigenetic reprogramming (Wossidlo, Nakamura et al. 2011). 
Nevertheless, the role of this cytosine modification in mature cells as well as 
its possible role in carcinogenesis has still to be elucidated (Rodriguez-
Paredes and Esteller 2011). 
Under physiological conditions, most CGis are never methylated in 
eukaryotic cells (Schulz and Goering 2011). However, some CGis become 
hypermethylated during aging, inflammation or preneoplasia, albeit not as 
dramatically as in cancer cells (Teschendorff, Menon et al. 2010). The main 
role of DNA methylation is to specialize groups of cells to perform specific 
functions during embryonic development and cell differentiation of 
multicellular systems. Furthermore, DNA methylation protects genomic 
stability through permanent suppression of transcription and homologous 
  Introduction 
 9 
recombination of ‘selfish’ repetitive sequences originated from ancient 
parasitical (e.g. human endogenous retrovirus HERV) or simple parasitical 
retroelements (e.g. short or long interspersed elements, SINEs or LINEs, 
respectively) (Smit and Riggs 1996; Bird 2002; Jones and Baylin 2007; 
Vaissiere, Sawan et al. 2008). In addition to repetitive elements, selective 
single copy genes, which are involved in cellular pluripotency, can be 
methylated in normal cells (Reik 2007). Indeed, DNA methylation is implicated 
in genomic imprinting, leading to a mono-allelic gene expression (e.g. H19 
expression from the maternal chromosome) (Reik and Walter 2001). 
Moreover, DNA methylation is involved in gonosomal X-chromosome 
inactivation (Panning and Jaenisch 1996). Finally, DNA methylation can 
induce gene expression. Indeed, methylation of the IGF2 Silencer element 
region inhibits the binding of the repressor protein and thus activates IGF2 
expression (Eden, Constancia et al. 2001; Murrell, Heeson et al. 2001). 
Noteworthy, opinions differ about the mechanisms associated with DNA 
methylation-mediated gene silencing (Figure 3). 
 
 
Figure 3: Possible mechanisms of DNA methylation-mediated gene silencing.  
Several mechanisms can block transcription factor binding to the gene promoter 
region leading to gene silencing. (A) Direct inhibition by blocking the access of a 
transcription factor (TF) to its binding site. (B) Chromatin condensation by DNA 
methylation and histone deacetylation prevent the access for TFs. (C) Indirect 
silencing through the binding of methyl-binding proteins (e.g. MeCP2) and the 
formation of a repressor complex (e.g. HDACs, DNMTs), which prevents the binding 
of TFs (Vaissiere, Sawan et al. 2008). 
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DNA methylation can directly block binding of transcription factors to 
promoters, interfering with RNA polymerase II elongation or loading on DNA 
template to prevent transcription (Figure 3-A). Alternatively, the combination 
of DNA methylation and histone deacetylation leads to chromatin 
condensation. The resulting heterochromatin constricts the access to 
transcription factor binding sites inhibiting gene expression (Figure 3-B). 
Indirect repression may also involve proteins such as MBDs (e.g. MeCP2, 
MBD2) specifically bind to methylated DNA via their methyl CpG-binding 
domains. Subsequently, MBDs recruit HDAC activity to the methylated DNA 
region. This mechanism includes histone deacetylation and results in a 
condensed and repressive chromatin structure (Figure 3-C) (Vaissiere, Sawan 
et al. 2008). 
Nevertheless, DNA methylation is not a static modification since it has to 
be modified during developmental and differentiation processes in order to 
adjust gene access rights (Haaf 2006). Indeed, remodeling of epigenetic 
marks happens first in primordial germ cells followed by a second wave during 
embryogenesis (Reik and Walter 2001). The final methylation signature 
should be maintained during lifetime; however, this pattern gets apparently 
altered in the course of life (Jones and Baylin 2007). 
A family of DNMTs catalyzes the reaction of cytosine methylation (Chen, 
MacMillan et al. 1991) (Figure 4). 
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Figure 4: Schematic representation of the DNA methyltransferase-catalyzed 
endocyclic cytosine methylation. 
DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group from the 
methyl donor S-adenosylmethionine (SAM) on the fifth carbon atom of the cytosine 
pyrimidine ring. SAH: S-adenosylhomocysteine. 
 
DNMT enzymes recognize specific sites on the DNA sequence and 
transfer a methyl group from the methyl group donor SAM to the cytosine 
within CpG dinucleotides. In a first step, base flipping fold out cytosine from 
the DNA helix. The subsequent nucleophilic attack of a cysteine HS-group 
from the DNMT’s catalytic region on the carbon in position 6 of the cytosine 
leads to a covalent binding between the DNMT and target cytosine. This 
conformation activates the C5-position of the cytosine ring, which interacts 
with the methyl group of SAM. The complex is disrupted after the binding of 
the methyl group to the cytosine (Figure 4) (Wu and Santi 1987; Jeltsch 
2002). 
The de novo DNA methyltransferases DNMT3A and 3B are responsible 
for the establishment of the primary methylation pattern during 
embryogenesis, for the methylation of newly integrated retroviral elements 
and to respond to gene expression changes (Oswald, Engemann et al. 2000; 
Fatemi, Hermann et al. 2002). Enzymes of the DNMT3 class have no 
preference for un- or hemi-methylated CpG sites (Okano, Xie et al. 1998; 
Siedlecki and Zielenkiewicz 2006). However, knock out (KO) experiments 
showed that, in mammalian cells, DNMT3A and 3B were not redundant in 
their function but possess respective region specificities. DNMT3B 
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preferentially methylate repetitive elements (e.g. centromeric satellites or 
retroviral elements) (Okano, Bell et al. 1999). In contrast, DNMT3A plays an 
important role in methylation of differentially methylated regions (DMR), which 
are regulatory elements involved in the control of gene expression (e.g. DMR1 
regulates H19 expression). Moreover, immunodeficiency syndrome, 
centromeric instability and facial abnormalities are linked to mutations in 
human DNMT3A gene (Hansen, Wijmenga et al. 1999; Okano, Bell et al. 
1999). The third DNMT3 homolog DNMT3-L (DNMT3-like) has no 
methyltransferase activity but acts as a regulator for DNMT3A and 3B during 
de novo DNA methylation in germ cells (Bourc'his, Xu et al. 2001; Suetake, 
Shinozaki et al. 2004). 
In contrast, DNMT1 methylates preferentially hemi-methylated CpGs 5- 
to 30-fold better than unmethylated sites. DNMT1 is associated with 
replication foci and is responsible for the post-replicative maintenance of 
genomic methylation patterns between cell generations. Thus, this enzyme is 
called the ‘maintenance methyltransferase’, which propagates the methylation 
pattern with an extreme fidelity from the mother cell to daughter cells 
(Siedlecki and Zielenkiewicz 2006; Vaissiere, Sawan et al. 2008). Lethality of 
DNMT1 KO mice underlines the importance of this enzyme during early 
embryogenesis (Li, Bestor et al. 1992; Jaenisch and Bird 2003). 
 
1.2.3. RNA-mediated gene regulation 
 
Britten and Davidson already postulated in 1969 that RNA is involved in 
gene regulation. However, the first ribo-regulator gene in animals was only 
described 24 years later in studies about the regulative potential of the small 
RNA lin-4 on the target mRNA lin-14 during the postembryonic development 
of C.elegans (Lee, Feinbaum et al. 1993; Wightman, Ha et al. 1993). Several 
years later, Reinhart et al. characterized another regulatory non-coding RNA 
let-7 (Reinhart, Slack et al. 2000). Apart from tRNA and rRNA, most widely 
known non-protein-coding RNAs are the 19- to 24- nucleotides short 
microRNAs (miRNAs), which regulate mRNA function between the post-
transcriptional and translational level (He and Hannon 2004; Bhagavathi and 
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Czader 2010). The highly conserved miRNAs are involved in many fine-tuned 
biological processes, such as development, tissue differentiation, cell 
metabolism, cell cycle, apoptosis, senescence, autophagy and metastasis 
(Sassen, Miska et al. 2008; Ruan, Fang et al. 2009). 
Genes encoding for miRNAs are located either in intergenic regions or in 
defined transcription units. Around 50% of the miRNA genes are found in 
introns or exons of both protein-coding and long non-coding transcripts and 
are consequently co-transcribed with the gene in which they reside 
(Rodriguez, Griffiths-Jones et al. 2004; Weber 2005; Kim and Nam 2006).  
MiRNA genes are usually transcribed by RNA polymerase (Pol) II into 
polycistronic primary transcripts (pri-miRNAs) with a length of about 1kb up to 
several kbs, except miRNAs located in Alu repeats that are transcribed by 
RNA pol lII (Figure 5) (Lee, Jeon et al. 2002; Lee, Kim et al. 2004; Borchert, 
Lanier et al. 2006). Pri-miRNAs are further characterized by a 5’ methyl cap 
structure, a 3’-end poly A-tail and at least one-hairpin structure of 
approximately 70 nucleotides. During the canonical miRNA pathway, a 
complex consisting of the double strand-specific endoribonuclease III Drosha, 
the binding protein Pasha and the DiGeorge syndrome critical region 8 protein 
(DGCR8), processes pri-miRNA into 70- to 100-nucleotide size range pre-
miRNAs (Figure 5). Besides a stem-loop structure, pre-miRNAs bear a 3'-
dinucleotide overhang (Kwak, Iwasaki et al. 2010). An alternative way of pri-
miRNA processing consists in the mirtron pathway, whereby the nuclear 
splicing machinery takes over the tasks of Drosha and provides the pre-
miRNA from introns, described as mirtrons (Figure 5) (Winter, Jung et al. 
2009). 
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Figure 5: MicroRNA biogenesis. 
MicroRNA (miRNA) biogenesis begins with the synthesis of a pri-miRNA. The 
following maturation of miRNA either happens by the canonical miRNA pathway or 
by the alternative mirtron pathway. In the first case, Drosha processes pri-miRNA in 
complex with DGCR8 into a pre-miRNA. As an alternative, pri-miRNA processing is 
undertaken by spliceosome. Nuclear export protein Exportin-5 together with Ran-
GTPase carries pre-miRNA through nuclear pores. In cytoplasm, pre-miRNA is 
cleaved by the DICER/TRBP complex, resulting in the mature miRNA/miRNA* (* 
passenger strand) duplex. In the assembly process, miRNA is loaded into the RNA-
induced silencing complex (RISC) complex where it is responsible for the sequence-
specific targeting. DGCR8: DiGeorge critical region 8, TRBP: trans-activation-
responsive RNA-binding protein, PACT: protein kinase R activating protein, RISC: 
RNA-induced silencing complex, Ago: Argonaute (Kwak, Iwasaki et al. 2010).  
 
Exportin 5 / Ran-GTPase heterocomplex transports pre-miRNA from 
nucleus to cytoplasm where it undergoes further maturation (Figure 5). 
Indeed, the pre-miRNA is subsequently processed by Dicer III into a 19- to 
24-nucleotide length double stranded miRNA/miRNA* (* passenger strand) 
duplex with 3’ dinucleotide overhangs. Thus, Dicer is associated with the 
trans-activator RNA binding protein (TRBP) or the dsRNA-dependent 
serine/threonine protein kinase R (PKR) activating protein (PACT) (Kwak, 
Iwasaki et al. 2010) (Figure 5). 
MiRNAs are on their own unable to induce silencing of targeted genes. 
Therefore, the mature miRNA require assembly into the multi-protein effector 
RNA-induced silencing complex (RISC). The essential core components of 
RISC are members of the Argonaute 1 to 4 (Ago 1-4) subfamily proteins. 
Noteworthy, the slicer protein Ago 2 is the only family member with an 
endonuclease activity (Liu, Carmell et al. 2004). 
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RISC assembly is initialized by the ATP-dependent incorporation of the 
miRNA/miRNA* duplex into the Ago complex (RISC loading) (Kawamata, 
Seitz et al. 2009; Yoda, Kawamata et al. 2010). Subsequently, the miRNA 
duplex get unwound and the miRNA passenger strand is discarded from the 
RISC complex either by a slicer Ago 2-dependent mechanism or a slicer-
independent unwinding (Kwak, Iwasaki et al. 2010). The remaining mature 
miRNA strand determines the RISC complex specificity, interacting with the 3’ 
untranslated region (UTR) of the target mRNA (Bhagavathi and Czader 2010). 
Noteworthy, RISC target recognition is primarily determined by base pairing of 
nucleotides in the ‘seed’ region and is enhanced by additional interactions in 
the middle of the 3’ region (Parasramka, Ho et al. 2011). 
How miRNAs induce translational repression is still an ongoing debate. It 
is known that perfect complementarity between miRNA and 3’UTR as well as 
the presence of Ago 2 in the RISC complex are prerequisites for targeted 
mRNA cleavage (Figure 5). Prevention of mRNA circularization by the RISC 
complex and thus translational inhibition or induction of mRNA degradation 
could possibly explain post-transcriptional gene silencing. Furthermore, RISC-
mediated inhibition may occur at the stage of translational initiation or by 
blocking the late initiation step. It is postulated that RISC complex could also 
act on post-initiation steps by reducing the elongation rate of ribosomal 
machinery or inducing the proteolysis of the newly synthesized peptide. 
Finally, RISC complexes associated with their target mRNAs are found in 
processing or parking bodies (p-bodies) where mRNA undergoes degradation 
or becomes recycled after leaving the p-bodies (Kwak, Iwasaki et al. 2010). 
In conclusion, interference of miRNAs with protein synthesis allows high 
flexibility in translational activity, fast response to changes, prevention of high 
levels of potentially harmful proteins (i.e. proteins involved in apoptosis), 
avoiding imbalances in gene expression. Thus, short non-coding RNAs 
provide “canalization” for the development of particular cell types via a strictly 
determined pathway (Cohen, Brennecke et al. 2006; Hornstein and Shomron 
2006). 
 
  Introduction 
 16 
1.2.4. Cross talk of epigenetic modifications 
 
The initiating event in epigenetic gene silencing remains unclear. DNA 
methylation may be the primary mark for gene silencing, triggering events that 
lead to non-permissive chromatin state. Another scenario proposes that the 
loss of histone acetylation may serve as the initial event for gene silencing, 
followed by DNMT targeting, leading to local hypermethylation (Tamaru and 
Selker 2001; Vaissiere, Sawan et al. 2008). Independently of this discussion, 
it is particularly important to stress that epigenetic modifications do not act 
independently, but are intimately interwoven and work together to establish, 
maintain, and modify global and local chromatin structures of a cell for life 
(Figure 6). 
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Figure 6: Schematic view of transcriptionally active and epigenetically silenced 
chromatin regions. 
Epigenetic modifications and protein complexes modulate the formation of an active 
(A) and repressive (B) gene promoter state. Me: methylation. White circles: 
unmethylated CpG dinucleotides, black circles: methylated CpG dinucleotides, Ac: 
acetylation, TF: transcriptional factor, RNAPolII: RNA polymerase II, DNMTs: DNA 
methyltransferases; HDACs: Histone deacetylases; MBDs: Methyl-CpG binding 
proteins; RC: transcriptional repressive complex (Leone, D'Alo et al. 2008). 
 
For example, histone H3 acetylation on lysine 9, 14, 18 and 56 are 
associated with unmethylated CGis, representative for open chromatin 
configuration, allowing transcription factor recruitment and gene transcription 
by RNA polymerase II. In contrast, histone H3 methylation on lysine 9 and 27 
and HDAC-induced depletion of H3 acetylation are associated with 
hypermethylated CGis, recruiting MBDs and DNMTs, leading to chromatin 
(A) Active chromatin 
(B) Silenced chromatin 
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condensation and transcriptional repression (Figure 6) (Leone, D'Alo et al. 
2008). 
 
1.3. Normal and malignant hematopoiesis 
 
Since functional mature blood cells have a limited lifetime in peripheral 
blood, they need to be continuously replaced. The pluripotent self-renewable 
CD34+ and lin- hematopoietic stem cells (HSCs) located in bone marrow can 
differentiate into different highly specialized mature blood cell types (Figure 7) 
(Okuno, Iwasaki et al. 2002). Mature hematopoietic cells are traditionally 
categorized into distinct lymphoid and myeloid lineages (Iwasaki and Akashi 
2007). During differentiation process, the various lymphoid and myeloid 
lineages develop independently out of the common lymphoid and myeloid 
progenitors stem cells (CLP and CMP, respectively) raised from the HSCs 
(Kondo, Weissman et al. 1997; Akashi, Traver et al. 2000). During 
downstream hematopoietic differentiation, mature cells lose stepwise 
developmental potential and self-renewable capacities, resulting in fully 
differentiated and functional blood cells (Warner, Wang et al. 2004). The 
lymphoid lineage consists of T, B and natural killer cells, while the myeloid 
lineage includes a number of morphologically, phenotypically and functionally 
distinct cell types including granulocytes (i.e. neutrophils, eosinophils and 
basophils), monocytes-macrophages and erythrocytes (Figure 7) (Iwasaki and 
Akashi 2007). The hematopoiesis process is tightly regulated by extrinsic (e.g. 
growth factors and cytokines) and intrinsic factors (e.g. lineage-specific 
transcription factors and epigenetic markers) (Rice, Hormaeche et al. 2007). 
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Figure 7: Hematopoiesis in adult mammalian organisms.  
Hematopoietic stem cells (HSC) give rise to the myeloid (CMP) and the lymphoid 
progenitor cells (CLP). Mast cells, platelets, erythrocytes, eosinophils and neutrophils 
as well as monocytes emerge from the myeloid pathway. Cells of the immune system 
such as B and T-cells emerge from the lymphoid progenitor (modified from © 2008 
Terese Winslow). 
 
The German pathologist Rudolf Virchow introduced in 1856 the term 
“leukemia” (Greek for white blood) to describe excessive clonal proliferation of 
white blood cells in cancer patients. This symptom is caused by a malignant 
neoplasm of blood forming organs with the clinical manifestation of an 
inappropriate expansion of hematopoietic progenitor cells, often due to a 
blockage of cell maturation at early stages (Altucci, Clarke et al. 2005).  
Hematological malignancies comprise all clinically, morphologically, 
immunophenotypically and pathologically heterogeneous neoplastic disorders 
of bone marrow and are first classified by the affected cell lineage (myeloid or 
lymphoid) and second by differentiation state or disease progression (acute or 
chronic). Abnormal white blood cells, consisting of primarily granulocytes or 
monocytes, are indicative for a myeloid disorder. In contrast, if abnormal 
blood cells arise form bone marrow lymphocytes, the cancer belongs to the 
class of lymphocytic disorders. The acute form of malignant hematopoiesis is 
characterized by very immature cells called blasts, which rapidly increase in 
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number in bone marrow and, in most cases, also in peripheral blood, leading 
to death within weeks without treatment. In contrast, the chronic form is 
characterized by an excessive accumulation of relatively mature but still 
abnormal and immunologically incompetent white blood cells. Without 
treatment, the relatively slow-growing chronic form is fatal within years after 
diagnosis (Figure 8). 
Hematological  
malignancies 
Lympoid disorders 
Lymphoma 
Chronic lymphoid 
leukemia 
Myeloma 
Acute lymphocytic 
leukemia 
Myeloid disorders 
Chronic 
myeloproliferative 
disorders 
Chronic myelogenous 
leukemia 
Myelodysplastic 
syndromes 
Acute myeloid 
leukemia 
Proliferation 
Differentiation 
 
Figure 8: Classification of hematological malignancies. 
Hematological malignancies (leukemia and lymphoma) are categorized by their 
lineage state (lymphoid (yellow) or myeloid (blue)) and functional differentiation state 
(acute or chronic). Highly proliferative acute myeloid and lymphoid leukemia cells are 
derived from cells in the early myeloid or lymphoid differentiation cascade, 
respectively. Chronic myeloid or lymphoid leukemia cells, myelodysplastic 
syndromes, myeloma and lymphoma are more differentiated but less proliferative 
and present therefore a reduced developmental potency compared to acute leukemia 
cells (modified from E. Attar; Leukemia Review: Types, Diagnostics, Treatments; 
www.calgb.org).  
 
By considering whether they are acute or chronic, and whether they are 
myelogenous or lymphocytic, leukemia can be divided in four major types: 
acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic 
myeloid leukemia (CML) and chronic lymphoid leukemia (CLL). ALL is primary 
a pediatric disease and occurs more commonly in children, whereas AML and 
chronic leukemia types mostly affect adults, but can appear theoretically in 
any age group. In leukemia, accumulation of leukemic immature and 
inoperable blood cells as well as suppression of the normal residual 
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hematopoiesis are responsible for crowding out other normal blood cells from 
bone marrow and bloodstream (Druker, Tamura et al. 1996; Deininger 2005). 
In consequence, normal blood cell features including immune defense or 
oxygen transport are disturbed, causing the characteristic blood cancer 
symptoms (e.g. anemia, thromobocytopenia and leukopenia). Noteworthy, 
lymphoma (i.e. Hodgkin’s disease and Non-Hodgkin’s lymphoma) and 
myeloma are further lymphoproliferative hematological malignancies, 
associated to a clonal proliferation of lymphoid cells. Myelodysplastic 
syndromes (MDS) are a clonal group of hematopoietic stem cell diseases 
characterized by hypercellular dysplasia and ineffective hematopoiesis by 
perturbed iron metabolism in one or more of the major myeloid cell lineages. 
 Leukemia appears to depend on a small population of leukemia stem 
cells (LSCs), characterized by their continuous growth and propagation. This 
assumption is supported by results showing that a highly proliferate clone of 
immature leukemic blast cells can lead to leukemogenesis (Kennedy and 
Barabe 2008). Nevertheless, the origin of LSC development is controversial 
(Passegue, Jamieson et al. 2003; Huntly and Gilliland 2005). Increased 
proliferation and differentiation capacities, telomere maintenance, uncoupling 
of self-renewal as well as decreased apoptosis rate lead to the development 
potential of blood cancer cells (Warner, Wang et al. 2004; Kennedy and 
Barabe 2008). Molecularly, leukemia are a heterogeneous disease entity with 
dysregulations of gene expression and pathways playing important functions 
in cellular growth, differentiation and cell death, resulting from different 
structural rearrangements or numerical chromosome aberrations. The 
presence of such specific genetic alterations allows the development of anti-
cancer therapies. For example, the BCR/ABL1 chimeric protein, resulting from 
a translocation between chromosome 9 and 22 and leading to the 
Philadelphia chromosome, is now targeted with imatinib mesylate in CML 
patients (Druker, Tamura et al. 1996; Deininger 2005). Moreover, clinical tests 
analyze the use of fms-related tyrosine kinase (FLT) 3 inhibitors for AML 
patients (Fiedler, Serve et al. 2005; Stone, DeAngelo et al. 2005). The 
receptor tyrosine kinase, which is involved in regulation of multiple 
cytoplasmic effector molecules in pathways of apoptosis, proliferation and 
hematopoietic differentiation, is commonly altered and leads to a constitutive 
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activation in AML and ALL. Indeed, up to 264 different gene fusions were 
found in hematological malignancies. Finally, it is now well accepted that 
epigenetic alterations play a key role in the abnormal developmental program 
of blood cancer cells (Mitelman, Johansson et al. 2007; Kennedy and Barabe 
2008).  
 
1.4. Epigenetic alterations in hematological malignancies 
 
In industrialized countries, cancer is ranked among the most prominent 
causes of death next to coronary heart disease and diabetes. Nutrition, 
environment, genetic background (predisposition) and previous anamnesis 
are important risk factors for cancer development. Malignant cells possess six 
characteristic hallmarks: (i) unlimited potential for cell division, (ii) invasion 
and metastasis potential, (iii) resistance to anti-growth signaling, (iv) self-
sufficient growth, (v) evasion of apoptosis, and (vi) sustained angiogenesis 
(Balch, Montgomery et al. 2005). Astonishingly, ubiquitous alterations in the 
elaborated DNA methylation pattern may be a causative factor as significant 
as genetic alterations for progression of a normal to a cancerous cell (Baylin 
and Bestor 2002; Hopkins, Burns et al. 2007). Genome-wide DNA 
hypomethylation was the first epigenetic abnormality that was identified in 
human tumors (Feinberg and Vogelstein 1983; Feinberg and Vogelstein 
1983). Several years later, opposite results claimed increased CGi 
methylation in human tumors (Baylin, Hoppener et al. 1986). The promoter 
region of the tumor suppressor gene (TSG) Retinoblastoma (Rb) was 
identified as the first hypermethylation hotspot that is unmethylated in normal 
cells (Greger, Passarge et al. 1989). Nowadays, it is well accepted that 
cancer cells are subjected to genome-wide loss of methylation and gene-
specific hypermethylation (Figure 9) (Sincic and Herceg 2011). Indeed, benign 
neoplasis or cancer cells in early developmental stages already possess the 
typical cancer-specific features of global hypomethylation and local 
hypermethylation, leading to the hypothesis that early epigenetic deregulation 
may precede genetic aberrations (Feinberg 2005). 
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Figure 9: Consequences of cancer-specific methylation alterations in tumor 
development. 
(a) Increase of CpG island promoter methylation can inactivate tumor suppressor 
genes and DNA repair genes. (b) Reduced global methylation might lead to 
chromosome instability, reactivation of transposons and activation of oncogenes 
(Strathdee and Brown 2002). 
 
The overall genomic methylcytosine content of approximately 4% 
(compared to total cytosines) in normal cells is decreased to 2-3% in cancer 
tissues. Even if loss of genome-wide methylation is a common feature of 
cancer cells, the degree of global hypomethylation varies among cancer 
subtypes. For example, undifferentiated germ cell tumors are hypomethylated, 
whereas their more differentiated counterparts show higher levels of global 
methylation. Testicular germ cells seminoma exhibit particularly high degrees 
of global hypomethylation (Wild and Flanagan 2010; Sincic and Herceg 2011). 
These observations emphasize that overall DNA hypomethylation may 
differentially play an essential role in disease onset or progression, and 
increased tumor frequency and malignancy (Wilson, Power et al. 2007).  
Hypomethylation mostly affects both intra- and extra-genic repetitive 
sequences, i.e. centromeric and pericentromeric regions (Figure 9). Indeed, 
failure of transcriptional repression of these satellite repeats may provoke 
DNA double-strand breaks, promoting aneuploidy formation. In the same way, 
global loss of methylation induces the reactivation of retrotransposons, 
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increasing the probability of translocations to other genomic regions and 
favoring chromosome instability (Strathdee and Brown 2002). Remarkably, 
transcriptional activation of LINE1 by promoter hypomethylation is an 
important feature of CML (Roman-Gomez, Jimenez-Velasco et al. 2005). In 
contrast, the SINE Alu appears to be resistant to demethylation and is rarely 
reported to be hypomethylated in cancer (Wild and Flanagan 2010). 
Moreover, single gene-specific DNA hypomethylation can achieve aberrant 
gene expression of proto-oncogenes, which mainly promote cell proliferation 
(Figure 9) (Strathdee and Brown 2002; Galm, Herman et al. 2006). Indeed, 
DNA hypomethylation and derepression of the oncogenes Harvey rat 
sarcoma viral oncogene homolog (H-RAS) and T-cell leukemia/lymphoma 1 
(TCL-1) were reported in CLL patients (Melki and Clark 2002). Furthermore, in 
vitro and in vivo studies described the activation of genes associated with 
tumor invasion and metastasis by the loss of DNA methylation (Ateeq, 
Unterberger et al. 2008). Finally, cancer-induced loss of imprinting leads to 
the biallelic expression of IGF-2 and thus stimulation of cancer cell 
proliferation (e.g. Wilms’ tumor) (Jirtle 1999).  
Partial or complete abrogation of DNMT expression and function might 
lead to the passive loss of DNA methylation in malignant cells. However, this 
is unlikely since it was shown that DNMT1, DNMT3A and DNMT3B were 
overexpressed in AML and CML patients (Mizuno, Chijiwa et al. 2001). 
Moreover, latest results reported that abnormal methylcytosine content in 
AML cells was independent of somatic mutations in DNMT3A gene (Ley, Ding 
et al. 2010). Furthermore, cancer cell-specific deficiency of the DNMT cofactor 
SAM could initiate similar effects. DNMTs have the property to bind with high 
affinity to DNA damages, leading to site-directed neglection of DNA 
methylation maintenance and subsequent DNA demethylation. Likewise, 
alterations in DNA repair mechanisms are probably responsible for active 
DNA demethylation of cancer methylomes (Wild and Flanagan 2010).  
Mainly ‘bona fide’ TSGs, implicated in all six aforementioned hallmarks 
of cancer, are repressed through hypermethylation of their promoter CGis 
(Jones and Baylin 2002; Herman and Baylin 2003; Hopkins, Burns et al. 
2007). Target genes of aberrant DNA hypermethylation play major roles for 
the physiological cell existence including DNA repair, cell cycle regulation, cell 
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invasion and adhesion, apoptosis, detoxification and hormonal response 
(Figure 9) (Esteller and Herman 2002; Galm, Herman et al. 2006). DNA 
hypermethylation-associated silencing of TSGs occurs in various 
hematological neoplasia and thereby may contribute to early carcinogenesis. 
Table 1 gives an overview of genes that are found frequently hypermethylated 
in hematological malignancies. 
 
Table 1: Genes found frequently hypermethylated in hematopoietic 
malignancies. 
Function Gene Hematological 
malignancy 
Literature 
Cell cycle control CDKN2B (p15INK5B) NHL, AML, ALL, CML, 
CLL, MDS  
(Herman, Jen et al. 1996; Herman, Civin et al. 
1997; Drexler 1998; Baur, Shaw et al. 1999; 
Rush and Plass 2002; Esteller 2003; Galm, 
Wilop et al. 2005; Galm, Herman et al. 2006) 
 CDKN2A (p16INK4A) ML, MM, AML, ALL, 
CLL 
(Melki and Clark 2002; Boultwood and 
Wainscoat 2007; Esteller 2008) 
 CDKN1C 
(p57KIP2) 
ML, MM, ALL, CLL (Li, Nagai et al. 2002) 
 TP73 ML, MM, ALL, AML (Kawano, Miller et al. 1999; Ekmekci, 
Gutierrez et al. 2004; Ropero, Setien et al. 
2004) 
Biosynthesis 
enzyme 
EXT1 ALL (Ropero, Setien et al. 2004) 
DNA damage 
repair 
MGMT NHL, ALL, AML (Esteller, Hamilton et al. 1999; Esteller, 
Gaidano et al. 2002; Margison, Povey et al. 
2003) 
Apoptosis DAPK1 ML, MM, ALL, AML, 
CLL 
(Ekmekci, Gutierrez et al. 2004; Rossi, 
Capello et al. 2004; Raval, Lucas et al. 2005) 
 RASSF1A Hodgkin’s lymphoma (Murray, Qiu et al. 2004) 
Cell adhesion CDH1 MM, ALL, AML, CLL, 
MDS 
(Melki and Clark 2002; Aggerholm, Holm et al. 
2006; Garcia-Manero, Yang et al. 2009) 
Growth regulation 
 
HIC1 NHL, ALL, AML, CML, 
MDS 
(Issa, Zehnbauer et al. 1997; Melki, Vincent et 
al. 1999; Aggerholm, Holm et al. 2006; 
Deneberg, Grovdal et al. 2010) 
Cytokine signaling SOCS1 MM, AML (Ekmekci, Gutierrez et al. 2004; Galm, Wilop 
et al. 2005) 
Nuclear matrix LMNA NHL, ALL (Agrelo, Setien et al. 2005) 
Hormone receptor 
 
RARB2 NHL, AML (Esteller, Guo et al. 2002; Ekmekci, Gutierrez 
et al. 2004; Galm, Wilop et al. 2005; 
Rethmeier, Aggerholm et al. 2006) 
 ESR1 ALL, AML, CML, MDS (Issa, Baylin et al. 1997; Melki, Vincent et al. 
1999; Galm, Wilop et al. 2005; Aggerholm, 
Holm et al. 2006; Yao, Huang et al. 2009) 
 AR NHL (McDonald, Gascoyne et al. 2000) 
Transporter 
(Importer) 
 
CRBP1 NHL, AML (Esteller, Guo et al. 2002; Takahashi, 
Shivapurkar et al. 2004) 
Transporter 
(Exporter) 
 
ABCB1 AML, ALL (Toyota, Kopecky et al. 2001; Garcia-Manero, 
Daniel et al. 2002; Taylor, Pena-Hernandez et 
al. 2007) 
Tyrosine kinase 
 
EPHA7 NHL (Dawson, Hong et al. 2007) 
 ABL1 ALL, CML (Asimakopoulos, Shteper et al. 1999; 
Asimakopoulos, Shteper et al. 1999; Shteper, 
Siegfried et al. 2001) 
Tyrosine SHP1 ML (Koyama, Oka et al. 2003) 
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Function Gene Hematological 
malignancy 
Literature 
phosphatase 
Differentiation MYOD1 AML, ALL (Toyota, Kopecky et al. 2001; Garcia-Manero, 
Yang et al. 2009) 
 PITX2 AML (Toyota, Kopecky et al. 2001) 
 ID4 ML, AML (Hagiwara, Nagai et al. 2007; Uhm, Lee et al. 
2009) 
Receptor SDC4 AML (Toyota, Kopecky et al. 2001) 
Homeostasis CEBP AML (Agrawal, Hofmann et al. 2007) 
Calcium 
metabolism 
CALCA AML, ALL, CLL (Nelkin, Przepiorka et al. 1991; Melki and 
Clark 2002; Paixao, Vidal et al. 2006; Ismail, 
El-Mogy et al. 2011) 
Purine metabolism FHIT AML, MDS (Iwai, Kiyoi et al. 2005) 
Detoxification AHR ALL (Mulero-Navarro, Carvajal-Gonzalez et al. 
2006) 
Cell adhesion THBS1 AML; ALL (Toyota, Kopecky et al. 2001; Garcia-Manero, 
Daniel et al. 2002) 
ABCB1: ATP-binding cassette, sub-family B (MDR/TAP), ABL1: c-Abelson oncogene 1 non-receptor 
tyrosine kinase, AHR: aryl hydrocarbon receptor, ALL: acute lymphoid leukemia, AML: acute myeloid 
leukemia, AR: androgen receptor, CALCA: calcitonin A, CDH1: E-cadherin, CDKN2A: cyclin-dependent 
kinase (CDK) inhibitor 2A, CDKN2B: CDK inhibitor 2B, CDKN1C: CDK inhibitor 1C, CEBP: 
CCAAT/enhancer binding protein, CLL: chronic lymphoid leukemia, CML: chronic myeloid leukemia, 
CRBP1: cellular retinol-binding protein 1, DAPK1: death-associated protein kinase 1, ER: estrogen 
receptor, EPHA7: EPH receptor A7, EXT: exostosin 1, FHIT: fragile histidine triad gene, HIC1: 
hypermethylated in cancer 1, ID4: inhibitor of DNA binding 4, INK: kinase inhibitor, KIP: kinase inhibitor 
protein, LMNA: lamin A/C, MGMT: O-6-methylguanine-DNA methyltransferase, ML: multiple lymphoma, 
MM: multiple myeloma, MDS: myelodysplastic syndrome, MYOD1: myogenic differentiation 1, NHL: Non 
Hodgkin’s lymphoma, PITX2: paired-like homeodomain 2, RARB2: retinoic acid receptor beta 2, 
RASSF1: Ras association domain family protein 1, SDC4: syndecan 4, SHP1: Protein-tyrosine 
phosphatase SHP-1, SOCS1: suppressor of cytokine signaling 1, THBS1: thrombospondin 1, TP73: 
tumor protein p73. 
 
Noteworthy, late stage AML patients who relapsed after a chemotherapy-
induced remission showed abnormal methylation of hypermethylated in 
cancer 1 (HIC1) gene (Issa, Zehnbauer et al. 1997; Deneberg, Grovdal et al. 
2010). The transcriptional repressor HIC1 is involved in regulation of genes 
involved in proliferation, tumor growth and angiogenesis. Validated 
transcriptionally repressed targets of HIC1 are silent mating type information 
regulation 2 homolog 1 (SIRT1) HDAC, fibroblast growth factor binding protein 
(FGFBP1), patched (ptch) 1 tumor suppressor, scavenger chemokine 
receptor 7 (CXCR7), ephrin-A1 (EFNA1), E2F1 and T-cell-specific 
transcription factor 4 (TCF4) (Jenal, Britschgi et al. 2010). As shown in 
xenograft tumor assays, constitutive expression of FGFBP1 results in highly 
angiogenic tumors (Jenal, Britschgi et al. 2010). Moreover, bidirectional 
ehrin/eph-signaling has been implicated in many aspects of malignancy, such 
as tumor growth, invasion, metastasis and angiogenesis (Pasquale 2010). In 
consequence, epigenetic inactivation of the transcriptional repressor HIC1 
plays an important role in leukemogenesis. Furthermore, simultaneous cyclin-
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dependent kinase (CDK) inhibitor 2B and CDK inhibitor 1C hypermethylation, 
which leads to dysregulation of the cell cycle, has been reported in ALL cells 
(Garcia-Manero, Yang et al. 2009). Moreover, hypermethylation of the c-
Abelson oncogene 1 (ABL1) promoter region repressing the expression of the 
oncogenic fusion gene BCR/ABL is found in CML samples (Asimakopoulos, 
Shteper et al. 1999). Since intragenic hypermethylation of the enhancer-
blocking transcription factor CTCF binding region prevents silencing of the 
oncogene B-cell CLL/lymphoma (BCL) 6 in B-cell lymphoma, consequences 
of DNA hypermethylation appears to be region-specific (Lai, Fatemi et al. 
2010). Noteworthy, a recent study on colon cancer cells showed that aberrant 
methylation is not only limited to CGis, but also appears in highly conserved 
CpG island shores (Irizarry, Ladd-Acosta et al. 2009). Recently, methylation 
along the CGi borders was also described in human B-cells in transition to 
lymphoma (Conerly, Teves et al. 2010). However, the importance of 
differential methylation in these regions requires further studies.  
Cancer-associated TSG hypermethylation is probably established 
progressively in several waves of aberrant methylation. As previously 
mentioned, methylation pattern is not stable and changes arise in normal 
cellular processes such as aging, which is one of the strongest risk factors for 
cancer (Teschendorff, Menon et al. 2010). In addition, recent publications 
linked environmental and lifestyle factors to the acquisition of inappropriate 
DNA methylation of various genes (Marsit, Houseman et al. 2007; 
Christensen, Houseman et al. 2009). In both cases, initial abnormal DNA 
methylation acts as a seed and promotes further methylation (Song, Stirzaker 
et al. 2002). Another theory postulates that hypermethylation may spread from 
normally methylated genomic element (e.g. transposons) over to usually 
unmethylated genes (Graff, Herman et al. 1997). In addition, disruptions of the 
epigenetic machinery, for instance by genetic mutations, could lead to 
increase transcription rate and aberrant enzymatic activity of any of its 
component. Hence this could be attributed to abnormal epigenetic events in 
hematological cancers (Robertson, Uzvolgyi et al. 1999; Baylin, Esteller et al. 
2001; Mizuno, Chijiwa et al. 2001). For example, the AML-associated 
translocation t(15:17) leads to the expression of the oncogenic promyelocytic 
leukemia (PML) / retinoic acid receptor beta (RARB) fusion protein. The 
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chimeric transcription factor recruits DNMTs to target promoters and induce 
abnormal methylation (e.g. RARB2) (Di Croce, Raker et al. 2002). Moreover, 
substantial alterations were detected in apparently normal cells of individuals 
with infections. Indeed, virus-encoded proteins could affect DNMT activity. For 
example, DNMT expression gets upregulated by the hepatitis B virus specific 
protein X (Herceg and Paliwal 2011). Alternatively, a recent publication 
reported that Heliobacter pilori infection is associated with aberrant 
methylation (Niwa, Tsukamoto et al. 2010). 
Taking together, these data lead to the following question: why CGis of 
certain genes become hypermethylated and others remain unmethylated in 
cancer cells? Manuel Esteller is in favor of the Darwinian idea (natural 
selection) that a certain pattern of hypermethylated genes confers a selective 
survival or growth advantage of a particular cell and may play a pivotal role in 
the stepwise progression towards carcinogenesis (Esteller 2002). On 
average, 5% of genes of an individual tumor exhibit a hypermethylated 
promoter region. These alterations appear to be a far more drastic change in 
the cellular metabolism than genomic point mutations (Jones and Baylin 2002; 
Hirst and Marra 2009). However, since these epimutations can silence the 
remaining active allele of a previously mutated TSG, accordingly to Knudson’s 
two-hits hypothesis, they may provide the second hit for cancer initiation 
(Knudson 1971; Rodriguez-Paredes and Esteller 2011). Alternatively, the 
“Barker hypothesis” states that placental exposure or early life energy 
restriction cause errors in fetal reprogramming that persist into adulthood and 
may contribute to enhance risk for cancer development (Barker, Eriksson et 
al. 2002; Hughes, van den Brandt et al. 2009). 
Another layer of epigenetic modifications was added with the discovery 
of 5-hmc. Even if the knowledge about the relationship between 5-hmc and 
cancer is still at the beginning, it is already well known that TET genes, 
involved in methylcytosine metabolization, are often subject to somatic 
mutations such as fusion genes, homozygous null mutations or deletions in 
hematological malignancies (Burmeister, Meyer et al. 2009; Delhommeau, 
Dupont et al. 2009; Meyer, Kowarz et al. 2009; Ko, Huang et al. 2010). These 
observations lead to the assumption that 5-hmc may play a role in 
carcinogenesis.  
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Besides alterations in DNA methylation patterns, disruptions of covalent 
histone modifications are further hallmark of cancer. For example, repressive 
marks, i.e. loss of acetylation of H4K16 and increased methylation of H4K20, 
were found at hypomethylated repetitive sequences (e.g. pericentromeric 
repeats) in many primary tumors compared with normal tissues (Fraga, 
Ballestar et al. 2005). Alterations in histone modification patterns are the 
results of abnormal expression, activity or recruitment of histone-modifying 
enzymes and histone code-reading proteins, induced by genetic or epigenetic 
alterations (Cress and Seto 2000; Mahlknecht and Hoelzer 2000; Ellis, Atadja 
et al. 2009). Thus, H4K20 was correlated to hematological malignancy by a 
recent report about MMSET, a gene coding for a H4K20 histone trimethylase, 
which is overexpressed in an aggressive subset of multiple myeloma carrying 
the t(4;14) translocation (Schotta, Lachner et al. 2004). Moreover, AML is 
associated with the t(8;21) chromosomal translocation that is responsible for 
the AML1-ETO fusion protein. This chimeric protein is a potent dominant 
transcriptional repressor that recruits HDAC activity, inducing alterations in 
histone modification landscape and gene expression profiles (Wang, Hoshino 
et al. 1998; Wang, Saunthararajah et al. 1999). Other leukemia fusion 
proteins, such as PML-RAR or PLZF-RAR, have similar HDAC recruiting 
features (Minucci, Nervi et al. 2001). 
Finally, alterations in miRNA processing and expression profiles play a 
major role in carcinogenesis. The link between miRNAs and cancer 
pathogenesis has emerged from the discovery that miRNA expressing genes 
are frequently located in cancer-associated genomic regions (CAGR). Indeed, 
about 50% of all annotated human miRNA genes are located in minimal 
regions of amplifications, common breakpoint regions in or near oncogenes, 
TSGs and chromosomal fragile sites (Calin, Sevignani et al. 2004; Sevignani, 
Calin et al. 2007; Melo and Esteller 2010). Since miRNAs are frequently 
expressed as polycistronic transcripts, deregulation of one member of the 
cluster is accompanied by a deregulation of other cluster members. 
Obviously, the miRNome varies between normal and pathological tissue 
as well as between different cancer types. Expression of miRNAs seems to be 
generally downregulated in cancer cells excepting a few cancer type-specific 
miRNA genes, whose increased expression is associated with carcinogenesis 
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(Deng, Calin et al. 2008; Zhang, Li et al. 2010). Rather than a change of a 
single miRNA gene that regulates one oncogene or TSG, miRNome-wide 
alterations contribute to carcinogenesis. Thus, miRNAs with a protective or 
tumor suppressive role, called anti-oncomirs, are commonly silenced in 
cancer cells. Calin et al. reported for the first time abnormal expression of 
miR-15a and miR-16-1, a cluster often downregulated in CLL, which is 
involved in the regulation of human genes such as BCL-2 (Melo and Esteller 
2010; Zheng, Wang et al. 2010). Both miRNA genes are located at 
chromosomal position 13q14.3, which is frequently deleted in CLL and 
lymphoma (Chiorazzi, Rai et al. 2005). In contrast, the oncomir subclass 
regroups miRNAs that are mostly overexpressed in cancer cells and 
responsible for TSG silencing. Hence, the polycistron miR-17"92, which is 
often upregulated in lymphoma and CLL samples, suppresses the expression 
of both the pro-apoptotic gene Bim and the TSG PTEN, leading to enhanced 
cell survival and proliferation rate (Ota, Tagawa et al. 2004; Xiao, Srinivasan 
et al. 2008). In addition, some miRNAs such as miR-328 may even have a 
dual oncogenic and tumor-suppressive role in cancer, depending on cell type 
and gene expression pattern (Eiring, Harb et al. 2010; Melo and Esteller 
2010).  
In analogy with protein-coding genes, miRNA functions are also 
influenced by point mutations. Nevertheless, site restricted errors in the 
sequence of mature miRNA seed region seem to be rare (He, Jazdzewski et 
al. 2005; Diederichs and Haber 2006; Yang, Zhou et al. 2008). Nevertheless, 
point mutations in the 3’ UTR of the miRNA target mRNA can reduce or 
induce the loss of miRNA target sensitivity, specificity, and response to 
miRNA target recognition (Visone and Croce 2009). Genetic aberrations can 
also affect RISC complex assembly and compromise miRNA-mediated 
silencing (Kwak, Iwasaki et al. 2010). Furthermore, tumor-specific mutations 
in miRNA sequences influence the stability of precursor as well as mature 
miRNA, and play on miRNA expression level (Diederichs and Haber 2006). 
Moreover, alterations in the expression of miRNA regulating transcription 
factors induce aberrant transcription of pri-miRNAs. Finally, impairments in 
the miRNA processing step can change miRNA expression pattern in cancer 
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cells (Kwak, Iwasaki et al. 2010). Remarkably, since approximately half of all 
miRNA genes contain CGis, aberrant DNA hypermethylation-mediated 
silencing can also affect miRNA network (Calin and Croce 2006; Esquela-
Kerscher and Slack 2006; Deng, Calin et al. 2008). Thus, the miR-203 locus 
frequently undergoes DNA methylation in T-cell lymphoma compared to 
normal T-lymphocytes (Bueno, Perez de Castro et al. 2008). Additional 
miRNAs are targets for DNA hypermethylation, such as miR-9-1, miR124a, 
miR-127 and let-7 family in breast, colorectal, bladder or epithelial ovarian 
cancer, respectively (Lujambio, Ropero et al. 2007; Lehmann, Hasemeier et 
al. 2008; Guil and Esteller 2009).  
These observations clearly demonstrate that miRNA expression is often 
deregulated in cancer cells, with numerous miRNAs being overexpressed in 
one type of cancer and downregulated in another. Therefore, cancer-specific 
miRNA expression signature could be used as a cancer diagnosis or 
therapeutic tool. 
 
1.5. DNA methylation in the management of blood cancer 
 
Current knowledge indicates that the development of malignancies is 
based on a mixture of genetic and epigenetic defects (Issa and Kantarjian 
2009). Cytogenetic alterations in AML and multiple myeloma at diagnosis are 
considered to be valuable prognostic determinants (Grimwade, Walker et al. 
1998; Hideshima, Bergsagel et al. 2004). Nevertheless, genomic aberrations, 
leading to misexpression or appearance of a truncated gene form can occur in 
multiple sites of a gene such as the promoter or the gene body. This feature 
limits the effective use of somatic mutations as cancer biomarker. In contrast, 
hypermethylation occurs mainly in the regulatory gene promoter region. 
Moreover, aberrant hypermethylation of cancer cells is detectable in the 
background of hypomethylated normal cells, whereas tumor-associated loss 
of heterozygosity and homozygous deletions disappear in a healthy 
heterozygote background. Furthermore, DNA molecules per se as well as 
methylation at the 5’ position of cytosine are chemically stable and can only 
be modified by specific enzymes. Under most conditions turnover of 
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methylcytosine in slow. In consequence, DNA methylation changes can be 
robustly and specifically analyzed in a large variety of fresh or archived 
biological samples (e.g. biopsies or body fluids). The development of new 
highly sensitive analysis techniques (e.g. high throughput deep sequencing) 
allows the specific detection of hypermethylation signatures in small DNA 
amounts (Schulz and Goering 2011). Accordingly, four major clinical oncology 
areas could potentially benefit from the identification of methylation 
signatures. Powerful epigenetic biomarkers can be applied for cancer 
diagnosis (early detection and prevention), prognosis (tumor behavior), 
pharmacogenetics (drug response to follow efficacy of treatment) and as 
target for epigenetic drugs (Figure 10) (Esteller 2011). 
Analysis of the methylation signatures allow to distinguish normal 
surrounding tissues from cancer cells. Moreover, stratification of the different 
cancer types and stages by mapping of the CGi methylation pattern could 
improve early detection of tumor cells (Figure 10). For example, 
hypermethylation of O-6-methylguanine-DNA methyltransferase (MGMT) or 
CDKN2A can be observed up to three years prior to classical cancer 
diagnosis by medical check-up in squamous cell lung carcinoma. Moreover, 
hypermethylation of HIC1 is a poor prognosis marker in lung cancer (Hayashi, 
Tokuchi et al. 2001). Thus, the early presence of hypermethylated TSGs does 
not necessarily indicate an invasive cancer, as premalignant or cancer 
precursor lesions can also carry these epigenetic signatures. Hence, these 
signatures could be used for early cancer detection in individuals with genetic 
predispositions or exposed to carcinogens. Moreover, many tumors ‘shed’ 
DNA into the serum or other easily accessible body fluids (e.g. blood, 
bronchoalveolar lavage, lymph nodes, sputum, urine, semen, ductal lavage or 
saliva) simplifying epimutation detection in an early tumorigenesis stage 
(Ahrendt, Chow et al. 1999; Sanchez-Cespedes, Esteller et al. 1999; Goessl, 
Krause et al. 2000; Palmisano, Divine et al. 2000; Cairns, Esteller et al. 2001; 
Evron, Dooley et al. 2001; Rosas, Koch et al. 2001). Noteworthy, the gold 
standard epigenetic biomarker for prostate cancer is the hypermethylated 
status of the detoxification enzyme GSTP1, since neoplastic prostate cancer 
cells are hypermethylated in up to 90% of patients (Lee, Morton et al. 1994; 
Esteller, Corn et al. 1998).  
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As previously mentioned, these epigenetic markers could be used in 
cancer risk assessment, ‘cancer prevention’ and identification of 
predispositions that act epigenetically as a cause of cancer (Sincic and 
Herceg 2011). However, a clear definition about minimal genetic, epigenetic 
and phenotypic characteristics associated with tumor initiation and 
progression (i.e. from a benign to a malignant cell) of cancer cells is still 
pending. 
 
 
Figure 10: Application range for CpG island hypermethylation in cancer 
diagnostic and treatment routine.  
Possible biological samples used for the detection of hypermethylation as well as the 
possible application fields (prognosis, diagnosis, treatment). MGMT: O-6-
methylguanine-DNA methyltransferase (Esteller 2002).  
 
In addition, screening of the unique DNA methylation signature may 
reveal biomarkers with clinical potential, providing information about tumor 
behavior (Rodriguez-Paredes and Esteller 2011, Esteller, 2002 #145). For 
example, hypermethylation of CDKN2B and HOXA4 genes was considered to 
be a negative prognostic marker for AML (Wong, Ng et al. 2000; Chim, Liang 
et al. 2001; Strathdee, Holyoake et al. 2007). Furthermore, calcitonin A 
(CALCA) gene is frequently hypermethylated in ALL and is associated with 
enhanced risk of relapse (Roman, Castillejo et al. 2001). 
Mapping of DNA hypermethylation could further provide information 
about drug pharmacodynamics. Common chemotherapeutic agents target 
uncontrolled rapidly dividing cancer cells and induce DNA damages. 
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Consequently, genes involved in DNA repair (e.g. MGMT, mutL homolog 
(MLH) 1 or breast cancer (BRCA) 1) are promising epigenetic candidates to 
predict pharmacoepigenetic response. The methylation status of MGMT gene, 
which repairs alkylated guanines, is used to predict glioma tumor response to 
the alkylating drugs carmustine and temozolomide (Hegi, Liu et al. 2008). The 
MGMT gene was one of the first genes, where functionality and methylation 
status were commercially analyzed for the prediction of progression-free and 
overall cancer survival (www.oncomethylome.com) (Costa 2010). 
Hypermethylation-associated silencing of MGMT prevents repair of 
chemotherapy-induced DNA lesions, finally resulting in programmed cell 
death. Moreover, MGMT hypermethylation, in tumor samples from diffuse 
large B-cell lymphoma (DLBCL) patients receiving cyclophosphamide-based 
chemotherapy, was associated with a significant increase of overall survival 
(Esteller, Gaidano et al. 2002). Likewise, methylation status of genes involved 
in cell cycle regulation, drug transport and metabolization may have a 
predictive potential value for drug response or chemoresistance (Rodriguez-
Paredes and Esteller 2011). Accordingly, epigenetic silencing of organic 
solute carrier partner 1 (OSCP1), which is involved in drug transport, is 
associated with CML resistance to imatinib (Jelinek, Gharibyan et al. 2011). 
Since the aim of most cancer treatments is to induce cell death, 
chemotherapy sensitivity may also depend on the apoptotic potential of the 
targeted cancer cells. In accordance, cells with hypomethylated prosurvival 
genes (e.g. XIAP, BCL-2) as well as hypermethylated and repressed 
proapoptotic genes (e.g. PTEN, APAF-1) are highly resistant to cell death 
induction (Balch, Montgomery et al. 2005). 
In addition to classical epigenetic cancer markers, current research is 
dedicated to detect new candidate genes with abnormal methylation pattern 
for their translation into biomarkers. First indications for an epigenetically 
silenced gene are the loss of expression in tumors, the absence of genomic 
mutations in the gene of interest as well as the presence of a promoter CGi. 
The next step consists in the analysis of the CGi methylation status by 
bisulfite conversion and non-bisulfite methods in cancer cell lines and patient 
samples. To compare hypermethylation and transcriptional silencing, 
treatment with a demethylating agent should restore gene functionality. 
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Finally, it should be demonstrated that the epigenetic silencing of the gene of 
interest contributes to human tumorigenesis (Esteller 2002).  
Since every cancer type has its unique and complex epigenetic 
signature, it is unlikely that a single biomarker will be enough to predict the 
outcome of a cancer. For example, CDKN2A, CDKN1C and TP73 genes are 
found commonly methylated in cancer. When analyzed individually, none of 
these genes showed clear prognostic value. Nonetheless, patients with 
concomitant methylation of at least two of this triad had a lower median 
survival than patients either with methylation of only one these 3 genes or 
without methylation (Garcia-Manero, Yang et al. 2009). Assaying multiple 
methylation markers is mandatory in cancer management in order to cover 
the biological heterogeneity, arising during cancer progression and 
histological subtypes, to increase sensitivity and to discriminate age-related 
background noise (Schulz and Goering 2011). 
Similarly to DNA hypermethylation, global DNA hypomethylation may 
also be used in the future as an epigenetic marker for cancer diagnosis. In 
accordance, loss of LINE hypermethylation occurs with the progression of the 
hematological malignancy and could be used for cancer detection and 
prognosis (Roman-Gomez, Jimenez-Velasco et al. 2005). In addition, 
genome-wide analysis showed that AML cells are hypomethylated compared 
to isolated normal B- and T-lymphocytes. However, comparison of the global 
methylation level between malignant AML and benign bone marrow cells 
showed no significant differences (Giotopoulos, McCormick et al. 2006). Thus, 
the application of hypomethylation pattern for cancer management is still at its 
beginning. Establishment of appropriate control samples will help to get a 
clear view of leukemogenesis-associated global hypomethylation signatures 
and evaluate their prevalence and clinical relevance. 
 
1.6. DNA methylation as a therapeutic target  
 
During early embryogenesis as well as gametogenesis, cells are 
reprogrammed by undergoing a massive genome-wide DNA demethylation. 
This epigenetic remodeling also arises in adult cells after nuclear 
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transplantation (Rideout, Eggan et al. 2001). In the same way, this approach 
seems to reverse the malignant phenotype of cancer cells, even in a 
background of somatic mutations (Hochedlinger, Blelloch et al. 2004). DNA 
methylation is reversible, thus representing an attractive target for anticancer 
therapeutic intervention.  
In the early 1960s, Sorm et al. first synthesized the common cytosine 
analogue azacytidine (AZA) (Piimi 1964; Pískala 1965). The nucleoside 
analogue AZA is an S phase-specific prodrug, which is incorporated into RNA 
and during replication into DNA. In contrast, its derivate 5-aza-2'-
deoxycytidine (DAC, decitabine) is only incorporated into DNA (Figure 11). 
Initially designed as cytotoxic agents, their DNMT inhibiting and DNA 
demethylating activities were discovered by pure chance (Issa and Kantarjian 
2009).  
After its cellular uptake, DAC is successively phosphorylated to mono, di 
and triphosphate forms. The latter is incorporated into nascent daughter 
strands of replicating DNA (Figure 11-A) (Momparler and Derse 1979; Glover, 
Leyland-Jones et al. 1987). The azacytidine ring, which protrudes out from the 
DNA double strand, subsequently catches and covalently binds DNMTs. The 
following polyubiquitylation targets DNMTs for their subsequent proteasomic 
degradation (Figure 11-B) (Ghoshal, Datta et al. 2005). The resulting cellular 
depletion of DNMTs makes it impossible to maintain the methylation during 
replication and thus provokes a passive loss of DNA methylation (Figure 11-
B). Paradoxically, trapping of DNMTs onto DNA creates bulky adducts that 
can inhibit DNA synthesis and eventually result in cell death by cytotoxicity 
(Juttermann, Li et al. 1994). Dose-response analysis showed that optimal 
biological effects on DNA demethylation and gene expression induction are 
obtained at relatively low DAC concentrations (<5µM), whereas DNA 
synthesis and replication are blocked at higher doses (>50µM) impairing the 
DNA demethylation effect (Qin, Jelinek et al. 2009). Once a hypomethylation 
pattern has been induced, it can be carried over through subsequent cell 
divisions, resulting in prolonged alterations of gene expression. Unfortunately, 
cells show a tendency to remethylate DNA sequences that have been 
  Introduction 
 37 
demethylated by drug treatment, resulting in a gradual blunting of the cellular 
response (Bender, Gonzalgo et al. 1999). 
As previously described, nucleoside analog DNA methylation inhibitors 
(DNMTi) require incorporation into DNA to be effective. In consequence, they 
have no measurable effects on non-cycling cells, which constitute the vast 
majority of the human body cells. Since cancer cells tend to scavenge more 
effectively nucleosides than normal cells, they integrate more drugs into their 
DNA (Cheng, Yoo et al. 2004).  
 
  
Figure 11: Intracellular metabolic pathways of azacytidine and 5-aza-2’-
deoxycytidine. 
(A) After cellular uptake, both drugs require phosphorylation to triphosphate 
derivatives to be incorporated into newly synthesized RNA and DNA. 5-azacytidine 
diphosphate is also reduced by ribonucleotide reductase to 5-aza-2’-deoxycytidine 
diphosphate, which is furthermore phosphorylated and incorporated into DNA. 
Elevated expression of the cytidine deaminase can mediate a 5-azacytidine 
resistance. (B) The incorporated 5-azacytosine ring bind covalently DNA 
methyltransferase (DNMT) 1. Resulting adducts induce loss of DNA methylation 
through DNMT1 depletion by ubiquitylation-mediated proteasomal degradation. 
Adapted from (Leone, D'Alo et al. 2008; Stresemann and Lyko 2008). 
 
At the beginning, DNMTi were exclusively used in cell culture as tools to 
induce genomic demethylation, restore gene expression and trigger cell 
differentiation (Jones, Taylor et al. 1982; Jones 1985). Even though DAC is 
(A) (B) 
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one of the most effective DNA demethylating drugs, downstream effects of 
DNMTi-mediated DNA demethylation are quite unspecific and thereby 
complicate clinical application (Villar-Garea and Esteller 2003; Issa and 
Kantarjian 2009). Indeed, it must be taken into account that DAC-mediated 
demethylation, even at low doses, will affect a broad range of usually silenced 
pathways implicated in cell proliferation, differentiation, apoptosis, invasion 
(upregulation of motility genes) and angiogenesis (through angiogenesis 
inhibitors). Furthermore, DAC-induced demethylation can achieve detrimental 
effects such as the restoration of epigenetically silenced oncogenes, 
awakening of transposable elements, and activation of the deleterious 
expression of the X-chromosome or imprinted genes (Issa and Kantarjian 
2009). Similarly, non-coding RNAs such as miRNAs (i.e. oncomirs) that are 
often repressed by DNA methylation are inducible by DNA demethylating 
drugs (Saito, Liang et al. 2006). In consequence, effects of DNA methylation 
inhibition are probably cell-specific and it is likely that a mixture of effects 
reflecting the total sum of pathways activated is the reality in most cases.  
Early clinical trials have tested high doses of DAC for its cytotoxicity on 
cancer cells. DAC at 1500 to 2500 mg/m2 were administered for relatively 
short exposure time. However, disappointing results concerning efficacy and 
toxicity were largely unfavorable and the use of nucleoside analogs was 
abandoned by the U.S. Food and Drug administration (FDA) (Rivard, 
Momparler et al. 1981; Momparler, Rivard et al. 1985). Hypomethylating 
nucleoside analogs came back to life over the past decade through the 
persistence of a few investigators (Wijermans, Lubbert et al. 2000). Zagonel 
et al. explored low dose schedules of DAC (i.e. 45mg/m2/day over 4h for 3 
days and 50mg/m2/day by continuous daily infusion for 3 days) in 10 MDS 
patients. An overall response rate of 50% was obtained in these studies. 
Accordingly, a European clinical phase II trial was initiated in the early 90s, 
exploring this low-dose DAC schedule delivery. The overall response rate was 
around 50% in MDS and AML patients (Schwartsmann, Fernandes et al. 
1997; Wijermans, Krulder et al. 1997). Final phase III studies further 
confirmed DAC-mediated responses but failed to demonstrate substantial 
effects on survival, probably due to the limited numbers of treatment cycles 
(Kantarjian, Issa et al. 2006). In contrast, the use of an open-end approach for 
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DAC treatment resulted in a very high response and survival rate superior to 
what was observed with cytotoxic chemotherapy. Furthermore, treatments 
with hypomethylating agents improve disease burden and quality of life as 
well as the side effect profile, which is more favorable as compared with 
classical anti-cancer therapy (e.g. no hair loss or renal failure) (Issa and 
Kantarjian 2009). DAC is the first epigenetic drug specifically approved by the 
FDA in 2006 for MDS treatment. The fact that no standard of care exists for 
MDS was probably in favor for DAC application. Nevertheless, there is no 
special reason why MDS should be the only epigenetically responsive 
disease. Today, DAC is also tested in clinical trials for CML treatment (Altucci, 
Clarke et al. 2005). These interesting and promising results encourage 
research to further develop more effective and selective DNA demethylating 
agents.  
As mentioned above, demethylating drugs can restore apoptotic 
potential and thereby chemosensitized tumor cells. Therefore, successive 
first-line therapy with DNA demethylating agents followed by a conventional 
second-line therapy could resensitize tumor cells and induce cancer 
regression (Balch, Montgomery et al. 2005). Accordingly, combination of 
DNMTis with other epigenetic drugs such as HDAC inhibitors (HDACi) can 
improve cancer therapy (Altucci, Clarke et al. 2005). HDACi are inducing 
hyperacetylation of lysine residues in the histone tails, leading to chromatin 
decondensation and transcriptional activation. HDACi are categorized 
according to their structure into five categories: short fatty acids (sodium 
butyrate, valproic acid), hydroxamin acid derivate (trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA)), benzamides or cyclic peptides 
(Miller, Witter et al. 2003). In addition, many molecules with a potential 
inhibitory activity against HDACs but a chemical structure different than the 
first five were identified. HDAC inhibition induces diverse cell- and compound-
specific outcomes including inhibition of cell cycle and cell growth, induction of 
differentiation and apoptosis. Due to aberrant histone acetylation patterns in 
cancer, HDACs are novel targets for cancer therapy (Glaser, Staver et al. 
2003; Mitsiades, Mitsiades et al. 2004; Peart, Smyth et al. 2005). For 
example, combination of DAC and TSA acts synergistically in activation of 
PTGS2, hMLH1, TIMP3, CDKN2B and CDKN1C expression in colorectal 
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cancer cell lines (Cameron, Bachman et al. 1999; Suzuki, Gabrielson et al. 
2002). Similarly, the combined treatment leaded to the activation of ESR1 
gene in breast cancer cell lines (Yang, Phillips et al. 2001). 
 
1.7. Glutathione S-transferase P1 
 
As previously described, analysis of the cancer epigenome revealed 
useful diagnostic, prognostic and treatment response biomarkers. DNA 
methylation-mediated epigenetic silencing of the glutathione S-transferase 
(GST) P1 is considered to be a molecular hallmark and diagnostic marker for 
human prostate cancers (Lee, Morton et al. 1994; Lee, Isaacs et al. 1997). 
GST multi-gene superfamily is coding for homo- or heterodimeric 
metabolic enzymes, which represent the major group of multifunctional phase 
II detoxification enzymes. GSTs catalyze the conjugation of the tripeptide 
gamma-glutamyl-cysteinyl-glycine (glutathione, GSH) to genotoxic xenobiotics 
occurring from extracellular environment or intracellular phase I metabolism 
(Figure 12). In consequence, neutralization of the electrophilic site reduces 
genotoxic activity, improves water solubility and favors the cellular export of 
GS-X through ATP-dependent pumps (Eaton and Bammler 1999). This 
biotransformation-mediated detoxification of exogenic and endogenic 
molecules protects cellular macromolecules from damage and guarantees cell 
integrity. 
GS-X!
GSH!
X!
GST!
ADP + Pi 
GS-X!
MRP 
Reactivity ! 
Solubility  " 
ATP 
 
Figure 12: Schematic representation of GST-mediated cellular detoxification.  
GSTs catalyze the neutralization of the electrophilic compound (X) by conjugation 
with glutathione (GSH), reducing the reactivity, improving water solubility and 
promoting compound export by MRP/GS-X pumps in an ATP-dependent manner. 
GST: glutathione S-transferase, ATP: adenosine triphosphate, ADP: adenosine 
diphosphate, Pi: phosphate, MRP: multidrug resistance protein. 
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GSTP1 is the major isoform of the GST multi-gene superfamily and is 
implicated in oxidative stress response, proliferation and chemotoxic 
resistance. In accordance, GSTP1 interacts with c-Jun NH2-terminal kinase 
(JNK) and tumor necrosis factor receptor-associated factor 2 (TRAF2), and 
suppresses the induction of apoptosis (Ruscoe, Rosario et al. 2001; Wu, Fan 
et al. 2006). GSTP1 gene is located on chromosome 11 from position 
67,351,066 to 67,354,123 and is preceded by a high density of CGIs. The 
largest CGi, upstream of the transcription start site, is divided by a long 
ATAAA repetitive stretch (Figure 13). It is assumed that this repetitive element 
acts as an insulator to separate different epigenetic states (Millar, Paul et al. 
2000). GSTP1 transcription is controlled by the transcription factors AP-1, SP-
1 and NF-#B (Figure 13) (Duvoix, Schnekenburger et al. 2004; Morceau, 
Duvoix et al. 2004). Moreover, GSTP1 is a downstream transcriptional target 
of the tumor suppressor p53 (Lo, Stephenson et al. 2008).  
 
 
Figure 13: Organization of GSTP1 gene promoter in human. 
Map of GSTP1 promoter region that is located on chromosome 11. Transcription 
factors and their binding sites as well as untranslated region (UTR) and coding 
sequences (CDS) are indicated related to the transcription start site. NF-"B: nuclear 
factor-"B, SP-1: specificity protein 1, TRE: TPA response element. 
 
GSTP1 is expressed in normal epithelial tissues and cells of the urinary, 
digestive and respiratory tracts, and is increased after exposure to 
carcinogens (Sawaki, Enomoto et al. 1990; Terrier, Townsend et al. 1990; 
Zhang, Sun et al. 2011). In addition, GSTP1 null allele mice have a higher 
mutation risk after carcinogen exposure. This result suggests that even the 
lack of one single GST isoform could increase susceptibility to cancer 
(Ketterer 1998).  
Overexpression of GSTP1 gene may lead to an enhance detoxification 
activity and may protect human cells against cytotoxic drugs. Increased 
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expression of GSTP1 was detected in multiple cancers (e.g. ovary, bladder, 
pancreas, head and neck cancers) (Green, Robertson et al. 1993; Bentz, 
Haines et al. 2000; Trachte, Suthers et al. 2002; Simic, Mimic-Oka et al. 
2005). Consequently, electrophilic cytostatics are inactivated through 
conjugation with GSH or reduction of toxicity by GSH-dependent denitrosation 
(e.g. nitrosocaramide). Moreover, upregulation of GSTP1 peroxidase activity 
leads to enhanced elimination of DNA adducts (e.g. cisplatin) (Goto, Iida et al. 
1999). In contrast, genetic (e.g. deletions, polymorphism) or epigenetic 
alterations (e.g. DNA methylation-mediated silencing) may reduce the 
occurrence, function or activity of GSTP1. Accordingly, detoxification 
efficiency is attenuated leading to an increased sensitivity to environmental 
toxins and to subsequent higher risk for mutations and cancer development 
(Coughlin and Hall 2002; Coughlin and Hall 2002).  
Hypermethylation of the regulatory promoter region near the GSTP1 
gene has been associated with gene silencing in prostate, breast and kidney 
cancers (Dulaimi, Ibanez de Caceres et al. 2004; Hopkins, Burns et al. 2007; 
Lasabova, Tilandyova et al. 2010). GSTP1 hypermethylation is best 
investigated in prostate cancer, including prostatic intraepithelial neoplasia 
(PIN), adenocarcinoma biopsies and body fluids (i.e. plasma, serum, ejaculate 
and urine) of patients, whereas GSTP1 promoter is unmethylated in benign 
prostatic epithelium (Lee, Isaacs et al. 1997; Jeronimo, Usadel et al. 2002; 
Gonzalgo, Nakayama et al. 2004; Hopkins, Burns et al. 2007; Cao and Yao 
2010). GSTP1 silencing by DNA hypermethylation was detected in 90% of all 
prostate tumors and in 70% of the high-grade PIN (Nakayama, Bennett et al. 
2003; Henrique and Jeronimo 2004). Moreover, comparative analysis showed 
lower GSTP1 expression in correlation with hypermethylated promoter region 
in invasive than in non-invasive pituitary tumors, providing predictive 
information about pituitary tumor aggressiveness (Yuan, Qian et al. 2008). 
Interestingly, Lin et al. linked GSTP1 silencing in MCF-7 cells to promoter 
hypermethylation and enrichment of MBDs and DNMT1 in this region (Lin and 
Nelson 2003). Similar analysis of prostate cancer cell lines revealed that 
GSTP1 gene is hypermethylated in expressing LNCaP but hypomethylated in 
non-expressing DU145 cells (Song, Stirzaker et al. 2002). As previously 
shown, DAC treatment of LNCaP cells is associated with GSTP1 
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demethylation and induction of GSTP1 expression (Chiam, Centenera et al. 
2011). In addition, GSTP1 promoter hypermethylation was associated with a 
repressive histone modification pattern in LNCaP cells. The HDAC inhibitor 
depsipeptide reversed GSTP1 epigenetic silencing and induced its expression 
(Stirzaker, Song et al. 2004; Hauptstock, Kuriakose et al. 2011). Studies 
performed with a xenograft model and human prostate cancer LNCaP cells 
showed that hypermethylation and repression of GSTP1 was reversed in vivo 
after treatment with the nucleoside analog procainamide (Cairns, Esteller et 
al. 2001). Alternatively, recent results showed that natural products such as 
green tea polyphenols reactivate GSTP1 expression in prostate cancer cell 
lines (Pandey, Shukla et al. 2010). 
The significance of GSTP1 silencing in prostate cancer is still unclear. 
Nevertheless, heterogeneous distribution of methylation-mediated GSTP1 
repression leads to the assumption that this could be one of the initiating 
events in prostate carcinogenesis. Indeed, since GSTP1 acts as a ‘caretaker’ 
gene, its inactivation reduces cellular detoxification ability and therefore cells 
get more vulnerable to somatic alterations upon exposure to mutagens 
(Meiers, Shanks et al. 2007).  
In conclusion, these data reveal that a balanced and tightly regulated 
expression of GSTP1 is of major importance for cell integrity in order to avoid 
on the one hand drug resistance and on the other hand genetic damages. 
A previous work of the laboratory on the regulation of GSTP1 expression 
in blood cancer cell lines identified GSTP1 positive (e.g. K-562, U-937 and 
JURKAT) and the GSTP1 non-expressing RAJI lymphoma cell line. In 
addition, in vitro methylation of the GSTP1 minimal promoter had a 
transcriptional inhibitory effect. However, in vivo methylation analysis failed to 
correlate GSTP1 promoter methylation and expression (Borde-Chiche, 
Diederich et al. 2001).  
 
1.8. Prostaglandin-endoperoxide synthase 2  
 
In analogy to GSTP1 promoter aberrant methylation, prostaglandin-
endoperoxide synthase (PTGS) 2 represent another hotspot for epimutations 
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in various cancer types (Toyota, Shen et al. 2000; Wang, Guo et al. 2005; 
Meng, Zhu et al. 2010). 
The pro-inflammatory PTGS, also known as cyclooxygenase, genes are 
rate-limiting enzymes, which catalyze the conversion of arachidonic acid into 
the intermediate prostaglandins (PG) H2, from which prostaglandins, 
prostacyclines and thromboxanes are derived. PTGS1 is constitutively 
expressed in many tissues and is responsible for the maintenance of various 
cell physiological functions. In contrast, PTGS2 isoform is an immediate early 
response gene, which is induced by inflammation-related factors, 
proinflammatory cytokines, growth factors as well as mitogenic and tumor 
promoting agents (Toyota, Shen et al. 2000; Ma, Yang et al. 2004; Wun, 
McKnight et al. 2004).  
PTGS2 gene is located on chromosome 1 from position 186,640,945 to 
186,649,559 and its expression is regulated by a number of regulatory 
elements presented in Figure 14. 
 
COX-2-derived prostanoids may also play a critical
role in maintaining renal medullary blood supply, re-
nal salt excretion, and systemic blood pressure. COX-
2-rich medullary interstitial cells span the area be-
tween the vasa rectae and medullary tubules,
including thick limbs (54). Cultured medullary inter-
stitial cells produce abundant PGE2 (29), which has
been shown to directly dilate vasa rectae, counteract-
ing the constrictor effect of angiotensin and endothelin
and thereby helping to maintain renal medullary blood
flow (84). Measurements of medullary blood flow in
intact renal papilla show that prostaglandins play an
important role in maintaining the medullary blood
supply, particularly in the setting of volume depletion
(75). Recent studies in mice suggest that SC-58236, a
COX-2-selective NSAID, significantly reduced renal
medullary blood flow, whereas SC-58560, a COX-1-
selective NSAID, had no acute effect (73).
Regulation of renal medullary blood flow has signif-
icant implications for regulating salt excretion and
systemic blood pressure (13, 14). Reduced medullary
interstitial pressure increases renal salt absorption
(14). Medullary interstitial prostaglandins may modu-
late epithelial solute and water reabsorption not only
via hemodynamic effects but also through direct effects
on epithelial sodium absorption by the thick ascending
limb and collecting duct (6). Loss of the tonic inhibitory
effect of COX-2-derived PGE2 on salt absorption by
these segments may contribute to sodium retention
seen with NSAIDs (5). Taken together, these data
suggest that COX-2 inhibition in the renal medulla
might not only enhance salt retention but also compro-
mise medullary blood flow, risking hypoxic injury to
the cellular elements in the renal medulla as well as
directly risking medullary interstitial cell viability.
Long-term use of COX-inhibiting NSAIDs has been
associated with papillary necrosis and progressive re-
nal structural and functional deterioration (2, 82).
NSAID-induced renal damage is more likely to occur in
the setting of dehydration, suggesting a critical depen-
dence of renal function on COX metabolism in this
condition (79). Increased COX-2 expression after dehy-
dration is consistent with this finding. Interestingly, in
the present experiments, only patches of apoptotic
medullary interstitial cells were seen after COX-2 in-
hibition and water deprivation, and papillary necrosis
was not detected. This result, which is consistent with
an earlier report that renal medullary interstitial cells
are an early target of injury in analgesic nephropathy
(66), also suggests that repeated injury to these cells
may be required for development of analgesic nephrop-
athy. Other roles for medullary interstitial cell COX-2-
derived prostanoids may relate to maintenance of med-
ullary blood flow. Taken together, increased COX-2
Fig. 4. Transcriptional regulation of
COX-2. A: multiple response elements
in the COX-2 promoter region. AP-2,
activator protein-2; CRE, cAMP-re-
sponsive element; NF, nuclear factor;
IL-6, interleukin-6; MEF-2, myocyte-
enhancer factor. B: activation of COX-2
expression by several of the response
elements in response to growth factors,
cytokines, serum, and hypertonicity.
Activation of COX-2 expression by hy-
pertonicity has been shown to involve
nuclear factor (NF) B, c-Jun-NH2-ter-
minal kinase (JNK), and mitogen-acti-
vated protein or extracellular signal-
regulated kinase (ERK; MEK1). In this
sense COX-2 expression may be con-
sidered another osmotic response gene,
responding to stimuli similar to the
betaine transporter (BGT1) and aldose
reductase (left). SAPK, stress-acti-
vated kinase; SEK, SAPK/ERK kinase;
MEK, mitogens-activated protein
(MAP) or ERK kinase.
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Figure 14: Configuration of PTGS2 promoter. 
Multiple response elements are involved in the transcriptional regulation of PTGS2 
expression. AP-2: activator protein-2, CRE: cAMP-responsive element, IL-6: 
interleukin-6, MEF-2: myocyte-enhancer factor, NF-"B: nuclear factor-"B, SP1: 
specificity protein 1 (Harris and Breyer 2001). 
 
PTGS2 promoter include basal elements such as a TATA-box as well as 
binding domains for specific transcription factors including cAMP response 
element binding (CREB), NF-"B and SP1 (Harris and Breyer 2001). The 
precise mechanism of PTGS2 regulation remains unclear. Nevertheless, it is 
known that PTGS2 is a K-RAS target gene, which can induce PTGS2 
  Introduction 
 45 
transcription or mRNA stabilization by mitogen-activated protein kinase 
pathways (i.e. MEKK/SEK/JNK, Raf/MEK/ERK or PI3-K/Akt/PKB) (Sheng, 
Shao et al. 2001). Moreover, PTGS2 expression is upregulated by the 
transcription factor encoding the proto-oncogene c-MYB, whereas p53 acts as 
a PTGS2 repressor (Subbaramaiah, Altorki et al. 1999; Ramsay, Friend et al. 
2000). 
It is generally accepted that PTGS2 is often overexpressed in breast, 
gastric, colorectal, lung, liver and prostate cancer cells (Eberhart, Coffey et al. 
1994; Liu and Rose 1996; Ristimaki, Honkanen et al. 1997; Liu, Yao et al. 
1998; Wolff, Saukkonen et al. 1998). Apparently, PTGS2 overexpression 
progresses with gastric and urinary bladder carcinogenesis, inducing the 
constitutive synthesis of PGE2 and activation of APC/#-catenin/Wnt signaling 
pathway (Wadhwa, Goswami et al. 2005). #-catenin in complex with 
transcription factors leads to the expression of metalloproteinases (MMPs) 
and vascular growth factors (VEGFs) (Figure 15) (Ben-Av, Crofford et al. 
1995; Cheng, Cao et al. 1998).  
 
Proteasomal 
degradation 
PTGS2 
PTGS2 
PTGS2 
 
Figure 15: Implication of PTGS2/PGE2 signaling in the hallmarks of cancer. 
Overexpression of PTGS2 leads to PGE2 oversynthesis inducing the expression of 
genes regulating cell survival, angiogenesis, cell proliferation and apoptosis through 
activation of Wnt and Ras/Raf signaling pathways (modified from May, O 
(http://www.caymanchem.com/app/template/Article.vm/article/2136)).  
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Activation of these genes induces proteolysis of extracellular matrix and 
promotes angiogenesis, which in turn favors the transition from limited tumor 
growth to invasion and metastasis (Price, Bonovich et al. 1997; John and 
Tuszynski 2001). Furthermore, high intrinsic PTGS2 expression constitutively 
activates the survival gene BCL2 through the Ras/Raf signaling pathway and 
inhibits apoptosis (Tsujii and DuBois 1995; Tsujii, Kawano et al. 1997; Murata, 
Tsuji et al. 2004) (Figure 15). Moreover, PTGS2 overexpression and 
enhanced prostaglandin production are associated with aggressive breast 
cancer subtypes (Rolland, Martin et al. 1980; Parrett, Harris et al. 1997; 
Ristimaki, Sivula et al. 2002). Accordingly, inhibition of PTGS2 by nonsteroidal 
anti-inflammatory drugs or specific inhibitors causes cell death in cancer cells 
(Sheng, Shao et al. 1998; Elder, Halton et al. 2000). These results suggest 
that PTGS2 overexpression attenuates the apoptosis potential of 
premalignant cells and leads to their protection against cell death. In 
consequence, prolonged cell survival will lead to the accumulation of multiple 
genetic mutations, resulting ultimately in a transformed phenotype with 
continuous cell growth. 
Paradoxically, ectopic PTGS2 overexpression seems to avoid 
chemically induced skin cancer in a transgenetic mouse model, confirming a 
preventive role of PTGS2 in carcinogenesis (Bol, Rowley et al. 2002). 
Moreover, PTGS2 overexpression was reported to induce cell cycle arrest 
and cell growth inhibition in various cancer and vascular epithelial cells 
(DuBois, Shao et al. 1996; Trifan, Smith et al. 1999). Finally, in adenomatous 
polyposis coli (APC) knockout mice, lack of PTGS2 expression resulted in the 
decrease of neoplastic growth and number of tumors (Oshima, Dinchuk et al. 
1996). Nevertheless, loss of PTGS2 expression blocks inflammatory response 
and thus compromise cellular integrity.  
In analogy to GSTP1 gene, a tightly regulated expression of PTGS2 is of 
major importance to avoid cancer development. Surprisingly, a short-term 
PTGS2 overexpression may suppress cell progression, whereas a long-term 
overexpression contributes to tumor growth, invasion and metastasis 
(Fosslien 2001; Murata, Tsuji et al. 2004). Accordingly, regulation of PTGS2 
expression as well as the consequences of abnormal expression should be 
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explored deeper in order to better understand the mechanisms of cancer 
development. 
Toyota et al. first proposed that dense PTGS2 promoter methylation is 
associated with transcriptional silencing in colorectal cancer (Toyota, Shen et 
al. 2000). Publications about human tumors of esophageal and gastric origin 
further evinced a strong correlation between PTGS2 inactivation and promoter 
hypermethylation. Moreover, treatments with demethylating agents such as 
DAC restored PTGS2 expression in various cancer cell lines (Toyota, Shen et 
al. 2000; Wang, Guo et al. 2005; Meng, Zhu et al. 2010). Taking together, 
these data suggest that PTGS2 promoter region is a target for DNA 
hypermethylation-mediated transcriptional silencing in cancer cells.  
Regarding hematological malignancies, it was shown that CML and CLL 
as well as lymphoma were shown to be constitutively overexpressed PTGS2 
(Ladetto, Vallet et al. 2005; Ohsawa, Fukushima et al. 2006; Ryan, Pollock et 
al. 2006). Nevertheless, Hazar et al. reported in 2004 that only 24 out of 42 
non-Hodgkin lymphoma patients as well as 7 out of 10 Hodgkin lymphoma 
patients expressed PTGS2 (Hazar, Ergin et al. 2004). However, the possibility 
that aberrant cancer-related DNA hypermethylation may be involved in 
PTGS2 repression in hematological malignant cells was never evaluated.  
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2. Hypothesis and aim of this thesis 
 
 Epigenetic alterations such as DNA methylation of CpG islands, which 
leads to gene silencing, play important roles in carcinogenesis. It is now 
established that methylation of genes or methylation patterns of groups of 
genes are tumor-specific. Therefore, DNA methylation signatures can be used 
as diagnosis biomarkers to detect cancer cells, and was found to be 
associated with responses to chemotherapeutics and prognosis. In contrast to 
DNA mutations, which are passively inherited through DNA replication, 
epimutations must be actively maintained because they are reversible, 
allowing therapeutic intervention with DNA demethylating/hypomethylating 
agents.  
In the past years, it clearly appeared that during the development of 
hematological malignancies, genes that suppress growth and induce 
differentiation could be silenced by aberrant DNA methylation. Significant 
advances have been made in the elucidation of these processes as well as in 
translating this knowledge to the clinic, as in the development of new 
prognostic biomarkers or targeted therapies. Among drugs inducing DNA 
demethylation, the cytosine nucleoside analogue 5-aza-2'-deoxycytidine is 
commonly used in clinical trials for various leukemia and promotes tumor cell 
death.  
Nevertheless, the potential of DNA methylomic regarding either disease-
specific biomarker discovery or for DNA demethylation-based therapeutic 
intervention in hematological malignancies still require attention. Hence, our 
general working hypothesis is that before we are able to properly target DNA 
methylation in cancer therapy against hematological malignancies, a better 
understanding of DNA methylation patterns tightly correlated with chromatin 
structure as well as of the effect of 5-aza-2'-deoxycytidine are required to 
improve targeted therapy. 
 Despite clinical observations involving GSTP1 and PTGS2 in 
carcinogenesis, mechanisms regulating their expression are not completely 
elucidated. Although both genes are commonly silenced by promoter 
hypermethylation in various cancers, molecular mechanisms leading to their 
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silencing by DNA hypermethylation in hematopoietic malignancies and its 
relationship with pathological alterations of the chromatin structure (i.e. 
histone modifications and co-repressor/co-activator complexes) remain poorly 
understood. Furthermore, it remains to evaluate, if the aberrant methylation of 
GSTP1 and PTGS2 gene promoters is characteristic for blood cancer 
patients.  
 Thus, the aim of our work is to gain further insight into GSTP1 and 
PTGS2 epigenetic regulation in hematological malignancies and to compare 
their implication to other already identified DNA methylation cancer 
biomarkers as well as the impact of 5-aza-2'-deoxycytidine at gene-specific, 
genome-wide and cellular levels. 
 
 In our attempt to reach these aims we will investigate the following 
points: 
 
1. First, we will investigate the epigenetic regulation of the expression of 
GSTP1 and PTGS2 genes in blood cancer cells presenting various gene 
expression levels, and evaluate the involvement of GSTP1 and PTGS2 
promoter hypermethylation in patients with malignant hemopathies. 
 
2. In a next step, we propose to extend our study regarding DNA 
methylation biomarkers in hematological malignancies by comparing the 
results obtained regarding PTGS2 and GSTP1 genes to other tumor 
suppressor genes found frequently methylated in cancer.  
 
3. Finally, we will investigate the effects induced by the DNA 
demethylating agent 5-aza-2'-deoxycytidine in leukemia and lymphoma cell 
lines on (i) cell proliferation and survival, (ii) local and global DNA 
demethylation, and (iii) the relationship between 5-aza-2'-deoxycytidine-
induced DNA demethylation and cell proliferation.  
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3. Material 
3.1. Chemicals 
Table 2: List of chemical products and their suppliers. 
Chemical Supplier 
Acetone Merck, Darmstadt, Germany 
30% Acrylamide Mix/Bis solution (37.5:1) Bio Rad, Nazareth Eke, Belgium 
Agar MP biomedicals LLC, Illkirch, 
France 
Agarose Promega, Madison, USA 
A/G agarose bead (50% slurry) Upstate, Millipore, Brussels, 
Belgium 
Ampicillin Sigma, St Louis, USA 
Ammonium persulfate (APS) MP biomedicals LLC 
Ultradistilled water (ddH20) Millipore, Brussels, Belgium 
Distilled water (dH20) Millipore 
Bovine serum albumin (BSA) MP biomedicals LLC 
Boric acid (H3BO3) MP biomedicals LLC 
5-Brom-4-Chloro-3-indoyl-beta-D-
galactopyranosid (X-Gal) 
Sigma 
Bromphenol blue LKB, Bromma, Sweden 
Protease inhibitor cocktail (Complete+/-
EDTA) 
Roche, Prophac, Howald, 
Luxembourg 
Carboxyfluorescein diacetate (CFSE) Invitrogen, Carlsbad, USA 
Chloroform Sigma 
5-aza-2'-deoxycytidine (DAC) Sigma 
Deoxycholic acid Sigma-Aldrich, Bornem, Belgium 
Deoxyribonucleoside triphosphate (dNTP) Invitrogen 
Diethylpyrocarbonate (DEPC) Acros, Geel, Belgium 
Dimethyl sulfoxide (DMSO) Sigma 
Di-sodium hydrogen orthophosphate 
(Na2HPO4) 
MP biomedicals LLC 
Dithiothreitol (DTT) Roche 
Ethanol (EtOH) VWR, Darmstadt, Germany 
Ethidium bromide (EtBr) Promega 
Ethylene diamine tetra acetic acid (EDTA) MP biomedicals LLC 
Ethylene glycol tetra acetic acid (EGTA) MP biomedicals LLC 
Ficoll-Paque PREMIUM GE Healthcare, Fischer Scientific, 
Tournai, Belgium 
Formaldehyde MP biomedicals LLC 
Glycerol (C3H5(OH)3) VWR 
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Chemical Supplier 
Glycine (C2H5NO2) MP biomedicals LLC 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
MP biomedicals LLC 
Hydrogen chloride (HCl) VWR 
(±)-6-Hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid 
Sigma-Aldrich 
Hoechst 33342 Calbiochem, Darmstadt, Germany 
IGEPAL MP biomedicals LLC 
Isopropanol (2-propanol, C3H7OH) VWR 
Isopropyl-beta-D-thio-galacto-pyranosid 
(IPTG) 
Invitrogen 
Lithium cloride (LiCl) Sigma-Aldrich 
Magnesium chloride (MgCl2) MP biomedicals LLC 
Magnesium sulfate (MgSO4) MP biomedicals LLC 
$-Mercaptoethanol (C2H6OS) Merck, Darmstadt, Germany 
Methanol (MeOH) VWR 
Monopotassium phosphate (KH2PO4) VWR 
Paraformaldehyde Merck 
Phenylmethylsulfonylfluorid (PMSF) Roche 
Piperazine-1,4-bis(2-ethanesulfonic acid) 
(PIPES) 
Sigma-Aldrich 
Potassium chloride (KCl) MP biomedicals LLC 
Potassium diphosphate (K4O7P2) VWR 
Potassium hydroxide (KOH) Merck 
Protein Assay Bradford solution Bio Rad 
Propidium iodide (PI) Sigma-Aldrich 
Salmon sperm DNA Upstate 
Suberoylanilide hydroxamic acid (SAHA) Cayman, Michigan, USA 
Sodium acetate (C2H3NaO2) VWR 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich 
Sodium butyrate Sigma-Aldrich 
Sodium chloride (NaCl) VWR 
Sodium dihydrogen orthophosphate 
(NaH2PO4) 
ICN, Eschwege, Germany 
Sodium disulfite Merck 
Sodium dodecyl sulfate (SDS) MP biomedicals LLC 
Sodium hydroxide (NaOH) MP biomedicals LLC 
Sodium phosphate monobasic anhydrous 
(NaH2PO4) 
ICN 
Sulfuric Acid (H2SO4) Merck 
N,N,N',N'-Tetramethylethylendiamin 
(TEMED) 
MP biomedicals LLC 
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Chemical Supplier 
Tris MP biomedicals LLC 
Triton-X100 Merck 
Trypan blue Lonza, Basel, Switzerland 
Tween® 20 Sigma 
Valproic acid (VPA) Sigma-Aldrich 
Xylene cyanol ICN 
 
3.2. Buffers and solutions 
3.2.1. General buffers 
Table 3: Common buffers and solutions. 
Name Composition 
10X Phosphate buffered saline 
buffer (PBS) 
80mM Na2HPO4, 20mM NaH2PO4, 100mM 
NaCl adjust pH at 5.7 
Autoclaved for cell culture use  
1X Phosphate buffered saline / 
Tween buffer (PBS-T) 
1X PBS, 0.1% (v/v) Tween® 20  
Tris/EDTA buffer (TE) 10mM Tris-HCl (pH 7.5), 1mM EDTA  
MACS buffer 1X PBS (pH 7.2), 0.5% BSA, 2mM EDTA 
 
3.2.2. Gel electrophoresis 
Table 4: Gel electrophoretic migration of DNA molecules. 
Name Composition 
10X Tris/Borate/EDTA Buffer (TBE) 89mM Tris, 89mM Boric acid and 2mM 
EDTA 
6X Blue/Orange Loading Dye 0.4% Orange G, 0.03% Bromophenol blue, 
0.03% Xylene cyanol FF, 15% Ficoll® 400, 
10mM Tris-HCl and 50mM EDTA  
0.8 to 1.2% TBE-agarose gel  0.8 to 1.2% agarose, 1X TBE buffer  
12% Polyacrylamide gel 12% Acryl/Bisacryl (37.5:1), 1X TBE 
buffer, 0.1% APS, 0.05% TEMED 
 
3.2.3. Western Blot 
Table 5: Buffers and solutions used for the Western Blot. 
Name Composition 
8 to 12% Separation 
gel  
8 to 12% Acryl/Bisacryl (37.5:1), 0.373M Tris-HCL 
(pH8.8), 0.1% SDS, 0.1% APS, 0.05% TEMED 
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Name Composition 
4% Stacking gel  4% Acryl/Bisacryl (37.5:1), 0.125M Tris-HCL (pH6.8), 
0.1% SDS, 0.1% APS, 0.05%TEMED 
Electrophoresis buffer 25mM Tris, 2M Glycine, 35mM SDS  
Transfer buffer I 25mM Tris, 0.2M Glycine, 5% (v/v) Methanol  
Transfer buffer II 25mM Tris, 0.2M Glycine, 5% (v/v) Methanol, 0.1% 
SDS 
2X Loading buffer 0.125M Tris-HCL (pH 6.8), 20% (v/v) Glycerol 100%, 
4% (v/v) SDS 10%, 0.005%(p/v) Bromphenol blue, 5% 
(v/v) $-Mercaptoethanol 
 
3.2.4. Nuclear extraction 
Table 6: Buffers used for the extraction of nuclear factors. 
Name Composition 
Buffer A 10mM Hepes (pH 7.9), 10mM KCl, 0.1mM EDTA (pH 8.0), 
0.1mM EGTA, 1mM DTT, 0.5mM PMSF, 1X protease 
inhibitor cocktail (Complete® plus EDTA) 
Buffer C 10mM Hepes (pH 7.9), 10mM NaCl, 0.1mM EDTA (pH 8.0), 
0.1mM EGTA, 1mM DTT, 0.5mM PMSF, 20% Glycerol, 1X 
protease inhibitor cocktail (Complete® plus EDTA) 
 
3.2.5. Acid extraction 
Table 7: Buffer used for histone isolation. 
Name Composition 
Hypotonic lysis buffer 10mM Tris-HCl (pH 8.0), 1mM KCl, 1.5mM MgCL2, 
1mM DTT, 10mM Sodium butyrate, 1X protease 
inhibitor cocktail 
 
3.2.6. Cross-linking chromatin immunoprecipitation 
Table 8: Buffers used for cross-linking chromatin immunoprecipitation (X-ChIP). 
Name Composition 
Cell lysis buffer 5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% IGEPAL 
Nuclei lysis buffer 50 mM Tris-HCl (pH 8.1), 10 mM EDTA, 1% SDS, 1X 
protease inhibitor cocktail 
IP dilution buffer 0.01% SDS, 0.5% Triton X-100, 2 mM EDTA, 16.7 
mM Tris-HCl (pH 8.1), 100 mM NaCl, 1 X protease 
inhibitor cocktail 
Low salt buffer 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl (pH 8.1), 150 mM NaCl and 1X protease 
inhibitor cocktail 
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Name Composition 
High salt buffer 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl (pH 8.1), 500 mM NaCl and 1X protease 
inhibitor cocktail 
LiCL buffer 1 mM EDTA, 10 mM Tris-HCl (pH 8.1), 250 mM LiCl, 
1 % Igepal, 1% deoxycholic acid and 1X protease 
inhibitor cocktail 
Tris-EDTA buffer 1 mM EDTA (pH 8.0) and 20 mM Tris-HCl (pH 8.1) 
Elution buffer 100 mM NaHCO3 and 1% SDS 
 
3.3. Kits 
3.3.1. Extraction/Purification 
Table 9: Kits for the extraction and purification of PCR products, DNA, RNA and 
proteins. 
Designation Supplier Application 
DNeasy Blood and Tissue Kit Qiagen, Venlo, 
Netherlands 
Genomic DNA extraction 
QIAamp DNA Micro Kit Qiagen Genomic DNA extraction 
AllPrep DNA/RNA Micro Kit Qiagen DNA/RNA extraction 
AllPrep DNA/RNA Mini Kit Qiagen DNA/RNA extraction 
NucleoSpin RNAII Kit Macherey-Nagel mRNA extraction 
miRNeasy Mini Kit Qiagen Total RNA extraction 
M-Per® Mammalian protein 
extraction reagent  
Thermo scientific, 
Waltham, USA 
Protein extraction reagent 
QIAquick PCR purification Kit, 
QIAEX II gel extraction Kit 
Qiagen PCR product and DNA 
purification 
AveGene Gel PCR DNA 
fragments Extraction Kit 
AveGene, Taipei, 
Taiwan 
PCR product purification 
and Gel extraction  
 
3.3.2. Bisulfite conversion 
Epitect® Bisulfite Kit (Qiagen) was used for bisulfite conversion of genomic 
DNA. Alternatively, for deep sequencing analyses, genomic DNA was 
conversed by the bisulfite conversion protocol 4.6.14 with the following 
solutions (Table 10). 
Table 10: Solutions used for bisulfite conversion of genomic DNA for deep 
sequencing analysis on the GS FLX-platform. 
Name Composition 
Conversion solution 2M NaOH 
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Name Composition 
Scavenger solution 0.39mM (±)-6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid in 1,4-
dioxane 
Desulphonation solution 0.3M NaOH  
 
3.3.3. Microfluidic Lab-on-a-Chip application 
Table 11: DNA and RNA capillary electrophoresis  
Name Supplier Application 
Agilent RNA 6000 Kit Agilent Technologies, Santa 
Clara, USA 
RNA Quality control 
Agilent DNA 1000 Kit Agilent Technologies CoBRA analysis 
Bio-CoBRA: Combined bisulfite restriction assay. 
 
3.3.4. DNA quantification 
Double-stranded PCR products were quantified with the Qubit® dsDNA 
HS assay Kit (Invitrogen). 
 
3.3.5. Western Blot 
Table 12: Immunodetection of blotted proteins. 
Designation Supplier Application 
ECL Plus Western Blotting 
Detection System 
Amersham Bioscience, 
Vienna, Austria 
Horse radish peroxidase 
immunodetection (Western 
Blot) 
 
3.3.6. Purification and separation of blood cells 
Separation of peripheral blood mononuclear cells by density gradient 
centrifugation was done on Ficoll-paque premium (GE Healthcare, Fisher 
Scientific, Illkirch Cedex, France). CD34 Microbead Kit (Miltenyi Biotec, 
Auburn, USA) was used for the separation of CD34+ cells from umbilical cord 
blood. 
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3.3.7. Analysis of GST activity 
GST activity was detected by the GST Fluorometric Activity Assay Kit 
(Biovision, Mountain View, USA). 
 
3.3.8. Analysis of cell proliferation 
Cell proliferation was assessed with the CellTrace™ CFSE Cell 
Proliferation Kit (Invitrogen). 
 
3.4. Media 
3.4.1. Mammalian cell culture 
Table 13: Medium and additives to culture mammalian suspension cells. 
Component Supplier 
Roswell Park Memorial Institute (RPMI-1640) Lonza 
Iscove's Modified Dulbecco's Medium (IMDM) Lonza 
Fetal bovine serum (FBS) Lonza 
Penicillin, Streptomycin, Amphotericin B Lonza 
Granulocyte macrophage colony-stimulating factor 
(GM-CSF) 
Relia Tech, Wolfenbüttel, 
Germany 
 
3.4.2. Bacterial culture 
Table 14: Medium and their additives used in bacterial culture. 
Component Supplier 
Luria-Beltani (LB) broth, Miller MP Biomedicals LLC 
Super optimal broth medium with catabolite 
repression (SOC) 
Invitrogen 
LB-Agar Miller  MP Biomedicals LLC 
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3.5. Cells 
3.5.1. Mammalian cell lines 
Table 15: Mammalian cell lines used in cell culture  
All cell lines were provided by the Deutsche Sammlung für Mikroorganismem und Zell 
linien (DSMZ, Braunschweig, Germany). 
Name Morphology Disease (Diagnosis) 
HEL Erythroblast AML 
HL-60 Lymphoblast-like AML 
JURKAT T-lymphoblast ALL 
JVM-2 Lymphoblast CLL 
K-562 Lymphoblast CML 
KBM-5 Blast-like CML 
KG-1 Myeloblast AML 
KG-1A Myeloblast AML 
MEG-01 Megakaryoblast CML 
MOLT-3 T-lymphoblast ALL 
RAJI B-lymphoblast Burkitt’s lymphoma 
TF-1 Lymphoblast AML 
THP-1 Monocyte AML 
U-937 Lymphoblast Histiocytic lymphoma 
AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, CML: chronic myelogenous 
leukemia, CLL: chronic lymphocytic leukemia. 
 
3.5.2. Prokaryotic cells 
Table 16: Bacterial cell clones and their suppliers. 
Name Supplier 
Escherichia coli JM109 Promega 
Escherichia coli TOP10 Invitrogen 
 
3.5.3. Patient samples 
Diffuse large B-cell, mantle cell, follicular and Burkitt’s lymphoma patient 
samples as well as chronic lymphocytic and myeloid leukemia, acute 
lymphoblastic and myeloid leukemia and myelodysplastic syndrome patient 
samples were provided in an anonymized form by the “Biothèque de 
l’Université de Liège” (Belgium), “Centre Hospitalier Universitaire de Nancy” 
(France), “Institut Paoli-Calmettes” (Marseille, France) and “Centre Hospitalier 
Luxembourg”. Blood cells from supposed healthy donors were provided by the 
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Red Cross Luxembourg. Cord blood was obtained from the “Clinique privée Dr. 
E. Bohler” (Luxembourg). Informed consent was obtained from patients. 
Detailed patient information is annexed. 
 
3.6. Enzymes 
3.6.1. Endonucleases 
Table 17: Endonucleases used for restriction assays. 
Name Buffer Supplier mCpG sensitivity 
BglII 10X Buffer D 
100X BSA 
Promega No 
HpaII 10X NEBuffer 1 NEB, Ipswich, USA Yes 
MspI 10X NEBuffer 4 NEB No 
RsaI 10X Buffer C 
100X BSA 
Promega No 
temp.: temperature, mCpG: methylated CpG. 
 
3.6.2. Polymerases 
3.6.2.1  DNA-specific DNA polymerases 
Table 18: DNA-specific DNA polymerases used for various PCR applications. 
Name Buffer Supplier Application 
GoTaq 
polymerase 
5X Colorless 
GoTaq® Flexi 
Buffer 
Promega Colony PCR 
Hot Fire Pol 10X Buffer B Solis BioDyne, 
Tartu, Estonia 
Bisulfite deep sequencing 
Hot Start Taq 10X PCR 
Buffer 
Qiagen BSP, Bio-CoBRA, MSP, 
Bisulfite deep sequencing 
Platinum Taq 10X PCR 
Buffer 
Invitrogen Bisulfite deep sequencing 
Platinum Taq 
high fidelity 
10X High 
Fidelity PCR 
Buffer 
Invitrogen MSP 
Power SYBR® 
Green PCR 
Master Mix 
n.a. ABI, Foster City, 
USA 
Real-time PCR 
n.a.: information not available 
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3.6.2.2 RNA-specific DNA polymerases 
Table 19: RNA-specific DNA polymerases used for expression analysis. 
Name Buffer Supplier Application 
Superscript RT 5X RT buffer  Invitrogen Reverse transcription of 
mRNA 
miScript Reverse 
Transcriptase mix 
5X miScript 
RT Buffer 
Qiagen Polyadenylation and 
reverse transcription of 
total RNA 
 
3.6.3. Other enzymes and proteins 
Table 20: Nucleases, proteases and proteins.  
Name Supplier Application 
DNase Machery-Nagel1, Düren, 
Germany, Qiagen2 
Nucleospin1, 
miRNeasy2 
Hot Start binding 
protein 
USB, Affimetrix, Santa Clara, 
USA  
BSP for deep 
sequencing 
Proteinase K Qiagen3, Roche4 DNeasy blood and 
tissue Kit3, X-ChIP4 
RNase Roche DNeasy blood and 
tissue Kit 
 
3.7. Oligonucleotides 
Table 21: Oligonucleotides used for BSP and Bio-CoBRA analysis. 
All primers were synthetized by Eurogentec (Seraine, Belgium). * PCR was done with 
35 repetitive cycles. 
Target Sequence (5’ to 3’) Annealing 
temp. (°C) 
Amplicon 
length (bp) 
GSTP1 F: GGAAAGAGGGAAAGGTTTTTT 55 * 292 
R: ACTCTAAACCCCATCCCC 
LacZ F: GGCTCGTATGTTGTGTGGAAT 65  592 
R: GTGCTGCAAGGCGATTAAGT 
temp.: temperature. 
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Table 22: Oligonucleotides used for MSP assays. 
All primers were synthetized by Eurogentec. Unless otherwise indicated, PCRs were 
done with Platinum Taq HIFI. Alternatively, $ Hot Start Taq was used for MSP analysis. 
Unless otherwise indicated, MSPs were done with 36 repetitive cycles. Alternatively, * 
32, **40, ***42 or **** 43 repetitive cycles were done for MSP analysis. Unmethylated 
(UM) and methylated (M) behind the gene name indicate the primer specificity. 
Sequences of MGMT, CASP8, TP73 and CDKN2A (p16), RASSF1A MSP primers were 
described by (Esteller, Hamilton et al. 1999), (Hopkins-Donaldson, Ziegler et al. 2003), 
(Siu, Chan et al. 2002), (Siu, Chan et al. 2002) and (Schagdarsurengin, Gimm et al. 
2002), respectively. 
Target Sequence (5’ to 3’) Annealing 
temp. (°C) 
Amplicon 
length (bp)  
AHR-UM F: GGGGATTTGGTTGTTAGTGTTT 63 116 
R: ACATTTTCTACACCAACTTCCA 
AHR-M F: GGATTCGGTCGTTAGTGTTC 63 116 
R: GTTTTCTACACCGACTTCCG 
APAF-1-UM F: GGTGGGATTTGATTGTTTT 57 143 
R: CTACAACACCTCAAATCTTCA 
APAF-1-M F: GCGGGATTTGATTGTTTC 57 143 
R: TACGACACCTCAAATCTTCG 
APC-UM F: TTTTGTGTTTTATTGTGGAGTGT 63 101 
R: ACAAACTCCCAACAAAAATAAA 
APC-M F: TGTGTTTTATTGCGGAGTGC 63 101 
R: CGAACTCCCGACGAAAATA 
BCL2-UM F: TTTTTAATTCGGGTTAGGGAGC 64.5 * 129 
R: CTCTACACAACCCGACCGAT 
BCL2-M F: GTTTTTAATTTGGGTTAGGGAGT 64.5 * 129 
R: TCTCTACACAACCCAACCAAT 
BCL-XL-UM F: TGTTGATTTTTTGTGTTTTTT 60 138 
R: ACTCAATCACTTCCAATACCA 
BCL-XL-M F: TGATTTTTTGCGTTTTTC 56.5 ** 138 
R: CAATCACTTCCGATACCG 
CALCA-UM F: GGGAATAAGAGTAGTTGTTGGT 63 149 
R: CTCAAAACTCACCTAACAAAA 
CALCA-M F: GGAATAAGAGTAGTCGTTGGC 64 149 
R: TCGAAACTCACCTAACGAAA 
CASP7-UM F: GTTTTTTAGGGATTATGTGTGT  60 142 
R: AAAATCTCAACACTACAAAAAA  
CASP7-M F: TTTTTAGGGATTATGCGTGC 63 142 
R: AAAATCTCGACGCTACGAAA 
CASP8-UM F: TAGGGGATTTGGAGATTGTGA  59 322 
R: CCATATATCTACATTCAAAACAA  
CASP8-M F: TAGGGGATTCGGAGATTGCGA  64 322 
R: CGTATATCTACATTCGAAACGA  
CDH1-UM F: TTTAGGTTTTAGTGAGTTATTGGT 62 117 
R: TAAACACAATAACCCTCTAACC 
CDH1-M F: TAGGTTTTAGTGAGTTATCGGC 64 117 
R: TAAACGCGATAACCCTCTAA 
CDKN2A (p14)-UM F: AGGTAGATTGTAGGTTTTGGGTT 62 133 
R: AAACAAAACTCAACTCTCATCCA 
CDKN2A (p14)-M F: TAGATCGTAGGTTTCGGGTC 62 133 
R: AAACGAAACTCGACTCTCGT 
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Target Sequence (5’ to 3’) Annealing 
temp. (°C) 
Amplicon 
length (bp)  
CDKN2A(p16)-UM F: TTATTAGAGGGTGGGGTGGATTGT  58 111 
R: CAACCCCAAACCACAACCATAA  
CDKN2A (p16)-M F: TTATTAGAGGGTGGGGCGGATCGC  63 111 
R: GACCCCGAACCGCGACCGTAA  
CDKN2B (p15)-UM F: GGGGTAGTGAGGATTTTGTGAT 62 143 
R: AATCATTAACTCCAAACTTTTCC 
CDKN2B (p15)-M F: GTAGTGAGGATTTCGCGAC 62 143 
R: CGTTAACTCCGAACTTTTCC 
DAPK1-UM F: TAAGGAGTTGAGAGGTTGTTTT 62 110 
R: AAACCCTACCACTACAAATTA 
DAPK1-M F: AAGGAGTCGAGAGGTTGTTTC 62 110 
R: AACCCTACCGCTACGAATTA 
ESR1-UM F: TTGTGGTTGGTTGTGTATGTAATT 65 169 
R: TACCCCATACCAAACTCCAATAT 
ESR1-M F: TGGTTGGTTGCGTATGTAATC 64 169 
R: CCCGTACCAAACTCCGATAT 
GSTP1 MGD-U F: GTGAAGTGGGTGTGTAAGTTTT 60 106 
R: ACAAAAAAAAAACCACAACAAA 
GSTP1 MGD-M F: AAGCGGGTGTGTAAGTTTC 62 106 
R: CAAAAAAAAAACCGCAACG 
GSTP1 MGP-U F: GTGGGATTTTTTAGAAGAGT 58.9 140 
R: CACATACTCACTAATACCAAA 
GSTP1 MGP-M F: CGGGATTTTTTAGAAGAGC 63 140 
R: CGCGTACTCACTAATAACGA 
HIC-UM F: GGGATAGTTTGGTTTTTGTGT 58 $ ** 111 
R: AAATCCAAAAAAAACAACACC 
HIC-M F: GGATAGTTCGGTTTTCGTGC 60 $ 111 
R: AATCCGAAAAAAACGACACC 
LINE1-UM F: GTGATGGATGTATTTGGAAAATT 62.8 123 
R: TCCATAAACATAAAACCCTCTAA 
LINE1-M F: ACGGACGTATTTGGAAAATC 64.5 123 
R: TCCGTAAACGTAAAACCCTC 
MGMT-UM F: TTTGTGTTTTGATGTTTGTAGGTTTTTGT 61 ** 93 
R: AACTCCACACTCTTCCAAAAACAAAACA 
MGMT-M F: TTTCGACGTTCGTAGGTTTTCGC 61 ** 81 
R: GCACTCTTCCGAAAACGAAACG 
MLH1-UM F: GTAGTTGTTTTAGGGAGGGAT 64 151 
R: CCTCAATACCTCATACTCACATTCT 
MLH1-M F: GTCGTTTTAGGGAGGGAC 67 151 
R: CAATACCTCGTACTCACGTTCT 
PTGS2-UM F: GTTTTTGGATTTTAGGGTT 60 **** 130 
R: TCTTCACAATCTTTACCCA 
PTGS2-M F: TTTTCGGATTTTAGGGTC 58 130 
R: CTTCGCAATCTTTACCCG 
RARB-UM F: TTAAGTTGTTGTAAATAAAAAGGT 60 144 
R: AACCAACATTTTCTTTCCTATTT 
RARB-M F: AGTCGTCGTAAATAAAAAGGC 64 144 
R: ACCGACGTTTTCTTTCCTAT 
RASSF1A-UM F: TTTGGTTGGAGTGTGTTAATGTG  62 ** 93 
R: CAAACCCCACAAACTAAAAACAA 
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Target Sequence (5’ to 3’) Annealing 
temp. (°C) 
Amplicon 
length (bp)  
RASSF1A-M F: GTGTTAACGCGTTGCGTATC  62 ** 105 
R: AACCCCGCGAACTAAAAACGA  
Rb-UM F: TTAGATATTTTTTGTGGGGTTT 63.5 145 
R: ACCCAAACATACTTCTACCCAA 
Rb-M F: GATATTTTTTGCGGGGTTC 65 145 
R: CCCGAACGTACTTCTACCC 
SOCS-UM F: GAGAGGGAAATAGGGTTGAAGT 63 130 
R: TAAACCAACTCAAAAACAAAACT 
SOCS-M F: AGGGAAATAGGGTCGAAGC 68 *** 130 
R: TAAACCGACTCGAAAACGAA 
TIMP3-UM F: GTTTAGGTAGTGGTGTAGAGT 64 * 137 
R: AAAACTACCTCAACACTAACAC 
TIMP3-M F: TTAGGTAGCGGCGTAGAGC 70 * 137 
R: AAACTACCTCGACGCTAACG 
TMS1-UM F: AGGATTTTAAGGTTTGGGGAATT 63 $ 123 
R: CTTACACCAACAAATACAAACCA 
TMS1-M F: GATTTTAAGGTTCGGGGAATC 62 $ 123 
R: TACACCAACGAATACAAACCG 
TP73-UM F: TTAGGTTAGTTGGGATGGAT 63 ** 141  
R: CCCAACTTCAAAACTACAAACCC 
TP73-M F: AGGTTAGTCGGGACGGAC 58 ** 141 
R: CAACTTCGAAACTACGAACCC 
temp.: temperature, primer specificity: UM: unmethylated, M methylated. AHR: aryl hydrocarbon 
receptor, APAF-1: apoptotic peptidase activating factor 1, APC: adenomatous polyposis coli, 
BCL-2: B-cell CLL/lymphoma 2, BCL-XL: apoptosis regulator Bcl-X, CALCA: calcitonin-related 
polypeptide alpha, CASP: caspase, CDH1: epithelial cadherin, CDKN cyclin-dependent kinase 
inhibitor, DAPK1: death-associated protein kinase 1, ESR: estrogen receptor, GSTP1: 
glutathione S-transferase P1, HIC1: hypermethylated in cancer 1, LINE1: long interspersed 
nuclear element, MGMT: O-6-methylguanine-DNA methyltransferase, MLH1: human MutL 
protein homolog 1, PTGS2: prostaglandin-endoperoxide synthase 2, RARB: retinoic acid 
receptor beta, RASSF1A: Ras association domain family protein 1A, RB1: retinoblastoma 1, 
SOCS: suppressor of cytokine signaling, TIMP3: tissue inhibitor of metalloproteinase, TMS1: 
target of methylation-induced silencing 1, TP73: tumor protein p73. 
 
Table 23: Oligonucleotides used for bisulfite deep sequencing analysis.  
Oligonucleotide primers were synthetized by Metabion (Martinsried, Germany). Every 
forward and reverse primers were supplemented by 5’ adaptors with the following 
sequences 5’-CGTATCGCCTCCCTCGCGCCATCAGTCTCTATGCG-3’ and 5’-
CTATGCGCCTTGCCAGCCCGCTCAGTCTCTATGCG-3’, respectively. PCRs were 
done with 2.5 units of Hot Fire Pol and 42 cycles. Otherwise, + 5 units of Hot Fire Pol 
(42 cycles), ++ 3.125 units of Hot Start Taq (42 cycles), +++ 1.5 units Platinum Taq (41 
cycles) were used for PCR amplification. 
Target Sequence (5’ to 3’) Anneal. 
temp. (°C) 
Amplicon 
length (bp) 
BCL2L11 F: GGGTGTAGATTTAGAGGATTGGAGAG 55 336 
R: CACTACATTTAACTAAAACCCCCAAAA 
CALCA F: GATTTTTTAGGTTTTGGAAGTATG 54 355 
R: AAAAAAAAACATATACCTAAACCAA 
CHFR F: TGGTTTGTTTTATATAAATGGATGTTT 55 466 
R: AACTTTTACCTCAATATCTCACTTCTTAAA 
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Target Sequence (5’ to 3’) Anneal. 
temp. (°C) 
Amplicon 
length (bp) 
DAB2IPA F: AAGGTGGTTGTTTTTGTTGGGGTA 58  347 
R: CCACACCCACCTAAAAAAATCCA 
DAPK1 F: TTTTTAGAATTTAGTTAGAGGGTAGT 54 337 
R: ACCAATAAAAACCCTACAAAC 
DCR1 F: GGAGGTGTTAGGGGAGGTTATGTTTT 55 280 
R: CCCTTACATCTCTAATCAAACTCCCAAA 
DLC1 F: TTTTGGAGGAGTGATTTTTGATTATTTT 55 357 
R: AATCTAAAATATTCCCAAACAATAAACTCTCC 
ESR1 F: TTTTATATGTTTGTTTAGATTTTAAGT 54 * 493 
R: TTATCACTCAAAAACTATCTTCTTATA 
EYA4 F: GTAAATTATGATAATAGGTAGTTATT 54 * 349 
R: CAACTCTTTCCCCCTCTCTAAAACAAC  
GSTP1 F: GGAAAGAGGGAAAGGTTTTTT 56 368 
R: ACTCTAAACCCCATCCCC 
H19 CTCF6 F: GATATTAGGGGAATAATGAGGTGTT 54 407 
R: ATAAATATCCTATTCCCAAATAACCC 
HIC1 F: GGGTTGTGTGGGTAATATTTTTGTTT 54 * 526 
R: CCTCCCACCTATACCCACCTAAA 
IGSF4 F: GTATGTTATTAGTATTTTATTAGTTGTT 56 342 
R: CTCTATAACCAAAACTACTAAAATA 
KLF4 F: TTTTTTTGGTTTTTTTTTGAGGTTT 54 294 
R: TAACTCATCCAACCCTCCATCT 
LINE1 F: TTATTAGGGAGTGTTAGATAGTGGG 54 247 
R: CCTCTAAACCAAATATAAAATATAATCT 
MGMT F: TTATTATAGGTTTTGGAGGTTGTT 54 322 
R: TACCTTTTCCTATCACAAAAATAAT 
RASSF5/ 
NORE1A 
F: GAAGGAAGGGGAAATTTAATTAGAG 54 468 
R: TAAACCTTCAACCCTACCTCTTTC 
OSMR F: GGGATGATAAGTGTTTTTGTGGGAT 54 $ 376 
R: ACACTCCTAAAACCCACAAAAATTCC 
PROX1 F: AGTTGTATTTGGGAAATGAAAAA 54 249 
R: CCCACCCTACCACAACTTC 
PTGS2 F: GTTATATGGGTTTGGTTTTTAGTT 54 * 402 
R: AAATACTAAAATAAACCCAAAAAATC 
RARB F: TGTTAGATTAGTTGGGTTATTTGAAGGT 54 450 
R: CAAATAATCATTTACCATTTTCCAAACT 
THBS1 F: GGAGAGAGGAGTTTAGATTGGTT 54 423 
R: CACCAAAAAAACTAAAACCTCAA 
TIMP3 F: TGGGTTAGAGATATTTAGTGGTTT 54 237 
R: TTCAAATCCTTATAAAAAATAATACC 
TP73 F: AAATAGTGGGTGAGTTATGAAGATGT 54 354 
R: TACACCAAACCCTAACTAAAAAACC 
temp.: temperature. BCL2L11: B-cell CLL/lymphoma 2-like 11, CALCA: calcitonin A, CHFR: 
checkpoint with forkhead and ring finger domains, DAB2IBA: DAB2 interacting protein, DAPK1: 
death-associated protein kinase 1, DCR1: decoy receptor 1, DLC1: deleted in liver cancer 1, 
ESR1: estrogen receptor 1, EYA4: eyes absent homolog 4, GSTP1: glutathione S-transferase 
P1, H19-CTCF: imprinted gene, HIC1: hypermethylated in cancer 1, IGSF4: cell adhesion 
molecule 1, KLF4: krueppel-like factor 4, LINE1: long interspersed nuclear element 1, MGMT: 
O-6-methylguanine-DNA methyltransferase, RASSF5/NORE1A: Ras association (RalGDS/AF-
6) domain family 5, OSMR: oncostatin M receptor, TP73: tumor protein P73, PROX1: prospero 
homeobox 1, PTGS2: prostaglandin-endoperoxide synthase 2, RARB2: retinoic acid receptor 
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beta, THBS1: thrombospondin 1, TIMP3: tissue inhibitor of metalloproteinase, TP73: tumor 
protein p73. 
 
Table 24: Oligonucleotides used for expression analysis. 
Primers were obtained from Eurogentec and have an annealing temperature of 60°C. 
Target Sequence (5’ to 3’) Amplicon length (bp) 
$-actin F: CTCTTCCAGCCTTCCTTCCT 116 
R: AGCACTGTGTTGGCGTACAG 
DNMT1 F: TCAGCAAGATTGTGGTGGAG 104 
R: CAAGTTGAGGCCAGAAGGAG 
DNMT3a F: TGCCAAAACTGCAAGAACTG 83 
R: CAGCAGATGGTGCAGTAGGA 
DNMT3b F: TTTGGCCACCTTCAATAAGC 119 
R: GGTCCTCCAATGAGTCTCCA 
GSTP1 F: GGCAACTGAAGCCTTTTGAG 128 
R: GGCTAGGACCTCATGGATAC 
 
Table 25: Oligonucleotides used for X-ChIP analysis. 
Primers were obtained by Eurogentec and have an annealing temperature of 60°C. 
Target Sequence (5’ to 3’) Amplicon length (bp) 
CG1 F: CTCTATGGGAAGGACCAGCA 81 
R: GATGTATTTGCAGCGGAGGT 
CG2 F: CCAGTTCGAGGTAGGAGCAT 103 
R: GATAAGGGGGTTCGGATCTC 
CG3 F: GCAGCGGTCTTAGGGAATTT 131 
R: CTTTCCCTCTTTCCCAGGTC 
CG4 F: AAGTAGGCAGCAAAGCCAAA 77 
R: GTCCCTGCAAAGGACATGAT 
CG5 F: AAGCCCAGGAACCTCAAGAT 86 
R: TGATCAGCCTGTGCCTGTAG 
 
Table 26: Oligonucleotides used for miRNA expression profile analysis. 
Primers were synthetized by Qiagen and have an annealing temperature of 55°C. 
Assay name Entrez Gene Symbol 
Hs_let-7f_1 MIRLET7F1, MIRLET7F2 
Hs_miR-124a_1 MIR124-1, MIR124-2, MIR124 
Hs_miR-125a_1 MIR125A 
Hs_miR-125a-3p_1 MIR125A 
Hs_miR-133a_1 MIR133A1, MIR133A2 
Hs_miR-142-5p_1 MIR142 
Hs_miR-148b_1 MIR148B 
Hs_miR-149_1 MIR149 
Hs_miR-150_1 MIR150 
Hs_miR-185_1 MIR185 
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Assay name Entrez Gene Symbol 
Hs_miR-193_2 MIR193B 
Hs_miR-198_2 MIR198 
Hs_miR-296-3p_1 MIR296 
Hs_miR-296-5p_1 MIR296 
Hs_miR-324-3p_2 MIR324 
Hs_miR-339_1 MIR339 
Hs_miR-339-3p_1 MIR339 
Hs_miR-345_2 MIR345 
Hs_miR-346_2 MIR346 
Hs_miR-422b_1 MIR378 
Hs_miR-432_1 MIR432 
Hs_miR-484_1 MIR484 
Hs_miR-486_1 MIR486 
Hs_miR-486-3p_1 MIR486 
Hs_miR-506_2 MIR506 
Hs_miR-512-3p_1 MIR512-1 
Hs_miR-512-5p_1 MIR512-1 
Hs_miR-516a-3p_1 MIR516A1, MIR516A2 
Hs_miR-516a-5p_1 MIR516A1, MIR516A2 
Hs_miR-516b_1 MIR516B1, MIR516B2 
Hs_miR-518c_1 MIR518C 
Hs_miR-519e_3 MIR519E 
Hs_miR-526b_1 MIR526B 
Hs_miR-539_1 MIR539 
Hs_miR-572_2 MIR572 
Hs_miR-574_1 MIR574 
Hs_miR-590-3p_1 MIR590 
Hs_miR-618_1 MIR618 
Hs_miR-637_1 MIR637 
Hs_miR-650_1 MIR650 
Hs_miR-657_2 MIR657 
Hs_miR-659_2 MIR659 
Hs_miR-767-3p_1 MIR767 
Hs_RNU1A_1 n.a. 
n.a.: not available. 
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3.8. Antibodies 
Table 27: Primary antibodies used for Western Blot analysis.  
Antibody working solutions were prepared at the appropriated dilution in 1X PBS-T 
with 5% milk. 
Target 
specificity 
Membrane saturation Dilution Supplier 
AcH4 5% BSA, 1X PBS-T 1:50000  Upstate 
CBP 5% milk, 1X PBS-T 1:1000  Santa Cruz, Tebu Bio, 
Boechout, Belgium 
DNMT1 5% milk, 1XPBS-T 1:250  Active motif, Rixensart, 
Belgium 
DNMT1 5% milk, 1X PBS-T 1:250  Active motif 
DNMT3A 5% milk, 1X PBS-T 1:200  Santa Cruz 
DNMT3B 5% milk, 1X PBS-T 1:500  Abcam, Cambridge, UK 
GSTP1 5% milk, 1X PBS-T 1:10000  BD bioscience, Franklin 
Lakes, USA 
H4 5% BSA, 1X PBS-T 1:10000  Upstate 
HDAC1 5% milk, 1X PBS-T 1:10000  Upstate 
HDAC2 5% milk, 1X PBS-T 1:10000  Abcam 
MBD1 5% milk, 1X PBS-T 1:1000  Abcam 
MBD2 5% milk, 1X PBS-T 1:250  Santa Cruz 
MBD3 5% milk, 1X PBS-T 1:250  Santa Cruz 
MeCP2 5% milk, 1X PBS-T 1:2500  Upstate 
p300 5% BSA, 1X PBS-T 1:500  Upstate 
Sp1 5% milk, 1X PBS-T 1:10000  Active motif 
Sp3 5% milk, 1X PBS-T 1:2500  Santa Cruz 
$-actin 5% milk, 1X PBS-T 1:5000  Sigma 
Ac: acetylation, CBP: cAMP-response element binding protein (CREB) binding protein, DNMT: 
DNA methyltransferase, GSTP1: glutathione S-transferase P1, H4: Histone 4, HDAC: histone 
deacetylase, MBD: methyl binding protein, MeCP2: methyl CpG binding protein 2, p300: 
histone acetyltransferase, SP: specificity protein. 
 
Table 28: Antibodies used for X-Chip. 
Target specificity Supplier 
AcH3 Upstate 
AcH4 Upstate 
CBP Abcam 
DNMT1 Active motif 
DNMT3A Active motif 
DNMT3B Active motif 
H3K4Me2 Abcam 
H3K4Me3 Abcam 
H3K9Me3 Upstate 
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Target specificity Supplier 
H3K27Me3 Upstate 
HDAC1 Upstate 
HDAC2 Abcam 
MBD1 Abcam 
MBD2 Upstate 
MBD3 Abcam 
MeCP2 Upstate 
p300 Upstate 
RNA pol II Upstate 
Sp1 Active motif 
Sp3 Santa Cruz 
Ac: acetylation, CBP: cAMP-response element binding protein (CREB) binding protein, DNMT: 
DNA methyltransferase, H: Histone, HDAC: histone deacetylase, K: lysine, MBD: methyl 
biniding protein, Me: methylation, MeCP2: methyl CpG binding protein 2, p300: histone 
acetyltransferase, RNA pol II: RNA polymerase II, SP: specificity protein. 
 
Table 29: Horseradish peroxidase-conjugated secondary antibodies used for 
Western Blot analysis. 
Secondary antibodies were obtained from Tebu Bio (Boechout, Belgium). Antibody 
dilutions were prepared with 5% milk in 1X PBS-T. 
1st antibody specificity Target specificity Dilution  
AcH4 Anti-rabbit IgG 1:5000  
CBP Anti-rabbit IgG 1:2500  
DNMT1 Anti-mouse IgG 1:2500  
DNMT3A Anti-rabbit IgG 1:500  
DNMT3B Anti-rabbit IgG 1:500  
GSTP1 Anti-mouse IgG 1:10000  
H4 Anti-rabbit IgG 1:5000  
HDAC1 Anti-mouse IgG 1:5000  
HDAC2 Anti-rabbit IgG 1:5000  
MBD1 Anti-rabbit IgG 1:2500  
MBD2 Anti-goat IgG 1:1000  
MBD3 Anti-goat IgG 1:2500  
MeCP2 Anti-rabbit IgG 1:2500  
p300 Anti-mouse IgG 1:2500  
Sp1 Anti-goat IgG 1:5000  
Sp3 Anti-goat IgG 1:2500  
$-actin Anti-mouse IgG 1:10000  
 
For indirect immunofluorescence detection, GSTP1 antibody (BD bioscience) 
was used at a dilution of 1:15 in 0.5% BSA, 1X PBS. 
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Table 30: Secondary antibodies used for immunodetection by cytometry or 
microscopy analyses. 
Secondary antibodies were diluted 1:50 in 0.5% BSA, 1X PBS. 
1st antibody 
specificity 
Target 
specificity 
Label  Supplier 
GSTP1 Anti-mouse IgG Alexa Fluor® 488 Molecular probes, 
Carlsbad, USA 
GSTP1 Anti-mouse IgG Alexa Fluor® 647 Molecular probes 
 
3.9. Markers 
Table 31: DNA markers used in electrophoretic migrations. 
All DNA markers were obtained from Promega. 
Name Fragment length (bp)  
1kb DNA Ladder 
 
250, 253, 500, 750, 1000, 1500, 2000, 2500, 3000, 
4000, 5000, 6000, 8000, 10000 
Bench TOP 100bp 
Ladder 
 
100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 
1500 
25bp DNA Step Ladder 
 
25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 
300 
bp: base pairs. 
 
Table 32: Protein marker used in Western Blot. 
As a protein size marker, Precision Plus protein standards, Kaleidoscope marker from 
Biorad was used. 
 
3.10. Plasmid/control DNA 
Table 33: Plasmid vectors and modified DNA.  
Name Supplier 
pGEM®-T Easy Vector Promega 
Epitect® PCR Control DNA Qiagen 
 
3.11.  Devices and instruments  
Table 34: Devices and instruments  
Description Name Supplier 
Autoradiography 
cassettes 
Hypercassette™ Amersham Bioscience, 
Vienna, Austria 
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Description Name Supplier 
Autoradiography 
films  
Hyperfilm ECL Amersham Bioscience 
Balances Explorer Pro Ohaus, Pine Brook, USA 
Biological safety 
cabinets 
Clean Air Clean Air, Minneapolis, USA 
Gel electrophoresis 
chamber 
Horizon 11-14, Horizon 20-
25 
Gibco, Carlsbad, USA 
Cell counter Cedex XS Innovatis, Roche, Howald, 
Luxembourg 
Centrifuge 5415R1, 5415D1, 5810R1, 
54241, KR25i2, RC10102, 
Cytofuge 23 
Eppendorf1, Hamburg 
Germany; Jouan2, St-
Herblain, France; Stat spin3, 
Westwood, USA 
Cytometer Facscalibur  BD bioscience 
Film processor Curix 60 AGFA, Mortsel, Belgium 
Fluorometer Qubit® Fluorometer  Invitrogen 
Fume cupboard Astec Monair, Hants, England 
Homogenizer Qiashredder Qiagen 
Incubator IGO 159 Memmert, Jouan, Binder 
Incubator with shaker 
function 
Thermoshake Gerhardt analytical systems, 
Königswinter, Germany 
Magnetic stirrer EM-1100-T Retsch, Haan, Germany 
Microplate 
spectrofluorometer 
SpectraMaxGemini EM Molecular Devices, 
Sunnyvale, USA 
Microscope DM20001, DMIRB1, IX812 
(MT10), Eclipse E2003 
Leica1, Zaventem, Belgium; 
Olympus2, Aartselaar, 
Belgium; Nikon3, Amstelveen, 
Netherland 
Microscopy slide for 
cell counting 
Malassez slide Marienfeld, Lauda-
Königshofen, Germany 
PCR plates Real-time PCR plates  Thermo, Waltham, USA 
PCR workstation Captair bio Erlab, Val de Reuil, France 
pH meter Cyberscan 500 Eutech instruments, Nijkerk, 
Netherland 
Pipet Pipetman Gilson, Middleton, USA 
Pipet-Aid Express Falcon, VWR, Leicestershire, 
England 
Power supply Power Pac HC, Power Pac 
Basic 
Bio-Rad Laboratories  
Protein blotting cells Mini Protean Tetra cells, 
Mini Protean 3-cells 
Bio-Rad Laboratories  
Pipetting robot Qiacube Qiagen 
Real-time PCR 7300 Real-Time PCR 
System  
Applied biosystems 
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Description Name Supplier 
Refrigerated cold 
traps 
RCT60 Jouan, St-Herblain, France 
Sequencer GS-FLX titanium system Roche 
Separator Midi MACS separation unit, 
MACS multi stand 
Miltenyi 
Shaker 3015 GFL, Burgwedel, Germany 
Sonicator Bioruptor™ Diagenode, Liège, Belgium 
Spectral photometer SpectraCount1, ND-10002 Packard1, Schwadorf, 
Austria; Nanodrop2, 
Wilmington, USA 
Storage (4°C1, -
20°C2, -80°C3, -
196°C4) 
VX490 E1, Comfort2, 
VWR3, LS750 4  
Jouan1, St-Herblain, France; 
Liebherr2, Biberach an der 
Riss, Germany ; VWR3, 
Leicestershire, England ; 
Taylor Wharton4, Husum, 
Germany 
Thermocycler Mastercycler Gradient Eppendorf, Hamburg 
Germany 
Tips, tubes, etc. Plastic ware Greiner, Wemmel, Belgium 
Tube roller-mixer SRT2 Rollomatic Stuart scientific  
UV Gel 
documentation 
UV illumination in a 
Molecular Imager% Gel Doc 
XR& System,  
Bio-Rad Laboratories  
Vortexer Vortex Genie 2 Scientific Industries, 
Bohemia, USA 
Water bath 1002 GFL, Burgwedel, Germany 
Water purification Elix3, Simplicity Millipore, Billerica, USA 
Western Blot 
densitometry 
Image station 440 CF Kodak, Stuttgart, Germany 
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4. Methods 
4.1. Bioinformation 
4.1.1. Oligonucleotide design 
Oligonucleotides (Primers) for semi-quantitative real-time or 
conventional non-quantitative PCRs were designed with the online tool 
Primer3 (Rozen and Skaletsky 2000). The Methyl Primer express software 
(Applied biosytems) was used to design primers for bisulfite sequencing and 
methylation-specific PCR (MSP) (Li and Dahiya 2002). 
 
4.1.2. CpG island identification 
CpG-rich regions were identified and plotted with the Methyl Primer 
express software applying the following conditions: GC%=50%, CpG O/E=0.6, 
min. length=200bp. Further analysis were realized with the online tool 
EMBOSS CpGPlot/CpGReport/Isochore (http://www.ebi.ac.uk/Tools/emboss 
/cpgplot/index.html) applying the following conditions: calculation window 
size=100, migration step=1, CpG O/E=0.6, GC%=50%, CGi length=200bp) 
(Gardiner-Garden and Frommer 1987; Rice, Longden et al. 2000). 
 
4.1.3. Bisulfite sequencing data analysis 
Chromatogram accuracy of sequencing data was checked with the 
Codon Code aligner software (CodonCode Corporation, Dedham, USA). 
Qualitatively acceptable sequences were then imported into the CLC 
Sequence viewer software (CLC bio, Aarhus, Denmark) and reoriented with 
the reverse complement tool. To identify eventual sequencing errors, resulting 
sequences were aligned against an in silico converted “ensembl”-based DNA 
sequence (Ensembl release 50 - Jul 2008, http://www.ensembl.org/). The BIQ 
conversion software (http://biq-analyzer.bioinf.mpi-sb.mpg.de/) was used for 
in silico conversions (Bock, Reither et al. 2005). Methylation percentages of 
bisulfite sequencing results were finally determined with the methylation 
quantification analysis tool (QUMA) (http://quma.cdb.riken.jp/) as well as with 
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the BIQanalyzer software (Bock, Reither et al. 2005; Kumaki, Oda et al. 
2008). Deep sequencing analyses were processed with the BIQanalyzer HT 
software (Lutsik, Feuerbach et al. 2011). 
 
4.1.4. Image analysis 
Bright-field microscopy images were recorded with the Leica Firecam 
software and processed with the ImageJ (rsbweb.nih.gov/ij/) or the Leica 
Firecam softwares (Leica Microsystems) (Rasband 1997-2008). Cell^R 
software (Olympus) was used to acquire and process fluorescence 
microscopy pictures. Kodak 1D image analysis (Kodak) and Image J 
softwares were used for densitometry analysis. DNA gels were documented 
with the Quantity One software (Bio-Rad Laboratories).  
 
4.1.5. Heat map analysis 
MSP methylation data and real-time PCR miRNA expression results 
were analyzed by the R software environment for statistical computing and 
graphics. Data were represented on a heat map (Team 2010). Correlation 
coefficient was used to determine cluster similarity. 
 
4.1.6. Prediction of putative miRNAs targeting GSTP1 expression 
A long list of approaches, based on different algorithms, has been 
developed for putative computational miRNA target prediction. In this study, 9 
different public online tools were used to analyze the 3’UTR of GSTP1 gene 
and predict possible miRNAs targeting GSTP1 mRNA (Table 35). 
Table 35: Tools and resources for GSTP1 miRNA target prediction. 
Tool Resource References 
Human miRNA 
target 
http://diana.pcbi.upenn.edu/CGi-
bin/TargetCombo.cgi  
(Sethupathy, Corda et 
al. 2006) 
Target Scan http://www.targetscan.org/ (Lewis, Burge et al. 
2005; Grimson, Farh 
et al. 2007; Friedman, 
Farh et al. 2009) 
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Tool Resource References 
Target Gene 
Prediction at 
EMBL 
http://www.russell.embl-
heidelberg.de/miRNAs/ 
(Stark, Brennecke et 
al. 2003; Brennecke, 
Stark et al. 2005; 
Stark, Brennecke et al. 
2005) 
miRNA map http://mirnamap.mbc.nctu.edu.tw/ (Hsu, Chu et al. 2008) 
Mirtar http://mirtar.mbc.nctu.edu.tw/human/  
RefGene http://refgene.com/  
miRwalk http://www.ma.uni-
heidelberg.de/apps/zmf/mirwalk/ 
 
EiMMO http://www.mirz.unibas.ch/ElMMo3/  
mimiRNA http://mimirna.centenary.org.au/mep/for
mulaire.html 
(Ritchie, Flamant et al. 
2010) 
 
4.2. Microbiology 
4.2.1. Bacterial cell culture 
 
Culture in liquid growth medium 
A preculture of 5ml lysogeny broth miller medium (LB, Luria Bertani 
broth) supplemented with 100µg/ml ampicillin was inoculated with a bacterial 
clone and incubated under agitation (200rpm) for eight hours at 37°C. The 
main culture of 150ml LB with ampicillin (100µg/ml) was afterwards inoculated 
with 1ml preculture and incubated under agitation overnight at 37°C. 
 
Culture on solid growth medium 
Autoclaved LB-agar miller medium was melted at 400W in a microwave, 
cooled down under agitation, supplemented with 100µg/ml ampicillin, and 
poured into sterile Petri dishes. The antibiotic agent ampicillin interacts with 
bacterial wall synthesis and thereby inhibits bacterial growth. Only bacterial 
cells expressing the ampicillin resistance gene survive to the selective 
pressure.  
LB-agar-Ampicillin-IPTG-X-Gal plates with 100µg/ml ampicillin, 0.05M 
IPTG and 0.004% X-Gal were used for Blue/White colony screening. IPTG 
induces the expression of the LacZ gene encoding $-galactosidase, which 
metabolizes the lactose analogue X-Gal into a blue reaction product. 
  Methods 
 74 
4.2.2. Transformation 
The procedure that induces the introduction of a foreign DNA molecule 
into any bacterial cell type is called transformation.  
For the transformation of pGEM-T easy vector into E.coli strain JM109 
high efficiency competent cells, 2µl of the ligation reaction were added to 50µl 
of chemocompetent cells. This mixture was incubated 20 minutes on ice, then 
heat shocked for 45 seconds at 42°C and stored for 2 minute on ice. During 
this process, the short-term increase of temperature to 42°C reduces the 
rigidity of the cell wall and induce DNA migration through the phospholipid 
bilayer. Cells were regenerated by adding 950µl SOC medium to the 
transformation mixture and incubated 1 hour at 37°C. SOC is a medium 
without antibiotics that allows cells to recover as well as to initiate plasmid 
replication and gene expression. Finally, cells were platted on solid growth 
medium and incubated overnight at 37°C.  
 
4.3. Cell culture 
All manipulations for cell culture were done under sterile conditions. 
 
4.3.1. Storage of eukaryotic cells 
Cell stock aliquots were prepared in regular cell culture medium 
supplemented with 10% DMSO and 10% FBS. Aliquots were slowly frozen 
until -80°C and stored in liquid nitrogen. Cells revitalized by quick thawing at 
37°C were then placed under their usual culture conditions. Cells were used 
during a limited number of passages (+/- 30) before thawing a new stock. 
 
4.3.2. Culturing of eukaryotic cells 
Cell lines were routinely maintained in RPMI 1640 medium 
supplemented with 10% FBS except KG-1a cells that require 20% FBS. 
Furthermore, growth medium for TF-1 was supplemented with 5ng/ml of GM-
CSF. KBM-5 cell lines were maintained in IMDM medium supplemented with 
15% FBS. All medium were supplemented with 1% of a mixture of antibiotic 
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and antifungal agents (Pen/Strep Amphotericin B). Cells were cultured under 
an atmosphere of 5% CO2 with 95% humidity at 37°C. Medium exchange and 
cell concentration adjustment were done regularly. Therefore, cells were 
counted and a defined volume of cells transferred into a falcon. To eliminate 
the old medium, cells were centrifuged at 350 g for 7 minutes at room 
temperature. The supernatant was discarded and cells resuspended in an 
appropriated volume of new medium at a concentration of 2.0 - 2.5 x 105 cells 
per ml.  
 
4.3.3. Trypan blue exclusion test 
Trypan blue staining is used to determine the number of viable cells. 
Live cells possess intact cell membranes that actively exclude the trypan blue 
dye. In contrast, dead cells do not exclude the dye and show a distinctively 
blue stain under the microscope. 
Cells in medium were mixed at an equal volume with trypan blue. Then 
20µl of this mix was directly transferred onto a Malassez cell counting 
chamber and stained (unviable) as well as unstained (viable) cells were 
counted separately. 
 
4.3.4. Cell line treatments 
The stock solution of 10mM 5-aza-2'-deoxycytidine (DAC) was prepared 
in DMSO, aliquoted and stored at -20°C. The stock solution of 2.3M valproic 
acid (VPA) was diluted in water, trichostatin A (TSA) (1mg/ml) and SAHA 
(10mM) were prepared in DMSO. All solutions were aliquoted and stored at -
20°C. Cells were treated in the beginning of exponential growth phase. Due to 
the reduced stability of DAC, cells were treated every day.  
 
4.3.5. Purification of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were purified from whole 
blood by density gradient centrifugation on Ficoll-Paque, taking in advantage 
the different densities of blood components (Boyum 1976). Anticoagulant-
  Methods 
 76 
treated whole blood is diluted with a balanced salt solution and then slowly 
layered above Ficoll-Paque. The differential sedimentation of blood cells in 
the density gradient during the following centrifugation leads to a separation 
into distinct phases (Figure 16).  
 
 
Figure 16: Sedimentation profile of whole blood cells separated by Ficoll.  
Ficoll is overlayed in a conical tube by diluted whole blood. After centrifugation, the 
following layers are visible from top to the bottom: plasma, mononuclear cells, Ficoll, 
polymorphonuclear cells and erythrocytes (www.life.umd.edu). 
 
The pellet on the bottom of the tube consists of the high-density 
erythrocytes and polymorphonuclear granulocytes that are overlayed by the 
Ficoll-Paque. With a similar density as the Ficoll, lymphocytes (mononuclear 
cells) stay in the interphase between Ficoll and the upper fraction containing 
blood plasma, monocytes and platelets (Figure 16). 
One volume of Ficoll-Paque PREMIUM (density: 1.077g/ml) was gently 
overlayed with 2 volumes of diluted blood (1:3 dilution with 1X PBS) in a 50ml 
falcon-type tube. Tube was centrifuged at 600 g without break for 30 minutes 
at room temperature. PBMCs were collected by transferring into a new tube 
the lymphocyte ring located in the interphase of Ficoll/Plasma. Collected cells 
were washed twice with 1X PBS and stored at -80°C. 
 
4.3.6. Separation of CD34+ cells from umbilical cord blood 
Umbilical cord blood is the fraction of blood that remains in placenta and 
in the attached umbilical cord after childbirth. Cord blood contains all the basic 
elements of blood such as red blood cells, white blood cells, blood platelets 
and plasma. In addition, it contains blood-forming stem cells, positive for the 
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transmembrane glycoprotein CD34 antigen. These human hematopoietic 
progenitor cells have the potential to develop into any blood cell types. 
CD34+ cells were separated from umbilical cord blood as described by 
Miltenyi Biotec’s protocol. Cord blood was collected in tubes containing 
Heparin as anticoagulant. PBMCs were purified by density gradient 
centrifugation on Ficoll-Paque (see 4.3.5). Purified PBMCs (108) were 
resuspended in 300µl MACS buffer (Table 3). Then, 100µl of FcR blocking 
reagent and 100µl of CD34 MicroBeads (anti-CD34 antibody-coupled 
magnetic beads) were added to the cell suspension. Fc fragments of 
antibodies in the blocking reagent bind to the Fc receptors of nucleated cells 
and block any non-specific binding of CD34 MicroBeads. After 30 minutes 
incubation on ice, cells were washed with 10ml of MACS buffer and gently 
resuspended in 500µl of the same buffer. Cells were passed successively 
through a pre-separation filter and a MACS LS separation column positioned 
in a MidiMACS Separation Unit on a MACS multi stand. The magnetic field, 
created by the interaction between the separation unit and the column allows 
unlabeled CD34- cells to elute through the column while positively labeled 
cells (CD34+ cells) remain in the column’s magnetic shaft. After the negative 
elution containing CD34- cells, the column was washed with 9ml of MACS 
buffer, removed from the separation unit and eluted with 5ml MACS buffer. 
The eluate containing CD34+ cells was purified an additional time on a MACS 
LS separation column to improve fraction purity. 
 
4.4. Biological chemistry 
Cells were collected and washed two times with ice-cold 1X PBS. All 
centrifugation steps were done at 4°C. 
 
4.4.1. Whole cell extracts 
A pellet of 10 X 106 cells was resuspended at a ratio of 1:10 (v/v) with 
lysis mix (25:1 M-PER / proteinase inhibitor cocktail) for 10 minutes at room 
temperature. The sample was vortexed for 10 minutes and subsequently 
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centrifuged at 15000 g for 15 minutes. The supernatant containing proteins 
was transferred into a new tube and stored at -80°C. 
 
4.4.2. Nuclear protein extraction 
A pellet of 107 cells was resuspended in 400µl buffer A (Table 6) and 
incubated for 15 minutes on ice. The cell lysate was supplemented with 25µl 
of 10% IGEPAL, vortexed for 10 seconds and centrifuged at 15000 g for 15 
minutes. The cytoplasmic protein fraction was transferred into a new tube and 
stored at -80°C. Nuclei were dissolved in 50µl buffer C (Table 6), vigorously 
vortexed at 4°C for 15 minutes and centrifuged at 10000 g for 5 minutes. The 
supernatant, containing nuclear proteins, was transferred into a new tube and 
stored at -80°C. 
 
4.4.3. Histone acid extraction 
A pellet of 5 X 106 cells was resuspended in ice-cold hypotonic lysis 
buffer (Table 7) and incubated for 30 minutes at 4ºC. Nuclei were collected by 
centrifugation at 10000 g for 10 minutes, resuspended in 0.4N H2SO4, and 
incubated for 30 minutes at 4ºC. Histones were collected by precipitation with 
25% trichloroacetic acid, incubated 30 minutes on ice, centrifuged at 15000 g 
for 10 min, washed with ice-cold 100% acetone, dissolved in water and stored 
at -80ºC.  
 
4.4.4. Protein quantification 
The Bradford Dye assay is the most common colorimetric method to 
determine the concentration of a protein solution. The maximum absorbance 
for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 
595 nm when binding to protein occurs. Under strong acidic conditions, the 
dye is most stable as a doubly-protonated, red form. However, binding to 
protein leads to a deprotonated, blue form. The reaction depends on the 
content of aromatic and basic amino acids (Bradford 1976). 
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The determination of protein concentration is based on the comparison 
of BSA calibration curve and sample extinction spectrum. Therefore, a dilution 
series with BSA and water was prepared with the following concentrations: 
BSA concentration 
(µg/ml) 0 1 2 2.5 5 7.5 10 12.5 15 20 
A volume of 40µl of Bio-Rad Protein assay solution was added to 160µl 
of either samples or BSA dilution series. The extinction coefficients of the 
calibration curve and samples were measured by a spectral photometer at a 
wavelength of 595nm. Data were plotted and the equation of the standard 
curve was used to calculate sample concentration.  
 
4.4.5. SDS-Page 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-Page) 
is a variant of the polyacrylamide gel electrophoresis to separate proteins in 
an electric field. The separation medium is a polyacrylamide gel consisting of 
acrylamide, bisacrylamide, APS, TEMED and SDS. Polymerization of acryl 
monomers with the cross-linking agent bisacrylamide is catalyzed and 
initiated by TEMED and APS, respectively. SDS is an anionic detergent and 
coats the proteins with its negative charge. Discontinuous gel electrophoresis 
consists of a large-pore stacking gel that concentrates proteins on one same 
starting point. The following separation gel has small pores, allowing the 
separation of proteins according to their size.  
The resolving gel (Table 5) was poured between two glass plates and 
covered by 100% ethanol. After polymerization, ethanol was removed, the 
resolving gel covered with stacking gel (Table 5) and a comb introduced to 
form wells. The electrophoresis apparatus was set up with electrophoresis 
buffer (Table 5), covering the gel in the anode and cathode chamber. Protein 
samples were diluted with 2X loading buffer (Table 5) and subsequently 
denatured for 5 minutes at 100°C. To avoid protein renaturation, samples 
were placed for 2 minutes on ice. Samples were loaded onto a gel and then 
the electrophoresis chamber was connected to a power supply under 
appropriate running conditions (migration in stacking gel: 80 Volts, migration 
in resolving gel: 160 Volts). 
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4.4.6. Western Blot 
Western blot is an analytical technique used to detect specific proteins in 
a given sample of tissue homogenate or extract. Proteins are separated on a 
SDS-page according to their molecular weight. A vertical electric field is 
applied on the SDS-page to transfer proteins from the polyacrylamide gel onto 
a high hydrophobic polyvinylidene fluoride (PVDF) membrane. Target proteins 
are analyzed by immunodetection. 
The PVDF membrane was activated by methanol and together with the 
SDS-PAGE gel pre-incubated in transfer buffer I (Table 5) for 15 minutes 
under agitation. The blotting unit was setup up, starting with a transfer buffer I-
soaked sponge on which three layers of filter paper are disposed. Next, the 
protein containing gel was added and overlaid by the PVDF membrane. This 
assembly was completed with another three filter papers and a sponge. The 
blotting unit was then introduced into the transfer chamber, which was filled 
up with transfer buffer I and blotted for 1 hour at 200mA. 
For the transfer of large proteins (>80kDa) onto the PVDF membrane, 
transfer buffer I was replaced by transfer buffer II (Table 5) and proteins 
transferred at 4°C for 15 hours at 40mA. 
After transfer, the blotting unit was disassembled and the PVDF 
membrane blocked overnight at 4°C or 30 minutes at 37°C either in a 5% milk 
or in a 5% BSA, 1X PBS solution, depending on the antibody. Afterwards, the 
membrane was incubated overnight at 4°C or 1h at room temperature with an 
appropriate dilution of primary antibody directed against the protein of interest. 
After 3 washing steps with 1X PBS-T 0.1%, the membrane was incubated 
with the secondary horseradish peroxidase-conjugated antibody for 1h at 
room temperature. Following 3 washing steps with 1X PBS-T 0.1%, the 
membrane was incubated in a mix of 4ml buffer A and 100µl buffer B of ECL 
plus Western blot reagents for 5 minutes at room temperature. The 
peroxidase coupled to the secondary antibody reacts with the luminol from the 
ECL plus reagents producing a light signal that is detected by an Amersham 
Hyperfilm. The autoradiography film was developed in a Curix 60 film 
processor. 
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4.4.7. GST activity assay 
GST Fluorometric Activity Assay Kit using monochlorobimane (MCB) 
as substrate was used to measure cellular GST activity. The free form of MCB 
is almost non-fluorescent, whereas the conjugated form with glutathione 
fluoresces in blue (ex.380/em.461nm). This reaction of MCB-glutathione 
conjugation is catalyzed by GSTs, whereby the MCB fluorescence level is 
proportional to the total amount of GST activities, present in the reaction. 
Briefly, 1 X 106 cells were collected in duplicates and subsequently 
homogenized by sonication (Diagenode Bioruptor, settings: mode high, 2 
cycles of 30sec on/30sec off) in 100µl of GST sample buffer. After 
centrifugation at 10000 g for 15min at 4°C, supernatants were collected and 
stored at -80°C. A mix constituted of 2µl of MCB solution, 98µl of GST assay 
buffer and 10µl of glutathione was incubated with supernatants. Fluorescence 
was read at ex.380/em.460nm after 1 hour of incubation at room temperature 
using a SPECTRA MAX Gemini EM. Standard calibration curve of GST 
activity was set with the GST standard. GST activity was expressed as mU of 
GST per million of cells.  
 
4.5. Cell biology 
4.5.1. Indirect immunofluorescence labeling 
Immunofluorescence is used to detect the clonal expression or the 
presence of a specific antigen in a cellular system. Indirect 
immunofluorescence labeling requires the use of two antibodies. The primary 
recognizes and binds to the antigen of interest. The fluorescence-tagged 
secondary antibody recognizes the constant fragment of the primary antibody 
allowing the localization of the antigen.  
Localization and quantification of GSTP1 expression was performed on 
paraformaldehyde-fixed cells. A pellet of 8 X 106 cells was resuspended in 
200µl of a 2% paraformaldehyde solution (in 1X PBS) (v/v) and incubated for 
15 minutes at room temperature in the dark. The reaction was diluted by 
adding 800µl of 1X PBS and then washed once with 1X PBS to remove the 
remaining paraformaldehyde. Fixed cells were subsequently permeabilized 
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with 100µl 0.1% Triton-X (in 1X PBS) (v/v) for 8 minutes at room temperature. 
This step allows antibodies to diffuse into cells and to label proteins in the 
cyto- and nucleo-plasma. This permeabilization reaction was stopped with 
900µl 1X PBS and the cells were additionally washed once with cold 1X PBS. 
The primary GSTP1 antibody was diluted with 0.5% BSA in 1X PBS. After 1h 
of incubation at room temperature, cells were washed twice with 1X PBS and 
incubated with a dilution of a fluorochrome-linked secondary antibody (Table 
30) for one hour at room temperature in the dark. After washing twice with 1X 
PBS, cells were preserved in a solution of 0.2% paraformaldehyde in 1X PBS. 
Alexa Fluor 488 and Alexa Fluor 647 fluorescences were read at 
ex.495/em.519nm and ex.650/em.668nm, respectively. 
 
4.5.2. Fluorescent nucleic acid staining 
The blue fluorescent Hoechst 33342 is a cell permeable nucleic acid 
dye, used for DNA labeling in viable cell. This bisbenzimid-azole derivative is 
a supravital minor groove-binding DNA dye that binds preferentially to A-T 
base pairs. AT-rich double stranded DNA enhance the Hoechst fluorescence 
~2-fold greater than GC-rich strands (Portugal and Waring 1988). Because of 
the lipophilic property of Hoechst 33342, cells do not require any 
permeabilization for labeling, but do require physiologic conditions since the 
dye internalization is an active transport process. Hoechst staining is analyzed 
at ex.350/em.461nm. 
The red-fluorescence dye (ex.536/em.617nm) propidium iodide (PI) is a 
DNA/RNA intercalating agent, is membrane impermeant and is excluded from 
living cells. This characteristic is taken in advantage to detect necrotic cells in 
a cell population (Moore, Donahue et al. 1998). 
Cells were incubated with Hoechst 33342 (1µg/ml) for 15 minutes at 
37°C in the dark. Then, PI was added at a final concentration of 1µg/ml and 
DNA staining was analyzed by fluorescence microscopy. 
 
  Methods 
 83 
4.5.3. Cell trace proliferation assay 
The colorless and non-fluorescent carboxyfluorescein diacetate 
succinimidyl ester (CFSE) diffuses passively into cells where it is metabolized 
by intracellular esterases to fluorescent carboxyfluorescein succinimidyl ester. 
This degradation product reacts with intracellular amines, forming fluorescent 
conjugates that are evenly distributed between two daughter cells during 
division. This property can be used to label cells and to trace cell proliferation. 
To analyze population-based proliferation, cells were CFSE-stained 
using CellTrace™ CFSE Cell Proliferation Kit. Cells in exponential growth 
phase were resuspended in pre-warmed 1X PBS/0.1% BSA in a final 
concentration of 1 X 106 cells/ml and stained with 0.2µM CFSE for 10 minutes 
at 37°C. Dye was quenched by the addition of 5 volumes of ice-cold culture 
media. After 5 minutes of incubation on ice, cells were centrifuged and the 
pellet washed twice with fresh media. CFSE staining was analyzed using 
FACSCalibur flow cytometer with 488 nm excitation and emission filter. 
 
4.5.4. Flow cytometry 
Flow cytometry uses the principles of light scattering, light excitation and 
fluorescence emission from molecules to simultaneously analyze multi-
parameters of single cells or particles in the size range between 0.2µm to 
150µm. This technique is applied to determine the expression profile of cell 
surface and intracellular molecules, to characterize and define different cell 
types in heterogeneous cell populations, to assess the purity of isolated 
subpopulations as well as to analyze cell size, granularity and cell volume. 
The flow cytometer is composed of three main systems: fluidics, optics and 
electronics. The sample is first transported through the fluidic system where it 
is hydrodynamically focused using sheath fluid and a very small nozzle 
(Figure 17). 
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Figure 17: Schematic representation of flow cytometry principle. 
Flow cytometer uses the technique of hydrodynamic focusing for presenting cells to a 
laser. The sample composed of unstained cells (blue bubbles) and fluorochrome-
stained cells (red bubbles) is injected into the center of a sheath flow. The combined 
flows are reduced into diameter, forcing cells into the center of the stream to pass 
through the laser beam. In line (1) and perpendicular (2) detectors with the light 
beam as well as fluorescence (3) detectors pick up the combination of scattered and 
fluorescence signals. Analyses of fluctuations in brightness and fluorescence allow to 
obtain various types of information about the physical and chemical structure of each 
individual particle (www.abcam.com/technical). 
 
In the stream of fluid, cells pass like a string of pearls, only one cell at 
the time, the laser light. Since cells intercept the light source, they scatter light 
and fluorochromes are excited. The optical part of the cytometer is constituted 
of a laser to illuminate samples in the stream as well as optical filters to direct 
the resulting light to different detectors (Figure 17). The electronic part collects 
the laser light scattered from cells and converts this information into a signal, 
processed by a computer. A detector in front of the laser light beam (Forward 
scatter, FSC) recognizes the cell size and a second perpendicular (Side 
scatter, SSC) is responsible for the density measurement that means the 
relative granularity and the internal complexity of the cell (Figure 17). 
Fluorescence detector, in the same position as the SSC detector, is used to 
measure the fluorescence intensity of cells (Figure 17).  
Based on the specific light scattering and fluorescent characteristic, it is 
possible to sort a heterogeneous mixture of cells. The FACSCalibur cytometer 
possess a mechanical device “catcher tube” to collect cells of interest. Cells 
(1) 

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pass through the detector system, the computer determines if cells fulfill the 
selected criteria and separate them mechanistically from the remaining 
population.  
Immunostained samples were quantitatively processed by flow 
cytometry using BD FACSCalibur& with the CellQuest Pro (BD bioscience) 
software and analyzed with FlowJo (Treestar, Ashland, USA). Results were 
expressed both as percentage of positive cells and as mean fluorescence 
intensity (MFI). Isotopic control labeling was performed in order to determine 
non-specific fluorescence and to calculate MFI ratios. To separate and collect 
cells of interest from a heterogeneous cell population, immunostained 
samples were sorted using BD FACSCalibur& with CellQuest Pro software. 
4.5.5. Fluorescence microscopy 
For the analysis of fluorescence- or immunofluorescence-labeled 
samples by microscopy, 100µl of cell suspension was precipitated on a glass 
slide with a cytofuge centrifuge system at 20 g for 4 minutes. A coverglass 
was mounted on the glass slide and cells were observed under the 
microscope. Observation and image acquisition were done with the IX81 
Olympus microscope under an UPlanFL 40X/0.75 objective. 
 
4.6. Molecular biology 
4.6.1. Electrophoretic migration 
Gel electrophoresis is a useful method to analyze DNA molecules. The 
naturally present negative charge of the DNA sugar phosphate backbone 
induces, in a direct current field, a migration of the molecule from the 
cathode (-) to the anode (+). Linear double-stranded DNA molecules migrate 
through the agarose matrix with a speed that is inversely proportional to the 
logarithm of its size. A lot of variables, such as size and form of DNA as well 
as current intensity, buffer conditions and gel concentration influence DNA 
migration speed into a gel. 
Samples were diluted with 6X loading buffer, loaded into a gel and 
migration was done in 1X TBE running buffer and 10 Volts per centimeter. A 
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DNA marker with known fragments length was simultaneously migrated to 
determine DNA sample length. The separation of short DNA fragments below 
300bp was realized in 12% TBE-polyacrylamide gels. Larger DNA fragments 
were separated in 0.8% TBE-agarose gels (Table 4). 
 
4.6.2. Ethidium bromide staining 
Ethidium bromide is a DNA/RNA intercalating agent with a detection limit 
of up to 20ng of DNA.  
TBE-polyacrylamide gels were stained in a solution of 0.5µg/ml ethidium 
bromide for 30 minutes at room temperature. Ethidium bromide was directly 
added to agarose gels in a final concentration of 0.5µg/ml. Results of 
electrophoretic migrations were documented on a UV illumination desk in a 
Molecular Imager% Gel Doc XR& System with the Quantity One® software.  
 
4.6.3. DNA extraction 
Genomic DNA extraction was performed using the DNeasy® Blood and 
Tissue Kit as proposed by the manufacturer. An additional step of RNase 
treatment was added in order to eliminate RNA in the extracted DNA. Thus, 
200µg of RNase A was added and incubated for 2 minutes at room 
temperature. Genomic DNA extraction from low number of cells (<5 X 105) 
was performed using the QIAamp® DNA micro Kit as proposed by the 
manufacturer. All genomic DNA samples were stored at 4°C. 
 
4.6.4. DNA quantification 
DNA concentration was measured using a NanoDrop ND-1000 Spectral 
photometer. The UV absorption of DNA solutions is measured at a 
wavelength of 260nm. The amount of absorbed UV-light is proportional to the 
quantity of DNA. A DNA solution with an OD of 1 at a wavelength of 260nm 
has a DNA concentration of 50µg/ml. 
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Double-stranded PCR products were quantified with the Qubit® 
fluorometer by using the Qubit® dsDNA HS assay according to the user 
manual. 
 
4.6.5. DNA precipitation 
Purification of colony PCR products by sodium acetate/ethanol 
precipitation allows optimal conditions for the following reactions. The addition 
of ethanol to the PCR batch causes a lowering of the dielectric constant (F), 
which induces the formation of ion pairs between the polyanion DNA and 
sodium cations. The neutralization of the negative charge on DNA backbone 
provokes its precipitation. 
To one volume of PCR mix, 0.1 volume of 3M Na acetate (pH 5.2) and 3 
volumes of 100% ice-cold ethanol were added. The mixture was incubated 
one hour at -80°C and DNA was precipitated by centrifugation at 15000 g for 
20 minutes at 4°C. The pellucid pellet was washed once with 70% ethanol, 
air-dried and dissolved in an adequate volume of ddH20. 
Avegene Gel PCR/DNA fragments extraction kit solutions and the 
corresponding protocol in combination with the econospin DNA columns 
(Epoch life science, Sugarland, Texas, USA) were used to purify PCR 
products for deep sequencing analysis. 
 
4.6.6. Gel extraction 
PCR products for sequencing were purified with the QIAquick® PCR 
purification Kit. PCR products for Bio-CoBRA assays were purified with the 
QIAEX® II Gel extraction Kit. Both kits were used as proposed by the 
manufacturer Qiagen.  
 
4.6.7. RNA extraction 
For mRNA expression analysis, total RNA was extracted following the 
protocol of the NucleoSpin® RNA II Kit. For miRNA expression analysis, total 
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RNA was extracted following the protocol of the miRNeasy® extraction Kit. All 
RNA samples were stored at -80°C. 
 
4.6.8. RNA quantification 
RNA concentration was measured using a NanoDrop ND-1000 
Spectral photometer. The amount of absorbed UV-light is proportional to the 
amount of RNA; a solution with an OD of 1 at a wavelength of 260nm has an 
RNA concentration of 40µg/ml. 
 
4.6.9. Determination of RNA quality 
RNA quality was verified using the Agilent chip technology (RNA 6000 
Nano Labchip®) on a Bioanalyzer 2100 following manufacturer’s protocol. 
 
4.6.10. Simultaneous RNA and DNA purification 
ALLprep® DNA/RNA Micro/Mini Kit was used to isolate both DNA and 
RNA from the same biological sample. 
Patient tissue samples fixed in OCT Tissue TEK were disrupted in 350µl 
RLT buffer supplemented with 1% #-mercapthoethanol and homogenized into 
Qiashredder spin columns. DNA and RNA were extracted from the lysate by 
following the protocol proposed by the manufacturer.  
Frozen patient samples in DMSO solution were quickly thawed at 37°C, 
transferred in 50ml of 1X PBS containing 10% FBS and centrifuge at 300 g at 
4°C for 7 minutes. Resulting pellets were disrupted as described above.  
 
4.6.11. DNA digestion 
Restriction enzymes were used to cut DNA into small and defined 
pieces. The recognition motives consist mostly in palindromic sequences of 
four to eight base pairs. Endonucleases may generate either blunt or sticky 
(overhangs) ends, where sticky ends are more suitable for a later directional 
ligation. Several enzymes are methylation sensitive and cut only 
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unmethylated sequences, a characteristic used to determine the methylation 
status of a restriction site. 
Restriction enzymes work only under defined buffer, cofactor and 
temperature conditions. Up to 1µg of genomic DNA was digested with 10 units 
of endonuclease in 1X of the corresponding buffer and 1X BSA for 3 hours at 
37°C. DNA digestion products were analyzed by gel electrophoresis. 
For methylation sensitive restriction assay (MSRA), 1µg of genomic DNA 
was incubated with 20 units of HpaII or MspI for 15 hours at 37°C. Then, 10 
additional units of each enzyme were added and incubated for 2 hours at 
37°C. Digestion products were analyzed by electrophoretic migration on a 
0.8% agarose gel. 
 
4.6.12. Cloning, ligation and Blue/White colony screening 
Cloning is a standard procedure to introduce a DNA insert into a 
vector. Both ends of the host vector possess T-overhangs, which prevent 
recircularization and allow fixation of inserts with the A-overhangs, produced 
by Taq polymerases during PCR. A T4-ligase covalently ligates PCR products 
into the pGEM®-T vector. 
The Blue/White selection allows the detection of successful ligation 
between a vector and an insert after transformation. The lacZ gene in the 
multiple cloning site of pGEM®-T Easy vector encodes the $-galactosidase 
enzyme, which can metabolize the X-Gal, present in the medium, into a blue 
dye. The ligation of an insert into the multiple cloning site disrupts the lacZ 
gene leaving cells unstained, whereas vector religation without insert leads to 
$-galactosidase expression and blue-stained cells. 
The pGEM®-T Easy vector cloning system from Promega and the 
enclosed protocol was used to clone PCR products into the pGEM®-T Easy 
vector. 
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4.6.13. PCRs 
PCR (polymerase chain reaction) is an in vitro process for the selective 
isolation and amplification of a specific DNA region (Mullis, Faloona et al. 
1986; Mullis and Faloona 1987).  
The multi stages PCR reaction relies on thermal cycling, consisting of 
cycles of repeated heating and cooling of the reaction for DNA melting and 
enzymatic replication of the DNA. 
- Initialization step: this first heating step (94-98°C) is required for 
activation of chemically- or immunologically-inactivated polymerases.  
- Denaturation step: this step is the first regular cycling event and 
consists of heating the reaction to 93°-97°C, causing DNA melting and the 
separation of double-stranded DNA. 
- Annealing step: the annealing temperature is depending on 
oligonucleotides (size and composition) and buffer conditions. Single strand 
oligonucleotides hybridize on heat-denatured single strand DNA template.  
- Extension/elongation step: the temperature of this step is depending 
on the DNA polymerase (60-72°C). Polymerase catalyzes the synthesis of a 
DNA strand in direction 5’ to 3’, complementary to the DNA template strand by 
adding dNTPs to the 3’-OH oligonucleotide end. Typically, the last three steps 
are repeated in this order up to 40 times. 
Final elongation: this single step is responsible for the A-tailing of PCR 
products. 
 To check whether the PCR generated the desired DNA fragment 
(amplicon), PCR products were resolved using gel electrophoretic migration. 
 
Bisulfite sequencing PCR 
Bisulfite sequencing PCR was used to amplify a specific region of 
bisulfite converted DNA (3.3.2). Depending on the gene, an appropriated PCR 
master mix was prepared as described in Table 36 in a final volume of 50µl. 
Reactions were incubated under polymerase- and primer-specific conditions 
in a thermocycler (Table 37, Table 38, Table 39). 
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Table 36: Composition of the bisulfite sequencing and bisulfite deep 
sequencing PCR master mixture. 
Component Final concentration 
 Hot Star Taq Hot Fire Pol Platinum Taq 
10X PCR Buffer  1X 1X 1X 
MgCl2 / 2.5mM 1.5mM 
dNTPs  0.2mM each 0.2mM each 0.2mM each 
Hot Start binding protein / 2µg 2µg 
Reverse primer  0.40mM 0.16mM 0.20mM each 
Forward primer  0.40mM 0.16mM 0.20mM each 
Template  40ng 20ng 20ng 
Hot Start Taq  2.5U 2.5U 1.5U 
 
Table 37: Cycling conditions for the bisulfite sequencing PCR with the Hot 
Start Taq polymerase. 
Phase  Temperature (°C) Time (minutes) 
Initialization 95 15 
Denaturation 94 1 
Number of cycles (see 
Table 21 and Table 23) Annealing Table 21 and Table 23 1 Extension 72 1 
Final extension 72 10 
 
Table 38: Cycling conditions for the bisulfite PCR with the Hot Fire Pol 
polymerase. 
Phase  Temperature (°C) Time (minutes) 
Initialization 95 15 
Denaturation 95 1 
42 cycles Annealing Table 23 1 
Extension 72 1.5 
Final extension 72 10 
 
Table 39: Cycling conditions for the bisulfite PCR with the Platinum Taq 
polymerase. 
Phase  Temperature (°C) Time (minutes) 
Initialization 94 2 
Denaturation 94 0.5 
42 cycles Annealing Table 23 0.5 
Extension 72 1 
 
Resulting amplicons were resolved on a 1.2% agarose gel. Acquisition 
of the ethidium bromide-stained gels was realized in the Molecular Imager® 
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Gel Doc XR& System. Selected amplicons were subsequently extracted from 
the gel and used for combined bisulfite restriction assay, cloned into an 
amplification vector for sequencing or directly used for deep sequencing. 
 
Colony PCR 
Colony PCR is an additional method to both identify clones with insert-
containing plasmids and amplify simultaneously regions of interest for 
subsequent processes. Instead of purified DNA, a whole bacterial clone is 
used as template in the PCR step. The high denaturation temperature, at the 
beginning of the PCR, lyses cells and denatures proteins responsible for DNA 
degradation. Plasmid DNA molecules enclosed in cells are liberated and used 
as template for amplification. 
A PCR master mix with a final volume of 40µl was prepared and 
inoculated with a bacterial clone. The reaction was then incubated under 
specific conditions in a thermocycler (Table 40 and Table 41). 
 
Table 40: Composition of colony PCR master mix. 
Component Final concentration 
5X GoTaq Buffer  1X 
MgCl2  1.5mM 
dNTPs  0.25mM each 
LacZ reverse primer  0.2mM 
LacZ forward Primer  0.2mM 
Platinum Taq DNA polymerase HIFI  1.5U 
 
Table 41: Cycling program for colony PCR. 
Phase  Temperature (°C) Time (minutes) 
Initialization 95 3 
Denaturation 95 0.5 
30 cycles 
 
Annealing 65 0.5 
Extension 72 1 
Final extension 72 5 
 
PCR products were analyzed on a 1% agarose gel. Colony PCR 
products were additionally precipitated and sequenced.  
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Methylation-specific PCR 
MSP is a bisulfite conversion-based PCR technique that can rapidly 
assess the methylation status of almost any group of CpG sites within a CpG 
island, even in regions with high CpG density (Figure 18).  
 
Figure 18: Methylation-specific PCR principal. 
Workflow of MSP technique, illustrated with an example of fully methylated (allele M) 
or unmethylated (allele UM) genomic DNA templates. Cm: methylated cytosine. 
 
This assay consists of an initial chemical DNA modification by sodium 
bisulfite, converting all unmethylated, but not methylated, cytosines to uracils. 
For the subsequent PCR amplification, primers are designed to specifically 
amplify the methylated or the unmethylated allele as well as to discriminate 
between unmodified and bisulfite modified DNA molecules (Figure 18). To get 
the highest specificity and provide maximal sensitivity to the assay, primer 
sequences are chosen for regions containing frequent cytosines and CpG 
pairs near the 3’ end of the primers. The initial report using MSP describes 
sufficient sensitivity to detect methylation of 0.1% of alleles. In general, MSP 
and its related protocols are considered to be the most sensitive approach 
when interrogating the methylation status of a specific locus. Successful 
amplification from methylated (M) or unmethylated (U) primer pairs indicates 
the methylated or unmethylated status of the original DNA template, 
respectively (Figure 18) (Herman, Graff et al. 1996).  
  Methods 
 94 
MSP conditions for a given gene locus and the corresponding primers 
set (Table 22) were optimized with fully methylated or unmethylated converted 
and unconverted DNA, provided with the EpiTect® PCR Control DNA Kit. This 
commercially available DNA was also used as positive and negative controls. 
MSPs were carried out under specific conditions (Table 42 and Table 43) with 
methylation-specific primers (Table 22) in a master mix with a final volume of 
25µl. 
Table 42: Composition of the MSP master mix.  
Component Final concentration 
10X HIFI Buffer  1X 
MgSO4  3mM 
dNTPs  0.2mM each 
Primer R  0.4mM 
Primer F  0.4mM 
Template 20ng 
Platinum Taq DNA polymerase HIFI  1.5U 
 
Table 43: Cycling conditions for methylation-specific PCR. 
Phase  Temperature (°C) Time (minutes) 
Initialization 94 2 
Denaturation 94 0.25 
Number of cycles 
(see Table 22) Annealing Table 22 0.5 Extension 68 0.5 
 
Hot Star Taq polymerase with the corresponding PCR protocol and annealing 
temperature was alternatively used to amplify certain gene regions (Table 22). 
PCR products were resolved in a 12% polyacrylamide gel, stained with 
ethidium bromide and documented under UV illumination on Molecular 
Imager® Gel Doc XR& System. 
 
Reverse transcription of mRNA 
Reverse transcription converts single-stranded RNA into single-
stranded cDNA using a RNA-dependent DNA polymerase. This conversion 
permits the detection of variation in RNA transcription levels. All compounds 
for reverse transcription of mRNA were provided by Invitrogen. 
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One microgram of total RNA and 0.5µg Oligo(dT) primer were 
denatured at 70°C for 10 minutes and immediately cooled down at 4°C. The 
denatured RNA was reverse transcribed in the presence of the following 
components: 
- 5X First strand buffer 1X 
- dNTPs  0.5mM (each) 
- 0.1M DTT 10µM 
- Superscriptase Reverse transcriptase RNase (SSII RT)  50U 
- RNaseOUT™ Recombinant Ribonuclease Inhibitor  40U 
This mixture was incubated in a thermocycler for 90 minutes at 42°C, then 
heated up to 70°C for 15 minutes and hold at 4°C. Two Units of RNase H 
were afterwards added to the mixture and incubated for 20 minutes at 37°C. 
RNase H treatment eliminates mRNA matrix. The cDNA synthesized during 
this process was diluted with ddH2O at 40ng/µl and stored at -20°C. 
 
Reverse Transcription of miRNA 
Unlike mRNAs, miRNAs are not polyadenylated in nature. During this 
reverse transcription step, miRNAs are polyadenylated by poly(A) 
polymerase. Reverse transcriptase converts all RNAs (including precursor 
miRNAs, mature miRNAs, other small non-coding RNAs, and mRNAs) to 
cDNA using oligo(dT) and random primers. Polyadenylation and reverse 
transcription are performed sequentially in the same tube. Oligo(dT) primers 
have a universal tag sequence on the 5’ end. This universal tag allows 
amplification in the following real-time PCR step. 
Reverse transcription of 1µg of total RNA was done with the miScript® 
Reverse Transcription Kit (Qiagen) following manufacturer’s protocol and 
cDNA was diluted to 1ng/µl. 
 
Real-time PCR 
Real-time PCR enables both detection and quantification of a specific 
DNA sequence in relation to an internal calibration gene (e.g. the 
housekeeping gene $-actin). Unlike the standard PCR, the accumulation of 
amplified DNA is detected in real-time during amplification cycles by 
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fluorescence measurement. Therefore, the double strand-specific DNA 
intercalant fluorescent dye SYBR®Green is used to quantify DNA synthesis. 
In this work, real-time PCR was realized using a specific master mix 
and under stringent conditions (Table 44, Table 45). 
Table 44: Composition of the real-time PCR master mix. 
Component Final concentration 
Power SybrGreen PCR Master Mix 1X 
Primer (reverse and forward) 0.1mM each 
Diluted cDNA  8ng 
 
All real-time primers were designed for an annealing temperature of 
60°C. Melting curve analysis and electrophoretic gel migration were done to 
test primers specificity.  
Table 45: Cycling program for the real-time PCR.  
Phase  Temperature (°C) Time (minutes) 
Initialization 95 10  
Denaturation 95 0.25 
40 cycles Annealing/ Extension 60 1 
 
For mature miRNA detection, cDNA of total RNA serves as template for 
real-time PCR analysis using a miRNA specific miScript primer assay (Table 
26) in combination with the miScript SYBR®Green PCR Kit. MiRNAs are 
amplified using the miScript universal primer, which primes from the universal 
tag sequence, together with the miScript primer assay, which is specific for 
the mature miRNA under study.  
For miRNA expression analysis, real-time PCR was realized under 
stringent conditions using a specific master mix (Table 46 and Table 47). 
Table 46: Composition of the real-time PCR master mix for miRNA expression 
analysis. 
Component Final concentration 
QuantiTect SYBR®Green PCR master mix 1X 
miScript Primer Assay 1X 
miScript Universal Primer Assay 1X 
Diluted cDNA  2ng 
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All real-time primers were designed for an annealing temperature of 
55°C.  
Table 47: Cycling program for the real-time PCR for miRNA expression 
analysis.  
Phase  Temperature (°C) Time (minutes) 
Initial activating step 95 15  
Denaturation 94 0.25 
40 cycles Annealing 55 0.5 
Extension 70 0.5 
Melting curve    
 
Data from real-time PCR are represented as an amplification curve, 
derived from the fluorescence intensity plotted against the number of 
amplification cycles. A threshold was set up in the log-linear range of this 
amplification curve. The threshold cycle (Ct) value is used to calculate the 
amount of starting template in each sample. This is the cycle at which the 
amplification plot crosses the threshold. The raw instrument data (i.e. Ct 
values) were normalized against a reference gene (i.e. $-actin for mRNA or 
RNU1A for miRNA), resulting in “delta Ct”. The relative expression ratio was 
finally calculated with the comparative Ct method by the arithmetic operation: 
2-delta Ct.  
 
4.6.14. Bisulfite treatment 
Methylated cytosines have nearly the same base pairing characteristics 
as unmethylated cytosines, and can therefore not be differentiated in normal 
sequencing reactions. In contrast, selective base conversion called bisulfite 
mutagenesis allows methylated DNA to be distinguished from unmethylated 
DNA (Figure 19). 
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Figure 19: Chemical process of the bisulfite-induced deamination of cytosine 
to uracil.  
Step 1: Sulphonation, Step 2: hydrolytic deamination, Step 3: alkali desulphonation 
(Hayatsu 2008). C: cytosine, U: uracil, C-SO3-: cytosine-sulphonat, U-SO3-: uracil 
sulphonate. 
 
Bisulfite has the property to efficiently convert cytosine bases into 
uracils, whereas methylated cytosines stay unmodified (Figure 19). The initial 
step of the bisulfite conversion is the denaturation of genomic DNA. The 
carbon atom in position 6 (C6) of the pyrimidine ring is sterically blocked in 
double-stranded DNA. Therefore, it has to be denatured to single-stranded 
DNA. The subsequent chemical process consists in sulphonation of the 
cytosine to cytosine-sulphonat (C-SO3-) (Figure 19). A methylation-free 
cytosine possesses in its pyrimidine ring a free C5-C6 carbon bond. This free 
binding capacity of the C5 atom allows adduct formation with bisulfite ions. In 
case of a methylated cytosine, this C5 atom is blocked, which is preventing 
the chemical modification. In aqueous phase, the intermediate sulphonated 
cytosine gets deaminated and transformed to uracil sulphonate (U-SO3-). The 
final alkaline treatment causes the desulphonation of the molecule to uracil 
(Figure 19) (Frommer, McDonald et al. 1992; Clark, Harrison et al. 1994). 
Bisulfite conversion was performed using the Epitect Bisulfite Kit as 
proposed by the manufacturer.  
For methylation analysis by deep sequencing, genomic DNA was 
converted by adding 187µl of conversion buffer and 73µl of scavenger 
solution to 500ng of genomic DNA in a final volume of 20µl. After incubation at 
the following conditions: 99°C 15min, 50°C 30min, 99°C 5min, 50°C 90min, 
99°C 5min and 50°C for 90min, the conversion mixture was diluted with 150µl 
ddH20 and loaded on a microcon centrifugal filter Ultracel YM-30 (Milipore). 
The column was centrifuged for 30 minutes at 11000 g, the flow-trough 
discarded and the column wash once with 500µl 1X TE, Then, 500µl 
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desulphonation solution was added on the column and incubated for 10min at 
room temperature. After a centrifugation step of 10000 g for 18 minutes, the 
flow-trough was discarded and the column washed with 500µl 1X TE. Column 
was then turned over and placed on a new tube and DNA eluted with 50µl of 
50°C pre-warmed 1X TE buffer. Converted DNA was stored at 4°C.  
 
4.6.15. Bio-CoBRA 
Combined bisulfite restriction assay (CoBRA) relies on the innovation 
of Sadri and Hornsby who have shown that restriction digestion can be used 
to reveal DNA methylation-dependent sequence differences in PCR-amplified 
bisulfite-treated genomic DNA (Sadri and Hornsby 1996). Bisulfite conversion 
of genomic DNA leads to methylation-dependent formation of new restriction 
enzyme sites or retention of the pre-existing sites. After PCR amplification, 
this feature can be exploited to determine DNA methylation levels at specific 
loci, with a very high quantitative accuracy. However, bisulfite-generated 
restriction sites are preferred because they allow the simultaneous control of 
complete bisulfite conversion. It is important to stress that the restriction 
enzyme cleavage itself is not methylation-dependent because PCR products 
do not contain 5-methylcytosine. Results of restrictions are classically 
analyzed by PAGE separation or southern blot. Alternatively, the restriction 
profile can be quantitatively analyzed by capillary electrophoresis in micro 
fluidics chips (Bio-CoBRA) (Brena, Auer et al. 2006; Brena, Auer et al. 2006).  
Conversions of DNA samples as well as PCR amplification of the target 
sequence were done as previously described (see 4.6.14 and 4.6.13). PCR 
products were electrophoresed in a 1X TBE-1.5% agarose gel, visualized by 
ethidium bromide staining and purified with the Qiaex® gel extraction Kit. 
Restriction digestion of 100ng of PCR product was realized as already 
mentioned (see 4.6.11). Digested samples were next concentrated using a 
SpeedVac and 20ng were loaded on the Agilent DNA 1000 LabChip as 
proposed by the manufacturer and analyzed using the Agilent Bioanalyzer 
2100.  
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4.6.16. Crosslinked chromatin immunoprecipitation (X-ChIP) 
Crosslinked chromatin immunoprecipitation (X-ChIP) is mainly used to 
investigate the interactions between proteins (e.g. transcription factors) and 
specific DNA regions such as gene promoters or other DNA binding domains 
in cells. In addition, X-ChIP is suitable for the mapping of histone 
modifications or to detect the recruitment of histone-modifying enzymes to 
specific gene regions. By incubating cells with a crosslinking agent, in vivo 
reversible cross-linking of proteins with DNA is achieved (Figure 20). After cell 
lysis, DNA-chromatin is sheared by sonication or using micrococcal nuclease 
(Figure 20). Protein-DNA complexes are selectively isolated using a specific 
antibody against the protein of interest (POI), coupled to magnetic, agarose or 
sepharose beads (Figure 20). Bead-antibody-POI-DNA complexes are then 
collected, washed and the crosslink reversed. DNA regions associated to the 
protein are identified by conventional PCR, real-time PCR or by Chip (ChIP on 
Chip) (Figure 20). 
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Figure 20: Schematic overview of cross-linked chromatin immunoprecipitation 
procedure. 
For preservation of protein/DNA interactions, intact cells are fixed with formaldehyde 
(step 1). After cell lysis (step 2), chromatin is sheared (e.g. sonication) into small size 
uniform fragments (step 3). DNA/Protein complexes are immunoprecipitated with 
antibodies specific for the protein of interest and recovered using protein A/G 
sepharose beads (step 4). The cross-link is reversed and DNA purified and analyzed 
by PCR to determine which DNA regions were interacting with the protein of interest 
(step 5). Modified from Nelson et al. (Nelson, Denisenko et al. 2006). 
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To analyze DNA/protein interactions by X-ChIP, 107 cells were cross-
linked with 1% formaldehyde for 8 minutes at room temperature. After cross-
linking, the reaction was quenched with 0.125M of glycine for 10 minutes at 
room temperature. Cells were washed twice with ice-cold 1X PBS, pelleted by 
centrifugation at 350 g for 7 minutes at 4°C, resuspended in 1ml of cell lysis 
buffer (Table 8) and 1X protease inhibitor cocktail and incubated 30 min at 
4ºC under agitation. After centrifugation at 2500 g for 5 minutes at 4°C, nuclei 
were resuspended in 300µl nuclei lysis buffer (Table 8) and incubated for 10 
minutes on ice. Chromatin with a size range from 0.5kb to 0.9kb was prepared 
by sonication using a Bioruptor (Diagenode) at the following settings: mode 
high, 16 cycles of sonication (30 seconds on / 30 seconds off). Cell debris 
were removed by centrifugation at 15000 g for 10 minutes at 4°C. 
Supernatant was pre-cleared 1 h at 4ºC with 25µl of a 50% gel slurry of 
protein A/G-agarose beads saturated with salmon sperm DNA and bovine 
serum albumin. After centrifugation at 800 g for 3 minutes at 4°C, supernatant 
was recovered, diluted 10 times in IP dilution buffer (Table 8) and 10% was 
used as input. The diluted chromatin was incubated overnight at 4°C with 1-
2µg of the antibody of interest (Table 28) and the immune complexes were 
recovered by 1h incubation at 4ºC with 30µl of a 50% gel slurry of protein 
A/G-agarose beads (Upstate). The precipitated complexes were washed 
sequentially at 500 g for 5 minutes at 4°C with low salt buffer, high salt buffer, 
LiCl buffer and twice with 1 X TE buffer. Chromatin was eluted twice with 60µl 
of freshly prepared 67°C pre-warmed elution buffer under agitation for 15 
minutes at room temperature (Table 8). Cross-link was reversed by an 
overnight incubation of the elute at 67ºC, in presence of 0.3M NaCl and 10µg 
of RNase A (Roche). Samples were then digested with 30µg of proteinase K 
(Roche) in the presence of 40mM Tris-HCL pH 6.5 and 10mM EDTA at 45ºC 
for 1 h. DNA was purified using QIAquick PCR purification kit (Qiagen) and 
analyzed by real-time-PCR. PCRs were performed using primers that covered 
different regions of the GSTP1 promoter (Table 25). 
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4.7. Statistical analysis 
Data are presented as means ± standard deviation (SD), and analyzed 
by the Student’s t-test. p-values below 0.05 were considered as statistically 
significant.  
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5. Results 
 
Pathological alterations in the native epigenetic pattern, such as 
aberrant methylation, have great potential for clinical use as promising 
cancer-specific biomarkers. Tumor biomarkers are useful in the identification 
of individuals at increased risk of developing cancer and in the early detection 
of malignant transformations. 
The hypermethylated GSTP1 gene is already used as a promising 
DNA methylation biomarker for prostate cancer diagnosis (Duffy, Napieralski 
et al. 2009). This aberration reduces or silences GSTP1 expression, 
decreasing cell detoxification and enhancing consequently the susceptibility of 
genomic mutations (e.g. breast, prostate and hepatocellular carcinoma). In 
contrast, DNA hypomethylation leads to high level of GSTP1 expression, 
improving cell detoxification ability and mediating resistance against 
cytostatics.  
In addition, PTGS2 overexpression is nowadays well accepted as a 
major player in cancer development by activating cell survival and growth-
promoting genes. In contrast, it is now becoming clear that in certain cancer 
types (e.g. gastric, colorectal), promoter hypermethylation represses PTGS2 
expression. In consequence, in these cells both inflammation response and 
cellular defense are attenuated.  
The cases of both epimutated genes demonstrate that a balanced 
gene expression, regulated by defined epigenetic modification patterns, is 
very important to avoid for instance prostate or gastric tumor development. 
This finding may be extended to hematological malignancies but requires 
therefore further investigations.  
Moreover, simultaneous analysis of a broad range of epigenetic 
biomarker genes will enhance clinical relevance of DNA methylation profiling, 
for example in the context of individualized medicine. However, aberrant 
methylation patterns need to be researched further in blood cancer cells in 
order to pass from a pure laboratory discipline to an area of  
great bedside relevance to practicing oncologists. 
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Considering that fact that cancer has an epigenetic etiology, one of the 
tasks to be tackled in the future will be the efficient and specific modulation of 
such epigenetic alterations in hematological malignancies as well as in other 
cancer types. At the moment, nucleoside analogs AZA and DAC are the most 
effective demethylating compounds. The FDA-approved drug DAC is used for 
MDS treatment and currently under clinical investigations for treatment of 
leukemia. However, the demethylation effects seem to be unspecific, leading 
to activation of genes such as oncogenes or transposable elements. Further 
investigations are required to elucidate detailed process of DAC-mediated 
demethylation as well as cellular consequences of DAC treatment. 
 
5.1. Epigenetic regulation of GSTP1 gene expression in 
hematological malignancies 
 
Since the relationship between epigenetic modifications and GSTP1 
expression in leukemia cells remains at the moment poorly understood, the 
first part of this thesis was focused on the analysis of the epigenetic regulation 
of GSTP1 expression in leukemia and lymphoma cell lines. Furthermore this 
study was extended to samples from hematological malignant patients, in 
order to test the possibility to introduce GSTP1 as a possible cancer 
biomarker. 
 
5.1.1. Analysis of the constitutive GSTP1 expression in human 
leukemia/lymphoma cell lines 
 
First, basal GSTP1 gene expression was assessed in various leukemia 
and lymphoma cell lines. Total mRNA from a panel of 10 leukemia and 
lymphoma cell lines was reverse transcribed and GSTP1 as well as !-actin 
mRNA levels analyzed by real-time PCR (Figure 21-A). To compare GSTP1 
transcription and translation, GSTP1 protein expression was determined by 
Western Blot (Figure 21-B). 
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Figure 21: Analysis of basal GSTP1 expression in human leukemia and 
lymphoma cell lines. 
(A) Total RNA extracted from various leukemia and lymphoma cell lines was reverse 
transcribed into cDNA and analyzed by real-time PCR with primers specific for 
GSTP1. !-actin was analyzed as a cDNA quantity control. Results represent the ratio 
of GSTP1/!-actin mRNA expression. (B) Total protein extractions from the indicated 
cell lines were analyzed by Western Blot with an antibody specific for GSTP1. !-actin 
was used as loading control. Pictures are representative of 3 independent 
experiments. (C) Chemiluminescence was acquired with the Kodak image station 
440 CF, quantified with the Kodak 1D image analysis software and normalized to the 
housekeeping gene !-actin. The relative level of GSTP1 protein in various cell lines 
is expressed compared to the level in K-562 cells set to 100%. Data are the means ± 
SD of 3 independent experiments.  
 
The highest amount of GSTP1, at both mRNA and protein levels, was 
detected in the CML cell line K-562, whereas GSTP1 was undetectable in 
RAJI and MEG-01 cells. Furthermore, relatively high basal GSTP1 expression 
was detected in JURKAT, TF-1, HL-60 and U-937 cell lines, in contrast to the 
B 
C 
A 
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moderate GSTP1 expression levels detected in JVM-2, HEL and MOLT-3 cell 
lines (Figure 21). 
 
5.1.2. Effect of DAC treatment on GSTP1 expression in human 
leukemia/lymphoma cell lines 
 
 Previous results about differential levels of GSTP1 expression in blood 
cancer cell lines and the fact that hypermethylation-mediated GSTP1 
silencing is established for other cancer types leaded to the hypothesis that 
hypermethylation could be involved in leukemia-specific GSTP1 
downregulation. Therefore, we assessed the effects of the DNA demethylating 
agent DAC on GSTP1 expression. Total mRNA from K-562, RAJI, MEG-01, 
HEL, MOLT-3 and JVM-2 cells, treated for various time points and doses with 
DAC was extracted and GSTP1 as well as !-actin mRNA expression 
quantified by real-time PCR (Figure 22-A, B, C). Moreover, evolution of 
GSTP1 protein expression was analyzed by Western Blot (Figure 22-D).  
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Figure 22: Effect of DAC treatment on GSTP1 expression in 
leukemia/lymphoma cell lines. 
K-562, RAJI and MEG-01 cell lines were treated with various DAC doses at different 
time periods. Total RNA was isolated and the (A) dose- and (B) time-dependent 
effects of DAC on GSTP1 mRNA expression were assessed by real-time PCR. 
Results represent the ratio GSTP1/!-actin mRNA. (C) Cells were harvested after 
various time points of DAC treatment and analyzed by Western Blot with an antibody 
specific for GSTP1. Relative level of GSTP1 protein expression in various blood 
cancer cell lines is normalized against !-actin and expressed compared to the 
GSTP1 expression level after 6 days of DAC treatment. Pictures are representative 
for 3 independent experiments. (D) Total RNA from various untreated (-) and DAC-
treated (+) leukemia cell lines was isolated and analyzed by real-time PCR. Results 
represent the ratio GSTP1/!-actin mRNA. Data are means ± SD of 3 independent 
experiments. *p<0.05, **p<0.01 vs control. 
 
A B 
C D 
  Results 
 109 
Results showed that DAC treatment further increased constitutive 
GSTP1 mRNA and protein expression in a time- and concentration-dependent 
manner in K-562 cell line. Regarding RAJI cells, DAC treatment drastically 
induced GSTP1 transcription after two days whereas GSTP1 protein was 
restored one day later. Similarly, DAC affected GSTP1 expression in MEG-01 
cells; however, the induction in MEG-01 was delayed and weaker compared 
to RAJI cells. In both GSTP1 silenced cell lines, the effect of DAC was time- 
but not concentration-dependent for the tested range of concentrations 
(Figure 22-A, C). Furthermore, DAC-mediated induction of GSTP1 expression 
was delayed in MEG-01 cells compared to RAJI cells. Based on these results, 
we used 2µM DAC to analyze the mechanism of induction of GSTP1 
expression in blood cancer cell lines (Figure 22-B). In HEL, MOLT-3 and JVM-
2 cells, DAC treatment significantly enhanced the moderate constitutive 
GSTP1 mRNA expression levels (Figure 22-D). 
 Western Blot as well as real-time PCR techniques give only an overall 
of the level of GSTP1 expression in a cell population. To evaluate the 
localization and cell-specific GSTP1 expression in our models, K-562, RAJI 
and MEG-01 cells were treated for 3 days with DAC and subsequently 
immunostained with a GSTP1 antibody. Nucleus were stained with Hoechst 
and samples analyzed by fluorescence microscopy.  
 
  Results 
 110 
GSTP1 Merged Hoechst 
Control 
DAC 
MEG-01 
DAC 
RAJI 
Control 
DAC 
Control 
K-562 
 
Figure 23: Analysis of GSTP1 expression in control and DAC-treated K-562, 
RAJI and MEG-01 cells by immunofluorescence.  
GSTP1 expression in DAC-treated (2µM, 3 days) was assessed by 
immunofluorescence using primary anti-GSTP1 and secondary Alexa Fluor-488 
conjugated (green) antibodies. Hoechst 33342 (blue) was used for nuclear staining. 
Fluorescence signals were observed with the fluorescence microscope IX81 
Olympus microscope under an UPlanFL 40X/0,75 objective and data were acquired 
by using the CCD camera Olympus XM10. GSTP1 sub-localization was evaluated by 
overlay (merged). Pictures are representative for 3 independent experiments. 
 
  Results 
 111 
Microscopy images of GSTP1-immunostained K-562 cells showed that 
all cells express GSTP1. Moreover, DAC treatment further enhanced GSTP1 
expression in some K-562 cells (Figure 23). In contrast, untreated RAJI and 
MEG-01 cell lines did not or expressed undetectable levels of GSTP1 protein. 
However, images clearly demonstrated that GSTP1 expression is induced in a 
subpopulation of RAJI and MEG-01 cells after 3 days of DAC exposure 
(Figure 23). Finally, DAC-induced GSTP1 expression was more pronounced 
in RAJI compared to MEG-01 cells (Figure 23). 
In order to quantify cell-specific GSTP1 expression in K-562, RAJI and 
MEG-01 leukemia cell lines, GSTP1-immunostained cells were analyzed by 
flow cytometry. Hence, untreated and DAC-treated K-562, RAJI and MEG-01 
cells were fixed, permeabilized and immunostained for GSTP1 (Figure 24).  
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Figure 24: Quantification of GSTP1 expression in DAC-treated K-562, MEG-01 
and RAJI cells. 
K-562, RAJI and MEG-01 cell lines were treated with 2µM DAC for 3 days and 
GSTP1 stained with primary anti-GSTP1 and secondary Alexa Fluor-488 conjugated 
anti-mouse antibodies. Fluorescence of 105 immunostained K-562, RAJI and MEG-
01 cells was detected by flow cytometry on a FACSCalibur and analyzed by 
CellQuest Pro. (A) Upper panel: The fluorescence intensity was measured as mean 
fluorescence intensity (MFI) ratios of immunostained leukemia cells in relation to the 
IgG. Lower panel: Fold induction of GSTP1 protein expression after 3 days of DAC 
treatment. (B) One dimensional GSTP1 frequency histogram of 105 wild type (red 
line) and DAC-treated (blue line) RAJI and MEG-01 cell lines, treated for 3 or 6 days. 
Data are means ± SD of 3 independent experiments. * p<0.05, **p<0.01 vs control. 
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The highest MFI ratio, representative for the GSTP1 expression level, 
was measured in K-562 cells (MFI ratio 23.8). In contrast, low MFI ratios were 
identified in RAJI (MFI ratio: 4) and MEG-01 (MFI ratio: 4.2) cells (Figure 24-
A). Quantification of the DAC-induced GSTP1 immunostaining revealed a 
drastic and significant 4.4-fold increase of GSTP1 expression after 3 days of 
DAC treatment. In correlation with microscopy results, frequency histogram 
showed that only a subpopulation of about 65% of the DAC-treated RAJI 
population was GSTP1-positive compared to untreated cells (Figure 24-B). In 
MEG-01 cells, 3 days of DAC exposure caused a significant induction of 
GSTP1 protein expression of about 1.6-fold (Figure 24-A). Moreover, 6 days 
of DAC exposure were required to induce GSTP1 expression in 33,8% of the 
MEG-01 cell population (Figure 24-B).  
Immunostaining and Western Blot analyses showed that GSTP1 is 
highly expressed in K-562 leukemia cells and can be induced by DAC 
treatment in RAJI and MEG-01 cells. Next, we wanted to evaluate the impact 
of DAC on GST enzymatic activity. Results are presented in Figure 25. 
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Figure 25: Total glutathione S-transferase activity in DAC-treated leukemia cell 
lines. 
K-562, RAJI and MEG-01 cell lines were treated with for 3 and 6 days with DAC and 
the intracellular glutathione S-transferase (GST) activity determined by measuring 
the fluorescence level of monochlorobimane, a dye that reacts with glutathione. 
Fluorescence results were interpolated by a calibration curve to obtain GST activity 
values. (A) Constitutive cell line-specific GST activity (mU/106 cells). (B) Cell line-
specific and time-dependent increase of GST activity was expressed as a fold 
induction in treated cells vs untreated cells. Data are the means ± SD of 3 
independent experiments. * p<0.05, **p<0.01 vs control.  
 
The highest basal GST activities were measured in K-562 (88.5mU/106 
cells) and MEG-01 (74mU/106 cells) cells in contrast to the lowest GST 
activity detected in RAJI cells (9.4mU/106 cells) (Figure 25-A). Furthermore, 
DAC exposure increased GST activity in a time-dependent manner and 
reached a 3- and 12-fold induction in 3 and 6-day treated RAJI cells, 
A 
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respectively. A slight but significant GST activity induction was observed in 
DAC-treated K-562 and MEG-01 cells (Figure 25-B). 
 
5.1.3. Effect of HDAC inhibitors on GSTP1 expression in human 
leukemia cell lines 
 
In addition to DNA methylation, histone modifications such as acetylation 
or methylation could be implicated in the epigenetic regulation of GSTP1 
transcriptional activity by modifying gene accessibility. Effects of common 
HDACis on GSTP1 expression in blood cancer cell lines were analyzed. Thus, 
K-562, RAJI, MEG-01 cells were first treated with DAC for 3 days and 
subsequently with 1mM VPA or 2µM SAHA for 16 hours. Total RNA was 
extracted and GSTP1 as well as !-actin cDNA amounts were analyzed by 
real-time PCR (Figure 26). Treatment of K-562, RAJI and MEG-01 cells with 
HDACis alone lack significant induction of GSTP1 expression. In contrast, 
sequential treatments with DAC and then HDACis caused a moderate but 
significant increase of GSTP1 expression in RAJI and MEG-01 cells, 
compared to DAC treatment alone.  
 Effectiveness of HDAC inhibition was verified by analyzing the status of 
histone H4 acetylation (Figure 26). Both HDACi increased total histone H4 
acetylation, whereas DAC alone failed to induce histone H4 acetylation. 
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Figure 26: Effects of HDAC inhibitors on GSTP1 expression in leukemia and 
lymphoma cell lines and on total histone H4 acetylation. 
Various leukemia cell lines were treated either with DAC, VPA, SAHA alone or were 
co-treated with DAC for 3 days followed by 16 hours in presence of VPA or SAHA. 
Upper panel: total RNA was extracted and GSTP1 mRNA expression assessed by 
real-time PCR. Results represent the ratio GSTP1/!-actin mRNA expression level 
and are the mean ± SD of 3 independent experiments. *p<0.05, **p<0.01 vs control; 
#p<0.05, # # p<0.01 vs DAC. Lower panel: acid extracts were analyzed by Western 
Blot with antibodies specific for histone (H4) and its acetylated form (AcH4). Pictures 
are representative for 3 independent experiments. DAC: 5-aza-2!-deoxycytidine, 
VPA: valproic acid, SAHA: suberoylanilide hydroxamic acid. 
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5.1.4. DNA methylation analysis of GSTP1 promoter region 
 
The effect of the DNA demethylating agent DAC on GSTP1 expression 
prompted us to hypothesize that methylation of the GSTP1 promoter region 
could explain the lack of GSTP1 expression in RAJI and MEG-01 cell lines. In 
silico, CpG density analysis identified 12 CGis in a region of approximately 
20000bp length 5’ upstream region of the GSTP1 gene (Figure 27-A). A long 
CGi, potentially involved in the epigenetic regulation of GSTP1, was identified 
near the GSTP1 transcription start site.  
 
 
Figure 27: CpG island analysis of the GSTP1 promoter region. 
(A) In silico CpG density analysis of the GSTP1 promoter region (-20353, +2834) 
using the Methylprimer express software. Vertical red bars represent CpG 
dinucleotides and horizontal blue bars indicate CGi positions. Position and length of 
the (ATAAA) repetitive sequence and the transcription start point (+1) are indicated. 
(B) In silico CG analysis of the GSTP1 5’ upstream (upper panel) and promoter 
(lower panel) region with the web-based tool CpGPlot. The observed vs expected 
ratio, the CG percentage and a putative CGi are represented. (C) Sequence of the 
putative CGi with the CpG dinucleotides highlighted in red. The positions of the 
binding sites for GATA-1, NF-"B, AP-1 and SP1 are framed in blue and the 
transcription start site is underlined and highlighted in green. 
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ACTAAAAGGAACGTGATCATGTCCTTTGCAGGGACATGGGTGGAGCTGGAAGCCGTTAGCCTCAGCAAACTCACACAGGAACAGAAAACCAGCGAGACCGCATGGTC
TCACTTATAAGTGGGAGCTGAACAATGAGAACACATGGTCACATGGCGGCGATCAACACACACTGGTGCCTGTTGAGCGGGGTGCTGGGGAGGGAGAGTACCAGGAA
GAATAGCTAAGGGATACTGGGCTTAATACCTGGGTGATGGGATGATCTGTACAGCAAACCATCATGGCGCACACACCTATGTAACAAACCTGCACATCCTCTACATG
TACCCCAGAACTTCAAATAAAAGTTGGACGGCCAGGCGTGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAAGCCGAGGCGTGCAGATCACCTAAGGTCAGGAGT
TCGAGACCAGCCCGGCCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATCAGCCAGATGTGGCACGCACCTATAATTCCACCTACTCGGGAGGCTGAAGC
AGAATTGCTTGAACCCGAGAGGCGGAGGTTGCAGTGAGCCGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCCACAGCGTGAGACTACGTCATAAAATAAAATAAA
ATAACACAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAAAAATAAAATAAAATAAAATAAAATAAAGCAATTTCCTTTCC
TCTAAGCGGCCTCCACCCCTCTCCCCTGCCCTGTGAAGCGGGTGTGCAAGCTCCGGGATCGCAGCGGTCTTAGGGAATTTCCCCCCGCGATGTCCCGGCGCGCCAGT
TCGCTGCGCACACTTCGCTGCGGTCCTCTTCCTGCTGTCTGTTTACTCCCTAGGCCCCGCTGGGGACCTGGGAAAGAGGGAAAGGCTTCCCCGGCCAGCTGCGCGGC
GACTCCGGGGACTCCAGGGCGCCCCTCTGCGGCCGACGCCCGGGGTGCAGCGGCCGCCGGGGCTGGGGCCGGCGGGAGTCCGCGGGACCCTCCAGAAGAGCGGCCGG
CGCCGTGACTCAGCACTGGGGCGGAGCGGGGCGGGACCACCCTTATAAGGCTCGGAGGCCGCGAGGCCTTCGCTGGAGTTTCGCCGCCGCAGTCTTCGCCACCAGTG
AGTACGCGCGGCCCGCGTCCCCGGGGATGGGGCTCAGAGCTCCCAGCATGGGGCCAACCCGCAGCATCAGGCCCGGGCTCCCGGCAGGGCTCCTCGCCCACCTCGAG
ACCCGGGACGGGGGCCTAGGGGACCCAGGACGTCCCCAGTGCCGTTAGCGGCTTTCAGGGGGCCCGGAGCGCCTCGGGGAGGGATGGGACCCCGGGGGCGGGGAGGG
GGGGCAGACTGCGCTCACCGCGCCTTGGCATCCTCCCCCGGGCTCCAGCAAACTTTTCTTTGTTCGCTGCAGTGCCGCCCTACACCGTGGTCTATTTCCCAGTTCGA
GGTAGGAGCATGTGTCTGGCAGGGAAGGGAGGCAGGGGCTGGGGCTGCAGCCCACAGCCCCTCGCCCACCCGGAGAGATCCGAACCCCCTTATCCCTCCGTCGTGTG
GCTTTTACCCCGGGCCTCCTTCCTGTTCCCCGCCTCTCCCGCCATGCCTGCTCCCCGCCCCAGTGTTGTGTGAAATCTTCGGAGGAACCTGTTTCCCTGTTCCCTCC
CTGCACTCCTGACCCCTCCCCGGGTTGCTGCGAGGCGGAGTCGGCCCGGTCCCCACATCTCGTACTTCTCCCTCCCCGCAGGCCGCTGCGCGGCCCTGCGCATGCTG
CTGGCAGATCAGGGCCAGAGCTGGAAGGAGGAGGTGGTGACCGT  
NF-!B 
AP-1 
GATA 
SP1 SP1 
 
(Figure 27 continued) 
 
The adjacent region to the GSTP1 transcription start site was further 
analyzed with CpGPlot. The elevated ratio observed versus expected (>0,6) 
B 
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and the high GC percentage indicated, consistently with the Methyl Primer 
Express software, a CGi in front of the GSTP1 transcription start site (Figure 
27-B) (Gardiner-Garden and Frommer 1987). This region includes GATA-1, 
NF-"B, AP-1 and SP1 binding sites as well as the GSTP1 transcription start 
site (Figure 27-C). 
BSP was applied to determine the methylation pattern of the CGi in 
GSTP1 promoter region (-198 to +1) in untreated K-562 and RAJI cells as well 
as in DAC-treated RAJI cells (Figure 28-A). Genomic DNA was extracted from 
leukemia cell lines and digested by the restriction enzyme BglII. After bisulfite 
conversion, the region of interest was amplified by PCR, cloned into the 
pGEM-T amplification vector and transformed into E.coli. Clones were 
selected for insert presence based on Blue/White screening and colony PCR. 
Colony PCR products were also used for subsequent sequencing. Results of 
the sequencing reaction were bioinformatically processed with QUMA and 
BIQanalyzer software (Figure 28-B, C, D).  
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Figure 28: BSP analysis of GSTP1 promoter region in K-562 and RAJI cells. 
(A) The Methylprimer express software was used to analyze in silico the CpG 
dinucleotide density of the CGi spanning from the base positions -1144 to +718. The 
physical map shows the distribution of CpG dinucleotides (vertical black bars) and 
their relative positions to the transcription start site (+1) in the 5’ regulatory area and 
the first exon region of GSTP1 gene. Arrows highlight bisulfite sequencing primer 
positions on GSTP1. The lower panel shows the sequence and CpG dinucleotide 
(gray) distribution in the analyzed GSTP1 region. Genomic DNA from untreated K-
562, untreated and DAC-treated (3 days, 2µM) RAJI were bisulfite converted, the 
specific methylation pattern was revealed by PCR amplification, subcloning and 
sequencing of the region of interest (BSP). Graphical illustration of the BSP results 
for the analysis of the GSTP1 promoter CGi methylation status in control K-562 cells 
(B), untreated (C) and DAC-treated RAJI (D) cells. Open and closed circles indicate 
unmethylated and methylated sites, respectively.  
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From the 380 analyzed CpG dinucleotides, about 0.3% were methylated in 
the GSTP1 promoter region of K-562, revealing that the analyzed GSTP1 
promoter CGi region was fully unmethylated (Figure 28-B). In contrast, BSP 
analysis of the GSTP1 promoter region in RAJI cells showed an average DNA 
methylation percentage of 96.3% (Figure 28-C). In addition, the 
hypermethylated state of GSTP1 gene in RAJI cells was decreased to 64.5% 
of methylated CpG dinucleotides. Interestingly, in our model, DAC-induced 
DNA demethylation was restricted to specific amplicons and therefore 
demethylation occurred without any CpG position preference (Figure 28-D). 
BSP results related to GSTP1 promoter methylation signature in 
untreated and DAC-treated K-562 and RAJI cells were validated using Bio-
CoBRA. Genomic DNA from untreated and DAC-treated cells was extracted, 
bisulfite converted and used as template for PCR amplification with BSP 
primers. The resulting amplicon was digested with the restriction enzyme 
RsaI, which recognizes a unique sequence appearing only in methylated and 
bisulfite-converted alleles. BioCoBRA was analyzed on the Bioanalyzer from 
Agilent (Figure 29-A-B). 
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Figure 29: Bio-CoBRA analysis of GSTP1 promoter methylation status. 
(A) Physical map generated with the Methylprimer software showing the distribution 
of CpG dinucleotides (vertical black bars) and the RsaI restriction site positions 
(/) in GSTP1 promoter. The amplicon obtained by BSP was used to analyze the 
methylation status of the RsaI restriction site in GSTP1 promoter. The localization 
and the methylation dependent RsaI cutting site in the GSTP1 BSP amplicon and the 
length of the corresponding restriction products are indicated. (B) Results of the Bio-
CoBRA assay to determine the methylation status of the RsaI restriction site in 
untreated and DAC (2µM, 3 days) treated K-562 and RAJI cell lines. Fluorescence 
units (FU) are plotted versus DNA fragment length (bp). Partitions of digested and 
undigested amplicons are indicated in percentage on electropherograms. 
Electropherograms are representative for 3 independent experiments. +1: 
transcription start site, Bio-CoBRA: Bioanalyzer combined bisulfite restriction assay, 
ML: low marker, MH: high marker. 
 
The peak at 291bp indicates that the analyzed CpG position in the 
GSTP1 promoter region of K-562 cells was unmethylated (Figure 29-C). In 
contrast, RsaI digestion of the GSTP1 amplicon from RAJI cells resulted in 
two fragments of 37bp and 255bp. RAJI restriction pattern and absence of 
undigested amplicons (292bp) confirmed that the RsaI restriction site was 
hypermethylated in RAJI cells. Decrease of fluorescence intensity peaks of 
B 
C 
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the 255bp and 37bp fragments and the appearance of a peak at 292bp 
indicated the demethylation of GSTP1 promoter in DAC-treated RAJI cells. In 
RAJI cells, the ratio between undigested and digested fluorescence intensity 
peaks identified a demethylation percentage of 36.7% after 3 days of DAC 
exposure (Figure 29-C). 
MSP technique was used to validate previous BSP and Bio-CoBRA 
results and to test the methylation status of further leukemia cell lines. MSP 
primer sets were located proximal at the transcription start site (MGP) and the 
distal at NF-"B binding site (MGD) (Figure 30-A).  
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Figure 30: MSP analysis of GSTP1 promoter methylation status in various 
leukemia and lymphoma cell lines. 
(A) Physical map generated with the Methylprimer software showing the distribution 
of CpG dinucleotides (vertical black bars) and MSP primer pair positions (MGD and 
MGP) relative to the transcription start site on the GSTP1 promoter region. (B) To 
check the primer specific for the unmethylated (U) or methylated (M) proximal (MGP) 
or distal (MGD) promoter region, MSP assays with the following control samples as 
templates has been carried out: complete bisulfite conversion procedure without 
genomic DNA (Bi), unmethylated converted DNA (UMC), methylated converted DNA 
(MC), unconverted unmethylated DNA (UC). (C) Genomic DNA was extracted from 
various leukemia cell lines, bisulfite converted and used as template for MSP. MSP 
amplicons were separated on a 12% PAA gel and stained with ethidium bromide. 
Images are representative of 3 independent experiments.  
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Empty lanes in the bisulfite conversion control (Bi) evinced that both bisulfite 
treatments and PCRs were realized without contamination that could affect 
results. Primer methylation specificity (U or M) was demonstrated by the 
amplification of GSTP1 PCR product only in presence of the correspondingly 
methylated and converted DNA template (UMC and MC). Lack of 
amplification with unconverted DNA (UC) shows that the used 
oligonucleotides are not mispriming with genomic unconverted DNA (Figure 
30-B). 
MSP results confirmed previous BSP (Figure 28) and Bio-CoBRA 
(Figure 29) results, showing that the GSTP1 promoter was unmethylated and 
methylated in K-562 and RAJI, respectively. Furthermore, MSP analysis 
revealed that GSTP1 promoter was unmethylated in JVM-2, MOLT-3 and HEL 
cell lines. Finally, MSP analysis revealed dense methylation on GSTP1 
promoter in the CML-derived GSTP1 non-expressing cell line MEG-01 (Figure 
30-C). 
In a next step, MSP was used to determine the influence of the 
demethylating agent DAC on the GSTP1 methylation pattern in various 
leukemia cell lines. Genomic DNA from K-562 and RAJI cells, treated up to 6 
days and JVM-2, MOLT-3, MEG-01 and HEL cell lines, treated up to 3 days 
with DAC, was bisulfite converted and methylation status analyzed by MSP 
(Figure 31).  
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Figure 31: Kinetic analysis of DAC-induced demethylation of GSTP1 promoter 
in various leukemia and lymphoma cell lines. 
Genomic DNA from various leukemia and lymphoma cell lines, treated with DAC 
were bisulfite converted and analyzed by MSP with primers specific for the 
unmethylated (U) and methylated (M) state of distal (MGD) (A) and proximal (MGP) 
(B) GSTP1 promoter regions. MSP amplicons were separated on a 12% PAA gel and 
stained with ethidium bromide. Images are representative of 3 independent 
experiments. DAC: 5-aza-2!-deoxycytidine. 
 
In RAJI and MEG-01 cells, DAC treatment induced a time-dependent 
demethylation of the hypermethylated GSTP1 promoter in both analyzed 
regions. GSTP1 demethylation was time-delayed in MEG-01 cells compared 
to RAJI cells. In K-562, MOLT-3, JVM-2 and HEL cell lines, promoter 
remained unmethylated (Figure 31). 
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5.1.5. Analysis of the chromatin structure of GSTP1 promoter 
 
In the next step, we performed X-ChIP analysis to determine 
repressor/activator protein complexes and histone marks associated with 
GSTP1 promoter. Enrichment of promoter fragments in X-ChIP assays using 
specific antibodies against various proteins involved in chromatin structure, 
DNA methylation, histone modifications and transcription were detected by 
PCR using two primer sets covering GSTP1 basal promoter (CG3) and, as a 
control, a non-genic 10kb upstream remote region (CG5) (Figure 32-A). The 
corresponding PCR products were resolved by gel electrophoresis (Figure 32-
B).  
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Figure 32: Characterization of GSTP1 chromatin structure in K-562, RAJI and 
MEG-01 leukemia cell lines by X-ChIP analysis. 
(A) Schematic representation of the 5’-upstream region of GSTP1 gene with the 
positions of PCR primers (CG1 to CG5) used to map the promoter in ChIP analysis. 
(B) Chromatin from K-562, RAJI and MEG-01 cell lines was immunoprecipitated with 
specific antibodies. Associated DNA was amplified using CG3 and CG5 primer pairs 
and PCR products were separated on a gel stained with ethidium bromide. Pictures 
are representative of 3 independent experiments. Me: methylation, Ac: acetylation, 
CBP: cAMP-response element binding protein (CREB) binding protein, DNMT: DNA 
methyltransferase, GSTP1: glutathione S-transferase P1, H4: Histone 4, HDAC: 
histone deacetylase, MBD: methyl binding protein, MeCP2: methyl CpG binding 
protein 2, p300: histone acetyltransferase, SP: specificity protein. 
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As shown in Figure 32, integral components of the transcriptional machinery 
(RNA pol II, SP1 and SP3) were associated with the hypomethylated and 
transcriptionally active GSTP1 promoter region in K-562 cells. Moreover, 
GSTP1 promoter in K-562 cells was highly enriched for di- and trimethylation 
of lysine K4 on histone H3, for acetylation of histone H3 and H4 as well as for 
the related HAT proteins (i.e. p300 and CBP). In addition, markers for 
transcriptionally silenced heterochromatin such as HDACs or MBDs were 
absent in K-562 cells. Concerning RAJI and MEG-01 cells, while GSTP1 
silencing was associated to hypermethylation, GSTP1 basal promoter was 
enriched for repressive histone modifications such as trimethylation of H3K9 
and H3K27. In addition, enrichment of acetylated histones H3 and H4 as well 
as the associated HATs was reduced at this position in RAJI and MEG-01 cell 
lines. Furthermore, GSTP1 promoter of RAJI and MEG-01 cells was enriched 
for DNA methylation- and heterochromatin-associated proteins (e.g. DNMTs, 
MBDs and HDACs), respectively (Figure 32). Finally, we used primers 
targeting a region 10kb upstream of the basal GSTP1 promoter as a negative 
control (CG5). As expected, this region was not enriched for proteins related 
to active transcription (Figure 32). 
 
5.1.6. Analysis of the DAC-induced acquisition of a GSTP1 
transcriptional permissive state in GSTP1 non-expressing 
cells 
 
In order to evaluate DAC-induced molecular reprogramming of the 
GSTP1 promoter complex associated to demethylation and transcriptional 
activation of GSTP1 gene, X-ChIP assay was performed. Using primers 
covering the GSTP1 promoter region (CG2 to CG4), the first coding region 
(CG1) in the gene body and a primer pair (CG5), specific for a 
transcriptionally silenced region 10kb upstream of the GSTP1 TSS, 
enrichment of DNA fragments was quantified by real-time PCR (Figure 32-A).  
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Figure 33: Analysis of the evolution of GSTP1 chromatin structure after DAC 
treatment of K-562, RAJI and MEG-01 leukemia cell lines by X-ChIP assay. 
Chromatin from untreated K-562, RAJI and MEG-01 cell lines as well as in RAJI and 
MEG-01 cells treated with 2 µM DAC for 3 days was immunoprecipitated with 
specific antibodies. The enrichment was measured by real-time PCR and results 
expressed as recovery (% of total input) = ((CtIP – CtIgG)/Ctinput). Data are the mean ± 
SD of 3 independent experiments. CBP: cAMP-response element binding protein 
(CREB) binding protein, DNMT: DNA methyltransferase, GSTP1: glutathione S-
transferase P1, H4: Histone 4, HDAC: histone deacetylase, MBD: methyl binding 
protein, MeCP2: methyl CpG binding protein 2, p300: histone acetyltransferase, SP: 
specificity protein. 
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(Figure 33 continued) 
 
Results demonstrated that DAC treatment leads to the release of both 
DNMT and MDB proteins from the analyzed region on the GSTP1 promoter. 
Furthermore, DAC exposure leaded to the enrichment of acetylated histone 
H4 and H3, the recruitment of HATs and the release of HDAC1 and 2 from 
GSTP1 promoter in RAJI and MEG-01 cells. In addition, in the same cells, 
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DAC reduced the occupancy of lysine K9 and K27 trimethylation on histone 
H3 and enhanced the presence of lysine K4 di- and tri-methylation on histone 
H3 in GSTP1 promoter (Figure 33-B). Moreover, DAC treatment increased the 
association of the transcription factors SP1 and SP3 as well as the RNA 
polymerase II on the GSTP1 promoter in non-expressing cells (Figure 33-B). 
In summary, these results showed that DAC treatment induced important 
changes in histone modification marks and protein recruitment to the GSTP1 
promoter in RAJI and MEG-01 cells, which correspond to a shift from a 
repressive to a more permissive chromatin state, close to the one observed in 
K-562 cell line. 
Lack of protein binding on DNA as well as cell line-dependent variations 
in protein expression could be responsible for low or absence of chromatin 
enrichment in X-ChIP analysis. Therefore, we assessed the constitutive 
expression of proteins analyzed by ChIP in K-562, RAJI and MEG-01 cell 
lines. Western Blot showed that lack of protein recruitment was not due to 
lack or high variance in protein expression (Figure 34).  
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Figure 34: Immunoblot detection of proteins analyzed in X-ChIP experiments. 
Total or nuclear proteins were extract from K-562, RAJI and MEG-01 cell lines and 
analyzed by Western Blot with the indicated antibodies. Pictures are representative 
for three independent experiments. CBP: cAMP-response element binding protein 
(CREB) binding protein, DNMT: DNA methyltransferase, GSTP1: glutathione S-
transferase P1, H4: Histone 4, HDAC: histone deacetylase, MBD: methyl binding 
protein, MeCP2: methyl CpG binding protein 2, p300: histone acetyltransferase, SP: 
specificity protein. 
 
5.1.7. GSTP1 promoter methylation status in leukemia patient 
samples 
 
For a transition from research to clinical application and the potential use 
of the epigenetic disruption of GSTP1 regulation and expression as a 
biomarker for hematological malignancies, patient samples have to be 
included into the study in order to evaluate the role of methylation-associated 
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GSTP1 silencing in development, progression or subsistence of malignant 
homeopathies. 
Leukemia and lymphoma patient biopsies as well as healthy PBMCs and 
CD34+ blood stem cells were used to extract genomic DNA. After bisulfite 
conversion, the methylation profile of the GSTP1 promoter region was 
determined by MSP analysis and summarized in Table 48.  
 
Table 48: Analysis of the GSTP1 methylation status in leukemia and lymphoma 
patient samples.  
Genomic DNA from 81 patients and 9 healthy donor samples was bisulfite converted 
and the GSTP1 methylation pattern analyzed by MSP. The table summarizes the 
GSTP1 methylation status. 
 
GSTP1 
Methylation 
status 
 
C
LL 
C
M
L 
A
LL 
A
M
L 
M
D
S 
D
LB
C
L 
M
C
L 
FL 
B
L 
C
D
34+ 
PB
M
C
 
Unmethylated 16 4 6 17 2 9 9 10 4 3 6 
Methylated 0 0 0 0 0 2 2 0 0 0 0 
! of samples 16 4 6 17 2 11 11 10 4 3 6 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BL: Burkitt’s lymphoma, 
CD34+: hematological stem cells, CLL: chronic lymphocytic leukemia, CML: chronic myeloid 
leukemia, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MCL: mantle cell 
lymphoma, MDS: myelodysplastic syndrome, PBMC: peripheral blood mononuclear cell. 
 
Almost every analyzed leukemia and lymphoma patient samples as well 
as PBMC samples from supposed healthy donors presented an unmethylated 
GSTP1 promoter (Table 48). However, out of 81 patients samples analyzed, a 
partially methylated GSTP1 promoter was identified in two mantle cell 
lymphoma (18%) and two diffuse large B-cell lymphoma (18%) samples 
(Table 48). Tumor samples were prepared without microdissection, possibly 
leading to the coexistence of methylated and unmethylated alleles.  
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5.1.8. Involvement of micro RNAs in regulation of GSTP1 
expression 
 
As mentioned in the introduction, miRNA is an additional epigenetic 
mechanism dysregulated in cancer. Moreover, we showed previously that 
certain leukemia cell lines (e.g. HEL and MOLT-3) moderately express 
GSTP1 in contrast to the highly expressing K-562 and JURKAT cell lines. It is 
reasonable to assume that overexpression of a GSTP1 targeting miRNA 
could silence GSTP1 gene expression, reducing cell detoxification and 
promoting genomic damages. In contrast, silencing of a GSTP1 repressing 
miRNA would lead to GSTP1 upregulation associated with enhanced 
detoxification potential and therefore possibly confers chemoresistance to 
cancer cells. Accordingly, the analysis of miRNA signatures in leukemia and 
normal cells could possibly contribute to the knowledge of the epigenetic 
regulation of GSTP1 expression and offer new promising approaches to 
control its expression.  
To the best of our knowledge, no published study has investigated the 
potential of miRNA-mediated post-transcriptional regulation of GSTP1 in 
leukemia cells or other cancer types. Thus, we investigated the potential of 
GSTP1 3’UTR for miRNA regulation as well as the possibility for GSTP1-
miRNA interactions using online prediction tools. Results of the screening of 
miRNA target databases are summarized in Figure 35. 
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Figure 35: Prediction of miRNA-GSTP1 mRNA interaction. 
 Computational target prediction tools were used to screen miRNA databases and to 
assess miRNAs targeting GSTP1 mRNA. A positive hit in a database is represented 
by a colored bar and the cumulative number of prediction hits is represented by a 
black bar. hsa: homo sapiens. 
 
Using 9 different online miRNA target prediction tools, up to 42 miRNAs were 
predicted as potentially involved in the post-transcriptional regulation of 
GSTP1 expression. Considering that almost every software use a different 
prediction algorithm or method, prediction results were not homogenous, i.e. 
hsa-miR-150 was predicted by 4 prediction tools and hsa-miR-365 by only 
one (Figure 35). 
 To detect a potential negative relationship between the miRNA and 
GSTP1 expression profile, total RNA of cell lines with high (K-562, JURKAT), 
moderate (HEL, MOLT-3) and no (RAJI, MEG-01) GSTP1 expression was 
extracted. PBMC cells were also included in the analysis. After conversion by 
reverse transcription, the expression profile of miRNAs that were predicted at 
least twice by bioinformatical tools was analyzed by real-time PCR and a heat 
map represented the results (Figure 36). 
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Figure 36: Expression pattern of potential GSTP1 silencing miRNAs in 
leukemia cell lines with high, moderate and low GSTP1 expression levels. 
Total RNA from leukemia and lymphoma cell lines and from healthy donors cells was 
reverse transcribed and analyzed by real-time PCR with specific primers for various 
miRNAs. The small nuclear RNA RNU1A was analyzed as a quantity control in each 
reaction. The heat map summarizes the expression levels of predicted GSTP1 
targeting miRNAs in various leukemia and lymphoma cell lines. For a better 
illustration, expression levels were normalized for each miRNA, going from blue (low 
expression) to red (high expression). White bars indicate moderate expression level 
and gray bars represent missing values. Correlations were used for data clustering. 
Data are the mean ± SD of 3 independent experiments. hsa-miR: homo sapiens 
micro RNA.  
 
The heat map shows a very heterogeneous expression pattern of the 
various miRNAs analyzed in the different cell lines (Figure 36). Correlation 
analysis between the analyzed miRNAs leaded to the definition of two main 
clusters, separating miRNAs upregulated in healthy samples from miRNAs 
upregulated in blood cancer cell lines. Several miRNAs were highly expressed 
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in samples derived from healthy donors (e.g. miR-516a-5p, -148b, -484 and -
185), whereas they were repressed in blood cancer cell lines and vice versa. 
Moreover, subclustering revealed high variations in miRNA expression pattern 
between the various analyzed cell lines. For example miR-346, -149, -650, -
519e, -345 and -515-3p are highly expressed in JURKAT cell line in contrast 
to RAJI, HEL, K-562, MEG-01 and MOLT-3 (Figure 36).  
 
5.2. DNA hypermethylation as a key player in PTGS2 
expression silencing in hematological malignancies 
 
As mentioned in the introduction, it is widely recognized that various 
cancer cells are associated with PTGS2 overexpression, which contributes 
thereby to the cancer phenotype by activating prosurvival and cell proliferation 
genes. In contrast, DNA hypermethylation-mediated silencing of PTGS2 was 
already observed for esophageal, prostate or epithelial cancer.  
In the second thesis part, the possibility of DNA methylation on 
regulation of PTGS2 expression in hematological malignancies was 
evaluated. The implication of promoter hypermethylation in the regulation of 
PTGS2 expression was, to our knowledge, never reported for cell lines and 
patient samples, derived from or with hematological malignancies, 
respectively.  
 
5.2.1. PTGS2 expression in leukemia/lymphoma cell lines and 
healthy blood cells 
 
First, the constitutive PTGS2 gene expression was assessed in various 
blood cancer cell lines and compared to PBMCs from healthy donors. Total 
mRNA from various leukemia and lymphoma cell lines was reverse 
transcribed and the cDNA amount of PTGS2 and !-actin quantified by a real-
time PCR assay (Figure 37). 
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Figure 37: PTGS2 expression in various leukemia/lymphoma cell lines and in 
healthy donor blood cells. 
Total RNA was extracted from various blood cancer cell lines and PBMCs, reverse 
transcribed into cDNA and analyzed by real-time PCR with primers specific for 
PTGS2. !-actin was also analyzed as a control of cDNA quantity in each reaction. 
Results represent the ratio PTGS2/!-actin mRNA expression level in PBMCs (A) and 
leukemia and lymphoma cell lines (A, B). Data are the means +/- SD of 3 
independent experiments. ALL: acute lymphoid leukemia, AML: acute myeloid 
leukemia, BL: Burkitt’s lymphoma, CML: chronic myeloid leukemia, CLL: chronic 
lymphoid leukemia, HL: histiocytic lymphoma, U: Ct value undetermined after 45 
cycles of amplification.  
 
PTGS2 expression is significantly higher in PBMCs, compared to the 
analyzed leukemia cell lines (Figure 37-A). Among the 14 leukemia- or 
lymphoma-derived cell lines, the highest expression of PTGS2 mRNA was 
A 
B 
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observed in the HEL cell line. MEG-01, KBM-5, TF-1, THP-1, KG-1, KG-1a 
and U-937 cell lines express relatively moderate level of PTGS2 mRNA 
compared to normal PBMCs. In addition, K-562, JVM-2, JURKAT, MOLT-3, 
HL-60 and RAJI cell lines showed very low or undetectable transcriptional 
activity for the PTGS2 gene (Figure 37-B).  
 
5.2.2. CpG density analysis of PTGS2 promoter and gene body 
 
For methylation-associated silencing, a CGi is required in the promoter 
or the first exon-intron region of PTGS2. In order to determine the CpG 
dinucleotide density, PTGS2 gene body ("10000bp) as well as a promoter 
region upstream of the transcription start site ("9000bp) were bioinformatically 
analyzed with the EMBOSS CpGPlot/CpGReport online tool (Figure 38). 
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Figure 38: CpG island prediction for PTGS2 promoter region. 
(A) In silico analysis of the GC content and the CpG dinucleotide positions (red bars) 
in the PTGS2 promoter and coding region (-9985 - +8632). (B) In silico CG analysis 
of the PTGS2 promoter region (-9985 - + 984) with the web based tool CpGPlot. The 
observed vs. expected ratio, the CG percentage and the putative island are plotted 
against the base position within PTGS2 sequence. : transcription start site. 
 
A 
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In silico assessment of the CG dinucleotide distribution in PTGS2 gene 
uncovered a large accumulation of CpG in the promoter region (relative 
position: 9000 to 11000bp) as well as in the coding region (relative position: 
14000 to 16000bp) (Figure 38-A). Close examination of PTGS2 promoter 
revealed a 394-bp long putative CGi with a CpG ratio of over 0.6 and a 
percentage of CG higher than 50%, satisfying the criteria of Gardiner-Garden 
for a CGi (Gardiner-Garden and Frommer 1987). The CGi starts just after the 
PTGS2 TSS and includes 34 CpG dinucleotides (Figure 38-B). 
 
5.2.3. Methylation status of PTGS2 promoter in leukemia and 
lymphoma cell lines 
 
To determine if lack of PTGS2 expression in certain leukemia and 
lymphoma cell lines was associated with PTGS2 promoter hypermethylation, 
DNA methylation profile of PTGS2 promoter was analyzed by MSP (Figure 
39). 
 
  Results 
 142 
PTGS2 
130 bp 
-436/-306 
3’ 5’ 
CLL CML ALL 
K-562 JVM-2 MOLT-3 MEG-01 JURKAT KBM-5 
U M 
RAJI 
HEL TF-1 THP1 HL-60 KG-1 KG-1a 
PTGS-2 M PTGS-2 U 
UMC MC UC  Bi 
Controls 
U M U M U M U M U M 
U M U M U M U M U M U M 
U M 
UMC MC UC  Bi 
AML 
BL 
-9985 +8632 
+1 
U-937 
U M 
HL 
 
Figure 39: Analysis of PTGS2 promoter methylation in leukemia and lymphoma 
cell lines. 
(A) Physical map generated with the Methylprimer software shows the distribution of 
CpG dinucleotides (vertical black bars) and MSP primer pair positions relative to the 
transcription start site ( ) on PTGS2 promoter. (B) To check primer specificity, MSP 
assays with the following control samples as templates were carried out: complete 
bisulfite conversion procedure without genomic DNA (Bi), unmethylated converted 
DNA (UMC), methylated converted DNA (MC), unconverted unmethylated DNA (UC). 
(C) Genomic DNA was extracted from various leukemia/lymphoma cell lines, bisulfite 
converted and used as templates for MSP with primers specific for the unmethylated 
(U) and methylated (M) state of PTGS2 promoter. MSP amplicons were separated on 
a 12% PAA gel and stained with ethidium bromide. Pictures are representative for 3 
independent experiments. ALL: acute lymphoid leukemia, AML: acute myeloid 
leukemia, BL: Burkitt’s lymphoma, CML: chronic myeloid leukemia, CLL: chronic 
lymphoid leukemia. 
 
MSP primers were designed to analyze the methylation profile of CG 
dinucleotides pertaining to a region 5’ upstream of the transcription start site (-
436bp/-306bp) (Figure 39-A). Control reactions showed methylation specificity 
A 
B 
C 
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of the MSP primers (Figure 39-B). Hypomethylation of the PTGS2 promoter 
region was detected for the CML-derived K-562 and MEG-01 cell lines as well 
as the AML-derived HEL, TF-1, THP-1 and KG-1 cell lines. PTGS2 promoter 
was hemi-methylated in JVM-2, MOLT-3, KBM-5, KG-1a, U-937 and HL-60 
cell lines, and hypermethylated in RAJI and JURKAT cell lines (Figure 39-C).  
 
5.2.4. Effect of DAC treatment on PTGS2 methylation and 
expression 
 
To determine the effect of the demethylating agent DAC on PTGS2 
promoter methylation status, cell lines presenting various hypermethylated 
and partially methylated PTGS2 promoters were treated with 2µM DAC. 
Genomic DNA was extracted, bisulfite converted and the methylation pattern 
of PTGS2 analyzed by MSP (Figure 40). 
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Figure 40: Kinetic analysis of the DAC-mediated demethylation of PTGS2 
promoter in leukemia and lymphoma cell lines. 
Genomic DNA from various DAC-treated leukemia and lymphoma cell lines was 
bisulfite converted and PTGS2 promoter methylation status analyzed by MSP with 
primers specific for the unmethylated (U) and methylated (M) state. MSP amplicons 
were separated on a 12% PAA gel and stained with ethidium bromide. Images are 
representative of three independent experiments. DAC: 5-aza-2'-deoxycytidine. 
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DAC treatment of KBM-5 cell line leaded to a time-dependent and 
complete demethylation of PTGS2 promoter region. Similarly, partially 
methylated JVM-2, HL-60, MOLT-3 and U-937 as well as fully methylated 
RAJI and JURKAT cell lines get demethylated by DAC exposure but not 
completely (Figure 40). 
To evaluate the consequences of DAC-induced PTGS2 promoter 
demethylation for the transcriptional activity, total mRNA from DAC-treated 
KG-1a, JVM-2, RAJI, JURKAT, HEL, MOLT-3 and KBM-5 cells was extracted. 
After reverse transcription, the cDNA amount of PTGS2 and !-actin was 
quantified by a real-time PCR assay. In addition, the effect of DAC treatment 
on the hypomethylated but silenced PTGS2 expression in K-562 was 
analyzed (Figure 41). 
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Figure 41: Kinetic analysis of PTGS2 expression after DAC treatment. 
Cell lines, derived from various hematological malignancies, were treated with 2µM 
DAC for the indicated times. Total RNA was extracted and 1µg was reverse 
transcribed into cDNA, and then analyzed by real-time PCR with primers specific for 
PTGS2. !-actin was also analyzed as a control of cDNA quantity in each reaction. 
Results represent the ratio PTGS2/!-actin mRNA expression level and are plotted for 
the various human leukemia cell lines and the time interval of DAC-treatment. Data 
are the means ± SD of 3 independent experiments. 
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Real-time PCR results demonstrated that DAC treatment reversed in a 
time-dependent manner DNA methylation-mediated silencing of PTGS2 
expression and induced transcriptional activity in most analyzed cell lines. 
Independently of the DAC exposure time, partially methylated JVM-2 and 
MOLT-3 cell lines as well as the unmethylated K-562 cell line staid repressed 
for PTGS2 expression.  
 
5.2.5. Methylation analysis of PTGS2 promoter in leukemia and 
lymphoma patient samples 
 
For a possible later clinical application of the preliminary results obtained 
in this work, the study was enlarged to blood and bone marrow samples from 
patients with hematological malignancies. Samples from leukemia patients 
(ALL, AML, CLL and CML), and lymphoma biopsies (DLBCL, FL, MCL, BL 
and MDS) as well as PBMCs from healthy donors were used for DNA 
extraction and bisulfite conversion. The methylation profile of PTGS2 was 
detected by MSP (Figure 42). 
 
  Results 
 146 
M
et
hy
la
tio
n 
fr
eq
ue
nc
y 
(%
) 
0 
20 
40 
60 
80 
100 
 AL
L (
n=
6) 
AM
L (
n=
16
) 
CL
L (
n=
16
) 
CM
L (
n=
5) 
DL
BC
L (
n=
11
) 
FL
 (n
=1
0) 
MC
L (
n=
11
) 
BL
    
 (n
=4
) 
MD
S (
n=
2) 
He
alt
hy
 (n
=9
) 
 
Figure 42: Frequency of PTGS2 promoter methylation in samples of patients 
with a hematological malignancy. 
Genomic DNAs from 81 patient samples and 9 healthy donor samples were 
extracted, bisulfite converted and PTGS2 promoter methylation patterns analyzed by 
MSP. Frequency (%) of PTGS2 promoter methylation was plotted against the type of 
hematological malignancy. ALL: acute lymphoblastic leukemia, AML: acute myeloid 
leukemia, BL: Burkitt’s lymphoma CLL: chronic lymphocytic leukemia, CML: chronic 
myeloid leukemia, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, 
MCL: mantle cell lymphoma, MDS: myelodysplastic syndrome. 
 
Except CML and MDS patients samples that were completely 
unmethylated, 77% of the analyzed leukemia and lymphoma patient samples 
showed a certain percentage of PTGS2 methylation (Figure 42). The highest 
methylation frequency was detected in diffuse large B-cell, follicular and 
Burkitt’s lymphoma samples. Regarding the leukemia samples, most PTGS2 
promoter methylation was found in CLL samples. Moreover, PTGS2 
hypermethylation was not detected in healthy control PBMCs (Figure 42). 
 
5.2.6. Correlation between PTGS2 methylation and expression in 
samples from patients with hematological malignancies 
 
In complement to the PTGS2 methylation profiling, the PTGS2 
expression level in leukemia and lymphoma patient samples was determined. 
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Total RNA was extracted from leukemia/lymphoma biopsy samples and 
healthy donor PBMCs as well as CD34+ cells from cord blood. Messenger 
RNA was reverse transcribed and the cDNA amount of PTGS2 and !-actin 
quantified by real-time PCR assay (Figure 43). 
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Figure 43: Distribution of PTGS2 mRNA expression levels in blood cells from 
healthy donors and patients with hematological malignancies. 
Total RNAs from lymphoma/leukemia biopsies and blood cells from healthy control 
groups (PBMC, CD34+) were extracted and cDNA analyzed by real-time PCR with 
primers specific for PTGS2. !-actin was analyzed as a control of cDNA quantity in 
each reaction. Results represent the distribution of the ratio PTGS2/!-actin mRNA 
expression level and are plotted for the healthy control cells as well as the various 
blood cancer types. The line indicates the median, the box is the interquartile range 
and the outer whiskers represent the maximum and minimum range including 
extreme outliers. Data are the means ± SD of 3 independent experiments. ALL: acute 
lymphoblastic leukemia, AML: acute myeloid leukemia, BL: Burkitt’s lymphoma CLL: 
chronic lymphocytic leukemia, CML: chronic myeloid leukemia, DLBCL: diffuse large 
B-cell lymphoma, FL: follicular lymphoma, MCL: mantle cell lymphoma, PBMC: 
peripheral blood mononuclear cell. 
 
Distribution and median PTGS2 expression levels were similar in 
PBMCs and CD34+ cells from supposed healthy donors. Moreover, median 
PTGS2 expression in Burkitt’s lymphoma, AML and CML samples was 
comparable to healthy controls. Noteworthy, PTGS2 transcriptional activity 
was highly variable in Burkitt’s lymphoma, AML and CML samples. In 
contrast, reduced or silenced PTGS2 expression was detected in lymphoid 
lineage derived leukemia and lymphoma samples, compared to the healthy 
controls. 
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Simultaneous DNA and RNA preparations from the same patient 
samples (n=52) and subsequent PTGS2 methylation and expression analysis 
allowed assessing a possible correlation between the methylation status and 
the expression level of PTGS2. For this purpose, patient samples were 
classified by their PTGS2 promoter methylation status and plotted for their 
PTGS2 expression (Figure 44). 
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Figure 44: Analysis of PTGS2 mRNA expression in relation to the promoter 
metylation state. 
Box whisker plots show the variations of PTGS2 expression depending on the 
methylation status of the PTGS2 promoter region in leukemia and lymphoma patient 
samples. Box denotes interquartile range, line within the box denotes the median, 
and whiskers denote the maximum and the minimum range. Outliers were excluded 
from the analysis (n=52). 
 
Patient samples with hypomethylated PTGS2 promoter region had 
highly variable PTGS2 expression levels. However, samples with 
hypermethylated PTGS2 promoter configuration presented reduced PTGS2 
expression.  
 
5.3. DNA methylation fingerprint of blood cancer cells 
 
Epigenetic alterations such as DNA hypermethylation (e.g. GSTP1 and 
PTGS2), lead to aberrant gene expression and are implicated in cancer 
initiation and progression. The epigenetic hype of the past decade allowed to 
compile a long list of epimutation hotspots, including genes involved in tumor 
suppression, DNA repair, cell metabolism, apoptosis or hormonal receptor.  
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With the objective to establish a map of epigenetic signatures of 
hematological malignancies, the third part of this thesis mainly dealt with the 
DNA methylation analysis of genes. Methylation status of some of the 
selected genes were already determined independently of each other, 
whereas the methylation states of other genes were never analyzed in blood 
cancer cell lines. However, in order to improve sensitivity and specificity of 
early cancer detection, it is an existential necessity to analyze a whole range 
of epigenetic marks. Moreover, the evaluation of distinctive aberrant 
methylation pattern can deliver potentially usable clinical insights concerning 
cancer progression (e.g. metastatic potential, chemosensitivity) and 
treatment.  
 
5.3.1. Methylomic profiling of hematological malignancies 
 
In order to establish a map of DNA methylation aberrations in various 
leukemia and lymphoma cell lines, the methylation of genes already 
established as cancer biomarkers for other cancer types was analyzed by 
MSP and represented by a heat map. Moreover, methylation frequency of 
each blood cancer cell line was calculated based on the gene-specific MSP 
results (except LINE1) (Figure 45).  
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Figure 45: Unique methylation signature of leukemia and lymphoma cell lines.  
Gene-specific methylation profile of various blood cancer cell lines was determined 
by MSP. Aryl hydrocarbon receptor (AHR), apoptotic peptidase activating factor 1 
(APAF-1), adenomatous polyposis coli (APC), B-cell CLL/lymphoma 2 (BCL-2), 
apoptosis regulator Bcl-X (BCL-XL, BCL2L1), calcitonin-related polypeptide alpha 
(CALCA), caspase 7 and 8 (CASP7 and 8), epithelial cadherin (CDH1), cyclin-
dependent kinase inhibitor (CDKN) 2A (p16/14INK4a), CDKN 2B (p15INK4b), death-
associated protein kinase 1 (DAPK1), estrogen receptor (ESR1), glutathione S-
transferase P1 (GSTP1), hypermethylated in cancer 1 (HIC1), long interspersed 
repetitive element 1 (LINE1), O6-methylguanine-DNA methyltransferase (MGMT), 
human MutL protein homolog 1 (MLH1), prostaglandin-endoperoxide synthase 2 
(PTGS2), retinoic acid receptor beta (RARB), Ras association domain family protein 
1A (RASSF1A), retinoblastoma 1 (RB1), suppressor of cytokine signaling (SOCS), 
tissue inhibitor of metalloproteinase 3 (TIMP3), target of methylation-induced 
silencing 1 (TMS1) and tumor protein p73 (TP73). MSP amplicons were separated 
on a 12% PAA gel and stained with ethidium bromide. (A) Results were represented 
on a heat map with clustering, indicating the DNA methylation status (green: 
B 
A 
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unmethylated, orange: partially and red: fully methylated, white: not analyzed or 
mutated) by gene and blood cancer cell line. (B) Representation of methylation 
frequency from the most hypermethylated to the least based on the methylation of 
the analyzed genes in leukemia and lymphoma cell lines. The repetitive element 
LINE1 was excluded from this analysis. Data are the mean of 3 independent 
experiments. 
 
Methylation analysis results show that the methylation pattern is highly 
variable and is different for each blood cancer type, cell line or gene. In 
hematological malignancies-derived cell lines, promoter methylation was 
never or rarely detected in the following genes: human MutL protein homolog 
1 (MLH-1), CDKN2A (p14ARF) and retinoblastoma 1 (RB1) as well as 
caspases 7 and 8, B-cell CLL/lymphoma 2 (BCL-2), apoptotic peptidase 
activating factor 1 (APAF-1) and apoptosis regulator Bcl-X (BCL-XL). 
Furthermore, HIC1 and suppressor of cytokine signaling (SOCS2) genes 
showed no methylation in their promoter region in the analyzed blood cancer 
cell lines (Figure 45-A). In contrast, moderate methylation frequency (15-40% 
of the analyzed leukemia and lymphoma cell lines) was measured for the 
promoters of MGMT, CDKN2A (p16INK4a), estrogen receptor (ESR1), aryl 
hydrocarbon receptor (AHR), GSTP1, PTGS2, tumor protein p73 (TP73), 
death-associated protein kinase 1 (DAPK), Ras association domain family 
protein 1 (RASSF1A), adenomatous polyposis coli (APC) and tissue inhibitor 
of metalloproteinase 3 (TIMP3) (Figure 45). High methylation frequency (40%-
70%) was detected for the promoter regions of CDKN2B (p15INK4b), RARB, 
calcitonin-related polypeptide alpha (CALCA) and target of methylation-
induced silencing 1 (TMS1). Genes encoding epithelial cadherin (CDH1) as 
well as the transposable long repetitive element LINE1 had the highest 
methylation frequency and were at least hemi-methylated in all 13 leukemia 
and lymphoma cell lines (Figure 45-A). 
The AML cell lines TF-1 and THP-1 showed the weakest methylation 
frequencies for the analyzed set of genes (4% and 9%, respectively), followed 
by the AML cell line HEL (25%) and the CML cell lines K-562 (25%) and 
MEG-01 (23%). Moderate amount of methylation (30-33%) was detected in 
KBM-5 cells (CML) and in the AML-derived cells KG-1 and HL-60. Methylation 
frequency was further increased in JVM-2 (CLL, 43%), MOLT-3 (ALL, 48%) 
and JURKAT (ALL, 52%) cell lines. The highest methylation frequencies for 
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the analyzed set of genes were detected in the AML cell line KG-1a (54%) 
and the Burkitt’s lymphoma cell line RAJI (60%) (Figure 45-B). Hierarchical 
clustering of the human leukemia and lymphoma cell lines by their CGi 
hypermethylation profiles clearly clustered lymphoma cell line RAJI outside of 
the leukemia cell lines. On the next cluster level JURKAT, KG-1a, MOLT-3 
and HEL were separated from the K-562 and MEG-01. Furthermore, JVM-2, 
THP-1, TF-1 and KBM-5 cells were separately clustered from the HL-60 and 
KG-1 cell lines (Figure 45-A). 
In addition, screening of methylation pattern in cell lines derived from 
hematological malignancies pointed out that the promoter region of CDKN2B 
was mutated (no amplification with both methylated and unmethylated primer 
sets) in K562, JURKAT and HEL cell lines. JURKAT cells possessed a further 
mutation in the CDKN2A promoter region (Figure 45-A).  
 
5.4. Analysis of DAC treatment response in blood cancer 
cell lines 
 
Since epigenetic lesions are potentially reversible, epimutations are 
promising therapeutic targets for DNA demethylating drugs (e.g. DAC). The 
nucleoside analog DAC binds covalently DNMTs after integration into DNA. 
Hence, maintenance of methylation is dysregulated leading to a passive loss 
of DNA methylation. This demethylation may lead to a restoration of TSG 
functions and therefore of growth-control and apoptosis mechanisms in 
tumors. However, it is assumed that DAC-mediated DNA demethylation is 
unspecific and can further enhance global hypomethylation, activating 
hypermethylated harmful elements such as transposons. Since DNA 
methylation is a main player in gene regulation, demethylation influences a 
broad range of cellular mechanisms, leading to a complex phenotypical 
response. Therefore, a side part of this thesis was focused in the genome-
wide and regional gene-specific effects of DAC-mediated demethylation as 
well as in the characterization of the cellular response to DAC exposure in 
leukemia and lymphoma cell lines. 
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5.4.1. Effect of DAC treatment on leukemia/lymphoma cell survival  
 
To analyze the impact of DAC treatment on leukemia cell survival, K-
562, RAJI, HEL, MOLT-3, MEG-01 and JVM-2 cells were treated with different 
DAC concentrations for 3 days and cell survival evaluated with the trypan blue 
exclusion test (Figure 46). 
 
!
0 
20 
40 
60 
T
ry
p
a
n
 b
lu
e
 p
o
s
it
iv
e
 c
e
ll
s
 (
%
) 
T
ry
p
a
n
 b
lu
e
 p
o
s
it
iv
e
 c
e
ll
s
 (
%
) 
DAC (!M) 0 0.5 1 2 5 
0 
10 
20 
DAC (!M) 0 0.5 1 2 5 
JVM-2 
0 
5 
10 
15 
0 
5 
10 
15 
* 
0 
20 
40 
60 
80 
K-562 MEG-01 
MOLT-3 HEL 
* 
** ** 
0 
10 
20 RAJI * 
* 
 
Figure 46: Analysis of DAC exposure on cell viability.  
Leukemia and lymphoma cell lines K-562, RAJI, MEG-01, HEL, MOLT-3 and JVM-2 
were treated with DAC at the indicated concentrations for 3 days. Cell viability was 
determined by trypan blue exclusion test. Results indicate the percentage of cell 
death plotted against the DAC concentration. Data are the mean ± SD of 3 
independent experiments. *p<0.05, **p<0.01 vs control. DAC: 5-aza-2!-deoxycytidine. 
 
Both CML cell lines K-562 and MEG-01 had only a reduced sensitivity to 
DAC treatment and showed in average 7.9% and 8.2% of cell death, 
respectively, after 3 days. In addition, minor proportions of dead cells were 
identified in RAJI (11.4%) and JVM-2 (16.5%) cell lines after DAC treatment. 
The highest rate of DAC-induced cell death was measured for the T-cell 
leukemia cell line MOLT-3 (67.2%) and the erythroleukemia cell line HEL 
(46.4%). Nevertheless, no significant variation in cell death was detected for 
the tested DAC concentration range (Figure 46). 
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Moreover, previous results showed that 2µM DAC was sufficient to 
induce GSTP1 promoter demethylation and expression in RAJI and MEG-01 
cells. Therefore, the evolution of cell growth and cell death was followed 
during 4 days of treatment with 2µM DAC. Various blood cancer cell lines 
were treated with DAC over a defined period of time. Progress of cell viability 
was determined by trypan blue exclusion test. Growth inhibition was 
determined by comparing cell growth of untreated and DAC-treated cells 
(Figure 47).  
 
!  
Figure 47: Effect of DAC on leukemia and lymphoma cell growth and viability. 
Blood cancer cell lines were treated daily with 2µM DAC for 4 days. Cell survival was 
assessed by trypan blue exclusion test and growth inhibition was calculated by 
comparing the cellular growth of treated and untreated cells. Data are means ± SD of 
3 independent experiments. DAC: 5-aza-2!-deoxycytidine. 
 
Results demonstrated that DAC moderately decreased (<20%) cell 
viability of K-562, MEG-01, RAJI and JVM-2 cells. In contrast, DAC treatment 
robustly decreased in time-dependent manner cell viability in HEL and MOLT-
3 to reach at 4 days 19% and 12%, respectively (Figure 47). Moreover, in all 
tested blood cancer cell lines, DAC strongly induced, in a time-dependent 
manner, growth inhibition and reached for example 86% in JVM-2 cells. 
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Since DAC treatment induced cell death in various leukemia cell lines, 
we then aimed to characterize the type of cell death induced after DAC 
exposure. K-562, RAJI, JVM-2, MEG-01, HEL and MOLT-3 cell lines were 
treated with 2µM DAC for 4 days and cells stained with Hoechst and PI dyes. 
Apoptosis and necrosis were assessed by nuclear morphology analysis 
(Figure 48). 
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Figure 48: Morphology analysis of cell death in DAC-treated leukemia and 
lymphoma cell lines. 
Leukemia and lymphoma cell lines were treated with 2µM DAC for 4 days. Every 
day, cells were stained with Hoechst and PI, visualized under fluorescence 
microscopy (HEL and MOLT-3 cell lines as example, A) and apoptotic and necrotic 
cell death quantified (B). Pictures are representative of 3 independent experiments 
and data are the mean ± SD of 3 independent experiments. *p<0.05, **p<0.01 vs 
control.  
  
A 
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DAC treatment of HEL and MOLT-3 cells resulted in a robust and time-
dependent increase of apoptosis and necrosis (Figure 48-A). After 4 days of 
DAC treatment, 65% of the HEL cells presented characteristic features 
(fragmented nuclei, condensed chromatin) of apoptosis and 18% of necrosis. 
In the case of MOLT-3 cells, 62% and 24% of the population was apoptotic 
and necrotic, respectively. In contrast, after 4 days of DAC treatment, only a 
slight percentage of K-562 (6%) and a moderate proportion of MEG-01 (25%) 
and RAJI (19%) cells showed apoptotic features. Moreover, DAC exposure 
leaded to a moderate increase of necrosis (19%) and slight occurrence of 
apoptotic nuclear morphologies (9%) in JVM-2 cell lines (Figure 48-B) 
In conclusion, leukemia and lymphoma cell lines presented a differential 
response to DAC exposure, from the highly sensitive (e.g. HEL) to the 
moderately sensitive (e.g. K-562) cells. Moreover, results showed that 
independently of the cell line considered, cell death was limited to a part of the 
DAC-treated cell population. 
 
5.4.2. Influence of DAC treatment on global DNA methylation in 
leukemia/lymphoma cells 
 
To unveil possible relationships between DAC-induced cellular response 
and genome-wide demethylation, global DNA methylation profile of various 
cell lines was determined by methylation-specific restriction assay (Figure 49).  
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Figure 49: Evaluation of global methylation in various leukemia cell lines by 
MSRA. 
Genomic DNA from various leukemia cell lines was digested by HpaII or MspI. 
Digested and undigested control DNA were separated on a 0.8% agarose gel and 
stained with ethidium bromide. The picture is representative of 3 independent 
experiments. MSRA: methylation sensitive restriction assay. 
 
Results of the methylation-sensitive restriction assay with HpaII are 
showing that the genomic DNA from RAJI, MOLT-3 and HEL cells is more 
methylated than the genomic DNA from K-562, JVM-2 and MEG-01 cells.  
In order to explain the cell line-specific variations in genome-wide 
methylation occurrence, constitutive expression of enzymes responsible for 
DNA methylation maintenance (DNMT1) and establishment (DNMT3A and 
DNMT3B) was analyzed on mRNA and protein levels. Total mRNA from K-
562, RAJI, MEG-01, HEL, MOLT-3 and JVM-2 was extracted and expression 
of DNMT1, 3A and 3B analyzed by real-time PCR assay (Figure 50-A). 
Moreover, evolution of DNMT1 protein expression after DAC exposure was 
analyzed by Western Blot (Figure 50-B).  
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Figure 50: Analysis of the effect of DAC on DNMT1 expression. 
(A) Total RNA from various human leukemia cells was analyzed by real-time PCR 
with primers specific for DNMT1, DNMT3A and DNMT3B. !-actin was analyzed as a 
control of cDNA quantity in each reaction. Results represent the ratio DNMT/!-actin 
mRNA expression levels. Data are mean ± SD of 3 independent experiments. (B) 
Proteins from untreated and DAC-treated cells were analyzed by Western Blot with 
an antibody against DNMT1. !-actin was used as loading control. Pictures are 
representative of 2 independent experiments. DNMT: DNA methyltransferase. 
 
Compared to K-562 and MEG-01 cell lines, leukemia and lymphoma cell 
lines RAJI, HEL and MOLT-3 expressed more DNMT1 mRNA and protein. 
The lowest DNMT1 mRNA level was identified in JVM-2 cells. Globally, the de 
novo DNMT3A and 3B expression rates are much lower than for DNMT1 in all 
analyzed leukemia cell lines. The highest expression for DNMT3A was 
A 
B 
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measured in K-562, MEG-01, HEL and MOLT-3 cells. For DNMT3B, the 
highest mRNA level was determined in K-562 and HEL cell lines (Figure 50-
A). Treatment of leukemia cell lines with 2µM DAC for 3 days reduced the 
DNMT1 protein amount in all analyzed cell lines except in K-562 cells. 
Following DAC exposure, the highest reduction of DNMT1 protein expression 
was observed in RAJI, HEL and MOLT-3 cell lines (Figure 50-B).  
Due to the inhibitory effect of DAC on DNMT1 protein expression, the 
influence of DAC treatment on global DNA methylation was assessed in 
various hematological malignancies. Genomic DNA from leukemia cell lines 
treated with DAC was analyzed by MSRA (Figure 51). 
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Figure 51: Kinetic analysis of the global DAC-induced DNA demethylation by 
MSRA. 
Various leukemia and lymphoma cell lines were treated for the indicated time with 
DAC, genomic DNA extracted and digested with MspI or the methylation sensitive 
HpaII enzymes. Separation profile was visualized on a 0.8% agarose gel, stained 
with ethidium bromide. Images are representative for 3 independent experiments. 
MSRA: methylation sensitive restriction assay. 
 
The high molecular band intensity in the HpaII digestion lane decreased 
and has a similar pattern as the MspI control digestion after DAC treatment, 
indicating global demethylation in all analyzed leukemia and lymphoma cell 
lines. In addition, demethylation efficiency was cell line-specific and time-
dependent (Figure 51).  
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In conclusion, amounts of DNA methylation of the various leukemia and 
lymphoma cell lines correlated with their DNMT1 expression levels. 
Depending on the blood cancer cell line, DAC treatment leaded to partial 
repression of DNMT1 protein expression and global demethylation. 
 
5.4.3. Analysis of DAC-induced growth inhibition by a single cell 
approach 
 
Previous results showed that DAC treatment leads to differential growth 
inhibition, cell death and global demethylation in various cell lines derived 
from hematological malignancies. Nevertheless, these results only provide an 
overall impression of the effects of DAC in a given population. RAJI cell line 
was selected as a cellular model in order to study the effects of DAC-
treatment on growth behavior on a single cell level. Decisive factors for this 
choice were linked to the fact that the RAJI genome is relatively high 
methylated and can be efficiently demethylated by DAC. Phenotypically, DAC 
treatment leads to growth inhibition of RAJI cells without inducing pronounced 
cell death. 
Cell division tracking using intracellular CFSE staining and flow 
cytometry analysis was used to determine the influence of DAC on 
proliferation of each single RAJI cell. During the first 24 hours of culture, cell 
proliferation patterns were similar in DAC- and mock-treated RAJI cells 
(Figure 52).  
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Figure 52: Evaluation of the influence of DAC treatment on RAJI cell 
proliferation. 
RAJI cells in exponential growth phase were stained with 0.2µM CFSE 
(CellTrace™CFSE Cell Proliferation Kit, Invitrogen) as proposed by the 
manufacturer. After a recovery phase of 24 hours, cells were treated for 72 hours 
with 2µM DAC. Cells were harvested at the indicated time points and CFSE staining 
analyzed by flow cytometry. Data were processed by FlowJo and represented as the 
mean of 3 independent experiments. 
 
After 72 hours under normal culture conditions, 42.5, 41.5 and 2.7% of 
the initial RAJI cell population had divided 4, 5 and 6 times, respectively. In 
contrast, 72 hours of DAC treatment were sufficient to consistently decrease 
cell proliferation activity in RAJI cells. Indeed, about 7.6% of the initial RAJI 
cells population stayed undivided or had divided only once during 72 hours of 
DAC treatment. The major amount of cells was found in generation 2 (20.3%) 
and generation 3 (54.9%). Generation 4 was only represented by 17.2% of 
the DAC-treated RAJI cells (Figure 52). 
In addition, the impact of DAC treatment on average RAJI cell growth 
and doubling time was compared between control and DAC-treated cells. As 
previously observed by the cell tracking method, the doubling time during the 
first 24 hours of cell culture was similar in control and DAC-treated RAJI cells 
(Figure 53). 
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Figure 53:!Effect of DAC treatment on the doubling time of RAJI cells. 
RAJI cells were treated with 2µM DAC for 72 hours and cells were counted using 
trypan blue exclusion test. Doubling time was calculated using the doubling time 
software (http://www.doubling-time.com/index.php). Data are the mean ± SD of 3 
independent experiments. 
 
However, in correlation with previous results about DAC-induced growth 
inhibition (Figure 47), doubling time of RAJI cells was moderately attenuated 
during the following day of culture and drastically affected at 72 hours. In 
contrast, the proliferation rate of untreated RAJI cells stayed constant (Figure 
53). 
 
5.4.4. Simultaneous analysis of DAC-induced GSTP1 expression 
and cell proliferation 
 
As previously shown, DAC-mediated demethylation is replication-
dependent and induces cell-specific growth arrest at different cell generations. 
These findings leads to the assumption that differential cell division may lead 
to differential gene demethylation and induction of expression, as already 
reported by the previous data about the heterogeneous induction of GSTP1 
expression in DAC-treated RAJI cells. 
In order to investigate more deeply the role of cell division in DAC-
induced demethylation and gene expression, we selected GSTP1 gene, which 
is hypermethylated in the RAJI cells as a model to analyze DAC-induced 
single cell-specific GSTP1 expression in relation to cell division. GSTP1 
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immunostaining was combined with the analysis of cell division by CFSE-
mediated cell tracking.  
At the beginning of DAC treatment, 99.8% of the control cells were 
CFSE-positive and GSTP1-negative (Figure 54-A).  
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Figure 54: Analysis of the link between cell division and GSTP1 expression in 
DAC-treated RAJI cells. 
RAJI cells were stained with CFSE and after 24 hours of recovery, treated for 72 
hours with DAC. GSTP1 expression was assessed by immunostaining using primary 
anti-GSTP1 and secondary Alexa-Fluor 647-conjugated antibodies. CFSE and 
GSTP1 fluorescence intensity were detected by flow cytometry and processed by 
FlowJo. (A) Dot plots, representative of three independent experiments, show the 
distribution of CFSE and GSTP1 fluorescence intensity relative to each cell. 
Percentages of control (blue) or DAC-treated (red) cells, present in each quadrant, 
are indicated and represent the mean of 3 independent experiments. (B) Untreated 
(black), DAC-treated GSTP1-negative (green) and GSTP1-positive (orange) cells 
were gated (left panel) and analyzed based on GSTP1 fluorescence (middle panel) 
or CFSE presence (right panel). Data are representative of 3 independent 
experiments. 
 
A 
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After 72 hours of DAC treatment, 96.6% of the cell population had 
divided (represented by the sum of cells in the lower left and right quadrants) 
and about 54% of the whole RAJI cell population was presenting low 
intensities for CFSE and GSTP1 staining. In contrast, 42.6% of the DAC-
treated RAJI cells were presenting a low intensity of CFSE but were also 
positive for GSTP1 expression (Figure 54-A). To get a better overview of 
CFSE- and GSTP1-positive cell distributions, subsets of GSTP1 expressing 
(green) and non-expressing (orange) DAC-treated RAJI cells were gated and 
CFSE pattern separately analyzed. Results show that both subpopulations 
had, independently of the GSTP1 expression level, the same cell proliferation 
pattern (Figure 54-B). 
In conclusion, all RAJI cells that were exposed to DAC were still 
dividing; even tough the cell proliferation rate was slowed down. However, 
DAC-mediated induction of GSTP1 expression was heterogeneously 
distributed over the RAJI cell population. In consequence, DNA demethylation 
is cell division-dependent but cell proliferation is not sufficient to induce 
GSTP1 expression in all RAJI cells. 
 
5.4.5. Analysis of the relationship between GSTP1 expression and 
methylation pattern in DAC-treated RAJI cells 
 
As previously shown, DAC treatment induces GSTP1 expression in only 
a subpopulation of RAJI and MEG-01 cell lines. In order to study a possible 
link between DAC-mediated heterogeneous GSTP1 expression and promoter 
demethylation, RAJI cells were treated with DAC for 3 days, immunostained 
and sorted based on GSTP1 expression level (high, low and intermediate). 
Then the methylation status of each sorted cell subpopulations was analyzed 
by MSP (Figure 55). 
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Figure 55: Analysis of GSTP1 promoter methylation after cell sorting based on 
GSTP1 expression in DAC-treated RAJI cells. 
Untreated and DAC-treated (2µM, 3 days) cells were indirectly stained with primary 
anti-GSTP1 and secondary Alexa Fluor 488-conjugated antibodies. The fluorescence 
amount of 105 immunostained RAJI cells was detected by flow cytometry on a 
FACSCalibur and analyzed by CellQuest Pro. Upper panel: one-dimensional GSTP1 
frequency histogram of 105 untreated (blue) and DAC-treated RAJI cell lines (green). 
Cells were gated by their fluorescence intensity and separated by fluorescence 
assisted cell sorting. Lower panel: one-dimensional GSTP1 frequency histogram of 
105 DAC-treated and sorted RAJI cells (G1 (red): GSTP1-negative, G2 (orange) 
GSTP1 intermediate and G3 (pink): GSTP1-positive cells). Genomic DNA was 
extracted from the different fractions (G1 to G3), bisulfite converted and GSTP1 
promoter methylation status determined by MSP. A representative picture of MSP 
analysis is inserted in each corresponding histograms. Results are representative of 
3 independent experiments. DAC: 5-aza-2'-deoxycytidine, U: unmethylated, M: 
methylated. 
 
As shown in Figure 55, it was possible to separate DAC-mediated 
GSTP1 expressing (G3) from non-expressing (G1) RAJI cells as well as to 
enrich a mixed fraction (G2). MSP analysis of the GSTP1 expressing cells 
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fraction (G3) revealed a hypomethylated state of GSTP1 promoter in these 
cells. In contrast, analysis of cells from the fraction regrouping GSTP1 non-
expressing cells (G1) showed that despite DAC exposure, DNA 
hypermethylation remained unaffected in the GSTP1 promoter region. 
Accordingly, the intermediate fraction composed by GSTP1-negative and 
GSTP1-positive cells showed a mix of hypo- and hyper-methylated GSTP1 
promoters.  
In conclusion, cell-sorting results showed that methylation status 
correlates with GSTP1 promoter activity in DAC-treated RAJI cells. 
 
5.4.6. Analysis of gene-specific demethylation in DAC-treated 
RAJI cells.  
 
DAC treatment leaded to a heterogeneous RAJI cell population 
consisting of cells with differential methylated promoter region and GSTP1 
expression pattern. To analyze whether this unequal demethylation of RAJI 
cells is specific for GSTP1 gene, the study was extended on further genes for 
which methylation patterns were analyzed by deep-sequencing on a GS FLX 
Titanium platform. Based on literature and own methylation analysis, genes 
that are hypermethylated in RAJI cells were analyzed. Results of these 
experiments were represented are presented in the form of a heat map, 
showing the evolution of DAC-induced demethylation. By comparing the mean 
methylation of each analyzed gene before and after DAC treatment, the 
demethylation efficiency was assessed (Figure 56). 
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Figure 56: Methylation analysis of various genes in control and DAC-treated 
RAJI cells. 
Genomic DNA from RAJI cells, treated for 3 days with 2µM DAC was bisulfite 
converted and regions of interest amplified by PCR. Methylation pattern was 
determined by next generation sequencing on a GS FLX platform. (A) Panel shows 
the methylation pattern before and after DAC treatment of all analyzed genes in RAJI 
cells. (B) Figure indicates the demethylation efficiency for each analyzed genes, 
calculated by comparing the mean methylation before and after DAC exposure. 
Mapping of the CpG dinucleotide distribution and detailed view on the sequence 
reads of (C) PROX1, (D) GSTP1 and (E) NORE1A genes, before and after 3 days 
DAC treatment. n=1, Blue: unmethylated, red: methylated CG dinucleotide. Results 
from one experiment. BCL2L11: BCL2-like 11, CALCA: calcitonin-related polypeptide 
alpha, CHFR: checkpoint with forkhead and ring finger domains, DAB2IBA: DAB2 
interacting protein, DAPK1: death-associated protein kinase 1, DCR1: decoy receptor 
1, DLC1: deleted in liver cancer 1, GSTP1: glutathione S-transferase P1, ESR1: 
estrogen receptor 1, EYA4: eyes absent homolog 4, H19-CTCF: imprinted gene, 
HIC1: hypermethylated in cancer 1, IGSF4: cell adhesion molecule 1, KLF4: 
krueppel-like factor 4, LINE1: long interspersed nuclear element 1, MGMT: 06-
methylguanine-DNA methyltransferase, NORE1A: Ras association (RalGDS/AF-6) 
domain family 5, OSMR: oncostatin M receptor, TP73: tumor protein P73, PROX1: 
prospero homeobox 1, PTGS2: prostaglandin-endoperoxide synthase 2, RARB2: 
retinoic acid receptor beta, THBS1: thrombospondin 1, TIMP3: tissue inhibitor of 
metalloproteinase 3. 
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(Figure 56 continued) 
 
Sequencing results indicated that the analyzed genes were differentially 
methylated in RAJI cells. The bulk of the genes (e.g. DCR1, DAPK1, GSTP1) 
were hypermethylated while some genes were moderately methylated (i.e. 
BCL2L11, ESR1, HIC1 and RARB2). Average methylation decreased after 3 
days of DAC treatment whereas the unequal methylation distribution was 
maintained (Figure 56-A). Furthermore, results showed that demethylation 
efficiency was specific for each gene. For example, the highest demethylation 
efficiencies were detected for BCL2L11, NORE1A, TP73 and PROX1 genes. 
In contrast, DCR1 gene was resistant against DAC-induced DNA 
demethylation. Remaining genes were moderately demethylated by DAC 
treatment associated with a demethylation efficiency that was highly variable 
between 7 to 28 % (Figure 56-B). Furthermore, detailed mapping of PROX1, 
E 
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GSTP1 and NORE1A methylation patterns revealed that DAC-induced 
demethylation was CpG position-independent but read-specific (Figure 56-B, -
C, -D). Only a small subset of the sequencing reads was completely 
demethylated, whereas the rest remained hypermethylated. Detailed results 
of the remaining analyzed genes are summarized in the appendix. 
Taking together, these findings showed that the analyzed genes are 
individually methylated in RAJI cells and get differentially demethylated in 
response to DAC. Moreover, individual analysis of the methylation pattern 
showed that DAC induced complete demethylation of certain reads, indicating 
that demethylation was restricted in certain cells.  
 
5.4.7. Analysis of GSTP1 promoter methylation recovery after 
DAC treatment 
 
As previously shown, DAC treatment can partially reverse DNA 
hypermethylation on GSTP1 promoter in RAJI and MEG-01 cells. To 
investigate whether DAC stably demethylates GSTP1 promoter or whether 
methylation is recovered after DAC exposure, leukemia cell lines RAJI and 
MEG-01 were exposed up to 3 days with DAC, cells washed and the medium 
subsequently exchanged by drug free medium. GSTP1 promoter methylation 
status during treatment and recovery phases was investigated by MSP 
analyses (Figure 57). 
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Figure 57: Analysis of GSTP1 promoter methylation pattern after DAC 
recovery. 
RAJI and MEG-01 cells were treated for 3 days with 2µM DAC. After a washing step, 
highlighted by a dotted line, medium was replaced by fresh medium without DAC. 
Samples were collected during the treatment phase at day 0 and 3, and during the 
recovery phase at day 6 and 10. Genomic DNA was then extracted, bisulfite 
converted and used as template for MSP with primers specific for the unmethylated 
(U) and methylated (M) state of GSTP1 gene. MSP amplicons were separated on a 
12% PAA gel and stained with ethidium bromide. Pictures are representative of 2 
independent experiments. 
 
Results showed that DAC-induced GSTP1 promoter demethylation in 
RAJI and MEG-01 cells was not stopped after removal of the demethylating 
drug but even continued up to a certain degree and then remained constant. 
Noteworthy, induction of GSTP1 demethylation was delayed, compared to 
RAJI cells. 
In conclusion, remethylation of the GSTP1 promoter was not observed in 
DAC-treated RAJI and MEG-01 cells. 
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6. Discussion 
 
In 1989, Greger et al. described for the first time the association 
between DNA hypermethylation and TSG silencing in human cancer based on 
a study on Retinoblastoma gene (Greger, Passarge et al. 1989). Nowadays, 
long lists of TSGs (e.g. DNA repair or metastasis genes) are showing aberrant 
methylation and thus gene silencing in cancer cells (Esteller 2011). Analysis 
of the cancer-specific epigenetic fingerprint, based on the evaluation of 
alterations in the methylation pattern, is a promising approach for cancer 
detection, assessment of individual’s risk for post-diagnostical recurrence and 
progression as well as for cancer therapy. Epigenetic disruptions occur during 
early carcinogenesis and are often responsible for loss of gene expression. 
Accordingly, methylation-associated silencing frequently affects genes, 
involved in DNA damage repair, tumor suppression, detoxification, 
inflammation, cell cycle regulation and motility. This inventory includes the 
detoxification gene GSTP1, which is hypomethylated and widely expressed in 
benign tissues, but hypermethylated and transcriptionally silenced in prostate, 
breast and kidney cancer cells (Dulaimi, Ibanez de Caceres et al. 2004; 
Hopkins, Burns et al. 2007; Lasabova, Tilandyova et al. 2010). Moreover, 
PTGS2, a key player in inflammation, was reported to be hypermethylated in 
several cancer types (e.g. breast, colon) and is newly used as a prognostic 
marker for prostate cancer (Phe, Cussenot et al. 2010). However, to the best 
of our knowledge, methylation-associated epigenetic silencing of GSTP1 and 
PTGS2 genes have never been studied in details for hematological 
malignancies. Hence, this study will provide compelling evidences for the role 
of DNA methylation in GSTP1 and PTGS2 repression in leukemia and 
lymphoma cells and can open up new strategies to detect, evaluate and treat 
hematological malignancies. 
 
 
 
 
 
 
  Discussion  
 175 
Reversible epigenetic fingerprint is associated to glutathione-S-
transferase P1 gene silencing in human leukemia cell lines. 
 
In the first part of this study, we investigated GSTP1 promoter 
methylation and the contribution of chromatin structure (i.e. histone 
modifications), chromatin-modifying enzymes and transcriptional regulators in 
relation to GSTP1 expression levels. Screening of various human leukemia 
and lymphoma cell lines confirmed the constitutively high level of GSTP1 
expression in K-562 and JURKAT cells and the lack of expression in RAJI cell 
line (Shea, Kelley et al. 1988; Borde-Chiche, Diederich et al. 2001). Moreover, 
our results identified several leukemia cell lines (JVM-2, HEL, MOLT-3) with 
moderate GSTP1 expression as well as an additional GSTP1-negative CML 
cell line (MEG-01). Methylation analysis by BSP, MSP and CoBRA as well as 
time-dependent but concentration-independent induction of GSTP1 
expression after DAC treatment pointed out accordingly the hypermethylation 
of the GSTP1 regulatory region in RAJI and MEG-01 cells. However, DAC-
mediated demethylation and induction of GSTP1 expression was time-
delayed in MEG-01 cells compared to RAJI cells. Since the proliferation rate 
of RAJI cells is higher than the one of MEG-01 cells, results are confirming 
that DAC-induced demethylation is a passive and replication-dependent 
process (Jones and Taylor 1980). In contrast, GSTP1 promoter was 
hypomethylated in K-562 cells. Therefore, promoter methylation status and 
GSTP1 expression pattern are correlated in blood cancer cell lines.  
These results prompt us to assume that, in accordance to prostate 
cancer, aberrant GSTP1 methylation could be linked to early leukemogenesis. 
Regarding its ‘caretaker’ gene function, DNA methylation-mediated GSTP1 
silencing might promote susceptibility to somatic genome alterations caused 
by electrophilic or oxidative carcinogens and thus provides cancer-associated 
growth advantages (Kinzler and Vogelstein 1997; Lin, Tascilar et al. 2001). 
Therefore, reactivation of the dormant GSTP1 gene and avoidance of its 
hypermethylation are not only beneficial for cell detoxification, integrity and 
survival but also for cancer prevention. This statement is confirmed by 
enhanced cancer susceptibility, detected in GSTP1 deficient mice (Ketterer 
1998). In non-malignant cells, DNA methylation is responsible for the long-
  Discussion  
 176 
term silencing of harmful tumor promoting genes and repetitive non-protein-
coding DNA regions (e.g. transposable elements) (Jones and Takai 2001). 
Apparently, gene-directed DNA methylation is truncated in cancer cells but 
the mechanistic reasons have still to be elucidated.  
Previous studies discussed the possibility to detect aberrant methylation 
on cell free DNA, extracted from serum, plasma or urine of prostate, lung and 
colon cancer patients (Esteller, Sanchez-Cespedes et al. 1999; Goessl, 
Krause et al. 2000; Cairns, Esteller et al. 2001; Grady, Rajput et al. 2001). 
This idea was adopted to detect urological malignancies during a minimal 
invasive DNA-based routine screening by analyzing GSTP1 methylation 
pattern on circulating DNA (Cairns, Esteller et al. 2001; Goessl, Muller et al. 
2001). According to our results, aberrant GSTP1 methylation could also be a 
characteristic of certain leukemia cells, implying that the detection of GSTP1 
hypermethylation in serological biopsies could not only stem from prostate 
cancer but could also originate from hematological malignancies. To prevent 
misdiagnosis, we propose to use aberrant GSTP1 methylation in various body 
fluids (e.g. blood, urine, ejaculate) as a first indication for cancer development 
whereas the analysis should be completed with further cancer-specific 
biomarkers. 
Although the herein used assay was not specific for the GSTP1 isoform, 
it was shown that DAC treatment had an enhancing effect on the enzymatic 
activity of the GST superfamily members in K-562, RAJI and MEG-01 cells. 
Basal GST activity was higher in K-562 and MEG-01 than in RAJI cells 
whereas DAC-mediated induction was higher in RAJI than in K-562 and MEG-
01 cells. We assume that, in addition to GSTP1, other GST isoforms, which 
are preceded by CGis, are hypermethylated in RAJI cells (Peng, Razvi et al. 
2009). Indeed, DAC induces simultaneous demethylation of GST genes and 
leads to a massive increase of GST activity. Regarding K-562 and MEG-01 
cells, GST genes except GSTP1 are probably hypomethylated and 
expressed, leading to the observed high basal GST activity. Moderate 
increase of GST activity in DAC-treated MEG-01 cells is probably due to the 
demethylation of GSTP1.  
GSTP1 immunostaining followed by microscopy and flow cytometry 
analyses showed that DAC treatment of RAJI and MEG-01 cells led to GSTP1 
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re-expression in only a limited subpopulation of cells, resulting in an 
heterogeneous mix of GSTP1 expressing and non-expressing cells. 
Furthermore, only a limited number of entirely demethylated GSTP1 promoter 
sequences were observed in DAC-treated RAJI cells. Fluorescence-assisted 
cell sorting of GSTP1-positive and GSTP1-negative DAC-treated RAJI cells 
and analysis of their methylation pattern revealed a correlation between DAC-
induced demethylation and GSTP1 expression in the heterogeneous cell 
population. This limited demethylation could be explained by a partial genomic 
demethylation related to a low efficiency of DAC in those cells. However, 
methylation-specific restriction assay showed a strong genomic 
demethylation. Interestingly, DAC-mediated heterogeneous cell population 
was already reported in a publication from dos Santos et al. about synovial 
sarcoma X gene expression in human melanoma cell lines (dos Santos, 
Torensma et al. 2000). Currently, it remains unclear why only a part of the 
DAC-treated cells looses GSTP1 promoter methylation and thereupon re-
expresses GSTP1. We assume that the GSTP1 surrounding heterochromatin 
structure could be responsible for the delayed demethylation. Another 
hypothesis is that differential DAC-mediated demethylation and GSTP1 re-
expression are cell cycle-related. At the moment of DAC treatment, 
asynchronous cells are in different cell cycle phases. Depending on their 
progress in cell division, cells either directly incorporate DAC leading to DNA 
demethylation or have to complete cell division before incorporation of DAC at 
the following cycle, leading to delayed demethylation in these cells.  
Although DNA methylation and histone acetylation act as synergistic 
layers in tumor-associated gene silencing, we demonstrate that HDACi alone 
failed to restore GSTP1 expression in non-expressing cell lines. Our findings 
are in agreement with a former study on CDKN2A (p15) and CDKN2B (p16), 
TIMP3 and MLH1 (Cameron, Bachman et al. 1999). HDACi had only an 
impact on GSTP1 expression after pre-incubation with the demethylating 
agent DAC. However, the incapacity of HDACis to restore GSTP1 expression 
was not due to lack of inhibitory activity. Therefore, our results demonstrate 
that dense CGi methylation of GSTP1 promoter is dominant for the permanent 
transcriptional silencing of the GSTP1 loci and has to be removed before 
HDACi can affect GSTP1 expression. Nevertheless, a recent publication 
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reported that treatment of the LNCaP prostate cancer cell line with the HDACi 
depsipeptide induced HDAC inhibition, DNA demethylation and GSTP1 re-
expression. However, it was published that besides HDAC inhibition, 
depsipeptide also decreases the recruitment of DNMT1 to the 
hypermethylated CDKN2B gene, which can be the origin of the discrepancies 
between the observations (Hauptstock, Kuriakose et al. 2011).  
The two SP1 binding sites on the GSTP1 proximal promoter region are 
essential cis-elements required for basal gene activity (Jhaveri and Morrow 
1998; Morceau, Duvoix et al. 2004). Although, the binding of the SP1 
transcription factor to its recognition site has been shown to be insensitive to 
cytosine methylation, our study showed that neither SP1 nor SP3 are 
associated to hypermethylated GSTP1 promoter region of RAJI and MEG-01 
cell lines (Harrington, Jones et al. 1988; Holler, Westin et al. 1988). This 
finding is in accordance to the current hypothesis that DNA methylation can 
induce conformational changes in chromatin structure, which block the 
accessibility of SP1 to its binding site and contribute to GSTP1 transcriptional 
silencing.  
GSTP1 expression and gene methylation patterns are correlated to the 
chromatin structure of its promoter. Indeed, ChIP analysis identified typical 
proteins and histone marks associated to a transcriptional active GSTP1 
promoter in K-562 cells. In addition, the hypermethylated GSTP1 promoter 
region of RAJI and MEG-01 cells was enriched for repressive proteins and 
histone marks, correlating with the lack of GSTP1 expression. GSTP1 
expression is therefore not exclusively regulated by DNA methylation, but also 
synergistically on level of histone modifications and transcription factor 
recruitments. In addition, the effect of DAC was not limited on GSTP1 
methylation pattern. Indeed, GSTP1 demethylation is associated with drastic 
changes of GSTP1 promoter-associated proteins including MBDs, HDACs 
and DNMTs in both non-expressing RAJI and MEG-01 cell lines, which 
correlate with GSTP1 re-expression (Jones, Veenstra et al. 1998; Nan, Ng et 
al. 1998; Jones and Baylin 2002). Thus, we clearly confirmed that DAC 
treatment triggered DNA demethylation and induced a substitution of 
repressive marks by active ones on GSTP1 promoter in RAJI and MEG-01 
cells. 
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The present study described methylation-associated silencing of GSTP1 
promoter and DAC-induced release of its repression. Moreover, it was shown 
that GSTP1 silenced cells are more vulnerable to somatic mutations after 
exposure of genome-damaging stress (Kinzler and Vogelstein 1997; Lin, 
Tascilar et al. 2001; Coughlin and Hall 2002). However, GSTP1 does not 
meet all criteria of Esteller’s candidate gene approach to identify new 
biomarkers (Esteller 2002). For a later potential clinical application of GSTP1 
as an epigenetic biomarker, the aberrant GSTP1 DNA methylation pattern 
should be detected in biopsies from patients with hematological malignancies. 
Unfortunately, GSTP1 promoter hypermethylation was not detected in 
leukemia patient samples and was clearly underrepresented in lymphoma 
patient samples. These observations are in contrast with results obtained by 
Rossi et al. and Amara et al., reporting that GSTP1 hypermethylation was 
common in patient samples derived from DLBCL, hairy cell leukemia, follicular 
lymphoma, Burkitt’s lymphoma and MALT lymphoma (Rossi, Capello et al. 
2004; Amara, Trimeche et al. 2008). Extending our analyses with further 
leukemia (e.g. CML) and lymphoma patient (e.g. Burkitt’s lymphoma) samples 
could reveal the presence of GSTP1 methylation in these specific 
hematological malignancy subtypes. 
Cell lines with high (i.e. K-562, JURKAT) and moderate (i.e. HEL and 
MOLT-3) GSTP1 expression possessed a hypomethylated promoter region. 
These data demonstrate that DNA methylation is not the only mechanism 
regulating the level of GSTP expression. Publications about miRNA 
expression and target prediction postulated that GSTP1 is post-
transcriptionally regulated by miRNAs in lung and ovarian cancer (Dahiya, 
Sherman-Baust et al. 2008; Wang, Xu et al. 2009). Screening of the GSTP1 
3’UTR by several online databases and prediction tools leaded to a long list of 
potential GSTP1 regulating miRNAs. It is assumed that in normal cells, native 
miRNA expression levels lead to moderate GSTP1 expression. In contrast, 
aberrant downregulation of an aforementioned GSTP1 targeting miRNA in 
cancer cells may enhance GSTP1 expression as observed in K-562 or 
JURKAT cell lines. In consequence, detoxification potential of these cancer 
cells is improved and possibly confers chemoresistance. Nevertheless, this 
hypothesis was never tested for hematological malignancies. Mutallip et al. 
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recently reported the post-transcriptional regulation of GSTP1 by miR-133a in 
head and neck squamous cell carcinoma (HNSCC), showing that artificial 
repression or induction of miR-133a expression leads to GSTP1 up- or down-
regulation, respectively (Mutallip, Nohata et al. 2011). However, an inverse 
correlation between GSTP1 and miRNA expression levels remained 
undetected in the analyzed leukemia and lymphoma cell lines and for the 
considered miRNAs, including miR-133a. The discrepancy between our 
observations and the finding of Mutallip et al. might be explained by possible 
minor effect of miR-133a in leukemia and lymphoma cells.  
 
Aberrant epigenetic silencing and reduced expression of prostaglandin-
endoperoxide synthase 2 gene are common events in human 
hematological malignancies. 
 
In the second part of this thesis, the correlation between PTGS2 
promoter methylation and expression in leukemia and lymphoma cells was 
assessed. Results showed that PTGS2 was differentially expressed in a 
broad range of leukemia and lymphoma cell lines. Our study pointed out that 
hypermethylation of the promoter region was associated to PTGS2 
expressional silencing in RAJI cells. Accordingly, the demethylating effect of 
DAC on PTGS2 promoter region, leading to the induction of PTGS2 
expression in RAJI cells, indicates that promoter methylation plays an 
important role in PTGS2 silencing. In contrast, Toyota et al. reported, in a 
publication about colorectal cancer, a partial methylation of the first PTGS2 
exon in RAJI cells. Moreover, they showed that hypermethylation of this 
region was responsible for the PTGS2 expressional deficiency in colorectal 
cancer cell lines (Toyota, Shen et al. 2000). The different locations of the 
analyzed regions (i.e. gene-body and promoter region) are likely responsible 
for the differing methylation results. According to Mori et al., PTGS2 was 
found to be hypermethylated and transcriptionally silenced in JURKAT cells 
(Mori, Inoue et al. 2001). The identification of leukemia cell lines that are 
methylated and thus do not express PTGS2 may be a good experimental 
model to study PTGS2-independent effects of non-steroidal anti-inflammatory 
drugs. 
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PTGS2 is highly expressed in various cancer types, including breast, 
gastric, colorectal, lung, liver and prostate (Eberhart, Coffey et al. 1994; Liu 
and Rose 1996; Ristimaki, Honkanen et al. 1997; Liu, Yao et al. 1998; Wolff, 
Saukkonen et al. 1998). However, in this study we demonstrated that in 
comparison to PBMCs from healthy donors PTGS2 is downregulated in all 
blood cancer cell lines. The leukemia cell line HEL showed the highest 
expression of all leukemia and lymphoma cell lines associated with a 
hypomethylated promoter. Moreover, moderate PTGS2 expression was 
detected in blood cancer cell lines with either partially methylated (e.g. KBM-
5, HL-60) or unmethylated (e.g. MEG-01, TF-1) PTGS2 promoter. Finally, 
unmethylated and methylated PTGS2 promoters were detected in non-
expressing K-562 and MOLT-3 cells, respectively. PTGS2 silencing in K-562 
was already reported by Waskewich et al. (Waskewich, Blumenthal et al. 
2002). In contrast, previous studies showed that the CML cell line K-562 as 
well as chronic-phase CML patients were positive for PTGS2 (Giles, 
Kantarjian et al. 2002; Zhang, Liu et al. 2006). Due to these discrepancies, it 
remains to be confirmed if, despite of promoter hypomethylation, PTGS2 is 
silenced in K-562 cells. 
Independently of the methylation status, DAC exposure induced PTGS2 
promoter demethylation and leaded to increased PTGS2 transcriptional 
activity in JURKAT, RAJI, HL-60 and KBM-5 cells. It is conceivable that in 
contrast to K-562 cells, promoter regions of these cell lines are constitutively 
activated by cell line-specific overexpression of growth factors, tumor 
promoters or cytokines. Alternatively, it was reported that ALL-associated 
HTLV-1 infection might be responsible for the permanent induction of PTGS2 
expression by the viral Tax protein via CREB and NF-!B pathways. For 
instance, Mori et al. associated lack of PTGS2 expression to the absence of 
HTLV-1 in JURKAT cells (Mori, Inoue et al. 2001). However, the current study 
clearly shows that promoter methylation is causal for PTGS2 repression and 
that DAC exposure can reverse PTGS2 silencing by demethylation in HTLV-
1-negative JURKAT, RAJI and HL-60 cells (Uphoff, Denkmann et al. 2010). 
These results imply that HTLV-1 does not affect PTGS2 expression in the 
analyzed cell lines. It is possible that DAC-induced demethylation increases 
PTGS2 promoter accessibility for other regulatory factors that are either 
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constitutively expressed or DAC-induced in JURKAT, RAJI and HL-60 cells. 
Moreover, our results are consistent with the role of promoter 
hypermethylation in PTGS2 silencing.  
In contrast to DAC-mediated induction of PTGS2 expression in JURKAT, 
RAJI and HL-60, DAC exposure was not sufficient to induce PTGS2 
expression in partially methylated JVM-2 and MOLT-3 cell lines. In these cell 
lines, DNA methylation release is obviously not enough to induce PTGS2 
expression. Similarly to K-562 cells, JVM-2 and MOLT-3 cells probably 
require an additional signal to be activated even after PTGS2 promoter 
demethylation. In addition to PTGS2-regulating factors, it has been 
demonstrated that oncogenes such as H-RAS and c-MYB can positively 
regulate PTGS2 expression (Sheng, Shao et al. 1998; Ramsay, Friend et al. 
2000; Sheng, Shao et al. 2000). It is presumed that JVM-2, MOLT-3 and even 
K-562 cells do not constitutively express such PTGS2-inducing factors or 
onco-proteins.  
Incidence of PTGS2 promoter hypermethylation was high in biopsies 
derived from leukemia patients and was even higher in lymphoma patient 
samples. In accordance, malignant samples were frequently PTGS2 deficient 
or depleted compared to blood cells from healthy donors. Moreover, PTGS2 
promoter hypermethylation was correlated to PTGS2 transcriptional silencing 
in blood cancer patient samples. In comparison, patients with 
hypermethylated PTGS2 promoter showed consistently the absence of 
PTGS2 expression, whereas PTGS2 expression was highly variable in patient 
samples with unmethylated PTGS2 promoter region. Since PTGS2 
expression is highly inducible by factors for instance from the inflammatory 
processes, PTGS2 expression variations are possibly caused by population-
based differences.  
As shown in this study, PTGS2 is epigenetically silenced in leukemia 
and lymphoma cell lines and can be induced by treatment with the DNA 
demethylating agent DAC. Similarly, PTGS2 is hypermethylated and 
transcriptionally inactive in samples derived from patients with hematological 
malignancies. Hence, PTGS2 promoter region fulfills all requirements of 
Esteller’s candidate gene approach for the identification of new biomarkers 
(Esteller 2002). However, a cohort study with a large number of samples, 
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especially CML, AML and Burkitt’s lymphoma, could improve the previous 
results. Noteworthy, methylation-associated PTGS2 silencing is mainly limited 
to lymphoid lineage-derived blood cancer patient samples. If this is confirmed 
in further lymphoma and lymphoid leukemia patient samples, PTGS2 
methylation could be used as a blood cancer classification marker.  
The role of epigenetic PTGS2 silencing in tumorigenesis is still under 
discussion. It is commonly assumed that PTGS2 is overexpressed, promoting 
carcinogenesis by inducing genes such as cell survival genes (Eberhart, 
Coffey et al. 1994; Liu and Rose 1996; Ristimaki, Honkanen et al. 1997; Liu, 
Yao et al. 1998; Wolff, Saukkonen et al. 1998). Accordingly, disruption of 
PTGS2 expression decreases tumorigenicity (Oshima, Dinchuk et al. 1996). 
However, it must be taken into account that loss of PTGS2 expression 
seriously affects pathways, in which PTGS2 is involved (e.g. attenuated 
inflammation reaction). Further studies needs to clarify the biological roles of 
altered PTGS2 expression in cancer development and progression. 
Moreover, the time point of PTGS2 overexpression is debated, 
assuming that it is an early event during carcinogenesis. PTGS2 
overexpression may suppress at short-term cell progression but contribute at 
long-term to cell growth, invasion and metastasis (Fosslien 2001; Murata, 
Tsuji et al. 2004). Accordingly, epigenetic silencing of PTGS2, as reported in 
this study, could possibly be a very late event in carcinogenesis. However, 
this would exclude PTGS2 as an early epigenetic cancer biomarker. 
Nevertheless, Ma et al. reported that the metastatic potential of breast cancer 
cells is positively correlated with increased PTGS2 expression and enzymatic 
activity (Ma, Yang et al. 2004). Since PTGS2 could be used as a prognostic 
metastasis marker, analysis of the methylation pattern of hematological 
malignancies after diagnosis could help to evaluate potential cancer 
progression and invasiveness of cancer cells. Regarding PTGS2 as a 
therapeutic target, it was reported that treatment of lung and colorectal cancer 
patients with selective PTGS2 inhibitors had a strong chemoprevention 
potential and reduced cancer incidence, respectively. (Sandler, Halabi et al. 
2003; Harris, Beebe-Donk et al. 2007). Furthermore, inhibition of PTGS2 in 
prostate cancer showed delay and prevention of disease progression (Pruthi, 
Derksen et al. 2006). Consequently, the analysis of early PTGS2 methylation 
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pattern of high-risk population for blood cancer development could predict 
success of cancer prevention and cancer treatment by PTGS2 inhibitors.  
 
DNA methylation profiling of leukemia and lymphoma cell lines: 
promising results for blood cancer detection and assessment. 
 
The systematic study of DNA methylation profiles of selected genes 
unveiled a map of frequent and distinct epigenetic aberrations in DNA 
methylation, specific for each leukemia and lymphoma cell line. DNA 
hypermethylation was detected in genes involved in normal cell physiology 
such as DNA repair (e.g. MGMT), cell cycle control (e.g. CDKN2A) or cell 
detoxification (e.g. GSTP1).  
By using gene-non-specific approaches (e.g. restriction landmark 
genomic scanning) and gene-specific high-resolution studies (e.g. DNA 
methylation microarray), several studies already reported differential 
methylation amount in cancer cells (Costello, Fruhwald et al. 2000; Ehrich, 
Turner et al. 2008; Figueroa, Lugthart et al. 2010). The present study extends 
this knowledge on hematological malignant cells, showing by a gene-specific 
technique (i.e. MSP) that methylation frequency was highly variable. 
Accordingly to Paz et al. the highest gene methylation frequency was 
detected in the RAJI (BL) cells, followed by the KG-1a (AML) cell line (Paz, 
Fraga et al. 2003). Furthermore, ranking cell lines based on descending CGi 
methylation levels led to the following order: JURKAT (ALL), MOLT-3 (ALL), 
JVM-2 (CLL), KBM-5 (CML), HL-60 (AML), KG-1 (AML), HEL (AML), K-562 
(CML) and MEG-01 (CML) cell lines. The lowest methylation frequency was 
detected for the cell lines THP1 (AML) and TF-1 (AML). Although the 
candidate gene approach in our study was more extensive (26 genes) than in 
the publication of Paz et al. (15 genes) and that gene lists slightly differ 
between both studies, ranking of leukemia and lymphoma cell lines by their 
amount of methylation was in line with the results of Paz et al. Moreover, both 
studies consistently reported equal percentage of hypermethylation for K-562 
and HL-60 cell lines (Paz, Fraga et al. 2003). 
Currently, histology and cytology are still important diagnostic tools for 
cancer management, detection and staging of neoplasia. Hence, the current 
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study should evaluate if the methylation pattern could be used for blood 
cancer classification. Hierarchical clustering of blood cancer cell lines 
according to their methylation profile revealed differences between the 
analyzed blood cancer cell lines and clustered the lymphoma cell line RAJI 
outside of the leukemia cell lines. Furthermore, microarray-based study for 
DNA methylation analysis reported the promising possibility to use 
methylation to differentiate healthy from leukemia samples and to classify 
leukemia samples (Adorjan, Distler et al. 2002). However, leukemia cell lines 
were often misclassified and thus only partially grouped together in their 
theoretical cell type branches. Noteworthy, K-562 and MEG-01 CML cell lines 
were closely grouped in the same cluster, whereas KBM-5 was excluded from 
this cluster. In addition, HL-60 and KG-1 AML cell lines were clustered, 
whereas for instance HEL was located in another cluster. Strikingly, the 
candidate gene approach separately clustered the parental KG1 cell line from 
its less differentiated subline KG-1a (Furley, Reeves et al. 1986). It might be 
possible that this study uncovered a cell line for which cell type was 
incorrectly classified in literature such as for MDA-MB-435, which has long 
been believed to be a breast cancer cell line (Paz, Fraga et al. 2003). Indeed, 
while in the past, MDA-MB-435 was used as a breast cancer model, a lot of 
studies later showed that this cell line is of melanocyte nature (Lacroix 2009). 
However, the restrictive factors of the present study are, on the one hand, the 
number of the analyzed genes and on the other hand the selection of these 
genes. Thus, differences between the methylation patterns are not significant 
enough to classify the various hematological malignancies. Therefore, the use 
of additional genes in this candidate gene approach or a methylome-wide 
analysis would increase the stringency of the approach and should allow the 
classification of hematological hemopathies based on their methylation 
profiles (Adorjan, Distler et al. 2002). 
From a qualitative point of view, a broad range of genes were frequently 
hypermethylated in the analyzed leukemia and lymphoma cell lines, including 
CDH1, CALCA, LINE1, CDKN2A, CDKN2B, TMS1, MGMT and RARB. Due to 
the extensive hypermethylation of these genes in leukemia cell lines, they 
could theoretically be used as markers for blood cancer detection, even in the 
background of other cell types (i.e. tumor or normal cells). However, the 
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analysis of these genes is largely inadequate to subclassify hematological 
neoplasms, for instance based on their lineage. Another subset of genes (i.e. 
GSTP1, TIMP3, DAPK1, HIC-1, CDKN2A, APC, AHR, ESR1, RASSF1A 
TP73 and PTGS2) was occasionally methylated on various blood cancer cell 
lines. These genes are potentially good biomarkers for clinical stratification of 
blood cancer cells into their different subtypes. Finally, promoter regions of 
SOCS-1, RB1, MLH1, CASP8, CASP7, BCL2 and BCL2L11 genes were 
unmethylated in our cancer cell lines, clustering amongst others apoptosis-
related genes. Even though the methylation state of these genes indicates the 
conservation of the apoptosis potential, they are useless for an application as 
epigenetic biomarkers. Cell lines are often used in basic research without 
taking into account the epigenetic environment. However, if we want to 
analyze apoptosis, it would be worth to know the epigenetic silencing of 
apoptosis-associated genes. This study may serve as a starting point, 
extending our knowledge on the field of cancer cell lines.  
In addition to cancer detection and diagnosis, the analysis of DNA 
methylation alterations is a valuable source for information about the 
constitution of the cancer cells. DNA methylation-associated silencing of 
GSTP1 in RAJI and MEG-01 was described in detail for the first time in the 
present study. In accordance to Paz et al., we reported TIMP3 promoter 
hypermethylation in RAJI cells (Paz, Fraga et al. 2003) and additionally in the 
KBM-5 cell line. Regarding the HL-60 cell line, TIMP3 methylation results 
were controversial (Paz, Fraga et al. 2003). In consistence with former 
studies, DAPK1 hypermethylation was detected in RAJI, HL-60 and KG-1a 
cells and hypomethylation in K-562 and KG-1 cells (Paz, Fraga et al. 2003; 
Takahashi, Shivapurkar et al. 2004; Raval, Tanner et al. 2007; Chim, Chan et 
al. 2008). Moreover, Paz et al. reported that DAPK1 promoter is 
hypermethylated in JURKAT cell line. However, our results in accordance with 
other publications reported DAPK1 hypomethylation in JURKAT cells 
(Katzenellenbogen, Baylin et al. 1999; Takahashi, Shivapurkar et al. 2004; 
Chim, Chan et al. 2008). Raval et al. showed that DAPK1 promoter is 
methylated in the gene body region, whereas the promoter remains 
unmethylated (Raval, Tanner et al. 2007). Thus, differences in the analyzed 
gene loci might be at the origin of such discrepancies between studies.  
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In accordance with an earlier study, we showed HIC1 promoter 
hypermethylation in RAJI and K-562 cell lines (Issa, Zehnbauer et al. 1997). 
Moreover, Paz et al. and Guo et al. already published HIC1 hypomethylation 
in JURKAT, K-562, KG-1a, HL-60 and RAJI cell lines (Paz, Fraga et al. 2003; 
Guo, Burger et al. 2005). In line with previous data, we reported CDKN2A 
(p14ARF) promoter hypomethylation in RAJI and HL-60 cells and 
hypermethylation in KG-1a cells (Paz, Fraga et al. 2003; Chim, Chan et al. 
2008). However, predominant methylation of this cell cycle regulator in MOLT-
3 cells was unpublished. Furthermore, lack of MSP products for K-562, HEL 
and JURKAT cells were consistent with homozygous deletion of the CDKN2A 
(p14ARF) locus. Moreover, hypermethylation of APC gene was reported for 
several solid tumor cancer cell lines, whereas its DNA methylation was mainly 
unknown in blood cancer cells. In correlation with our results, Wu et al. 
reported hypermethylation of the APC promoter in JURKAT cells (Wu, Shen 
et al. 2009). In addition, we showed APC methylation in JVM-2 and MOLT-3 
cell lines. Regarding the methylation status of APAF-1 gene, widely differing 
results were obtained. Furakawa et al. reported hypermethylation of APAF-1 
gene in RAJI and K-562 cell lines and hypomethylation in JURKAT, and HL-
60 cell lines. In contrast, our data correlate with results from Chim et al., 
showing that APAF-1 is unmethylated in RAJI, HL-60 and JURKAT cells 
(Chim, Chan et al. 2008). Hypermethylation of AHR promoter was also 
detected in RAJI and JURKAT cells in this study. In contrast, Mulero-Navarro 
et al. reported AHR promoter hypermethylation in K-562 cells (Mulero-
Navarro, Carvajal-Gonzalez et al. 2006). Moreover, hypermethylation of ESR1 
gene was extensively described in former publications (Guo, Burger et al. 
2005; Gebhard, Schwarzfischer et al. 2006; Gebhard, Schwarzfischer et al. 
2006). However, our data demonstrated in contrast to Gebhard et al., that 
ESR1 promoter was hypomethylated in THP-1 and K-562 cell lines (Gebhard, 
Schwarzfischer et al. 2006). In line with previous data published by Paz et al., 
we showed RASSF1A promoter methylation in JURKAT, K-562 and RAJI cell 
lines as well as promoter hypomethylation in KG-1a and HL-60 cells (Paz, 
Fraga et al. 2003). In accordance to results from Corn et al., we observed 
TP73 methylation in KG-1a, HL-60 and RAJI cells. However, methylation of 
TP73 in JURKAT and KBM-5 cell lines has never been mentioned before. 
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Interestingly, methylation-associated silencing of PTGS2 has never been 
considered as epigenetic mark in hematological malignancies and was 
described for the first time in this study.  
E-cadherin is one the most commonly methylated genes in 
hematological malignancies. As proven by Paz et al. and Corn et al., we 
confirmed CDH1 hypermethylation in JURKAT, K-562, KG-1a, HL-60 and 
RAJI cells (Corn, Smith et al. 2000; Paz, Fraga et al. 2003). Moreover, 
Lakshmikuttyamma et al. revealed a partial methylation and complete 
methylation of CDH1 in KG1 and KG-1a cells, respectively 
(Lakshmikuttyamma, Scott et al. 2010). We further completed the list of CDH1 
promoter methylation-positive cell lines with MOLT-3, HEL, MEG-01, JVM-2, 
THP-1, TF-1 and KBM-5. Even though, CALCA gene is found hypermetylated 
in various hematological neoplasia (Ismail, El-Mogy et al. 2011). We 
determined CALCA hypermethylation in RAJI, KG-1, HL-60, Hel, MOLT-3, 
KG1a and JURKAT cell lines. In correlation with Paz et al., the cell cycle 
regulating gene CDKN2A (p16INK4a) and CDKN2B (p15INK4a) were shown here 
to be methylated in RAJI and KG-1a cells and the promoter deleted in THP-1 
and JURKAT cells (Dodge, Munson et al. 2001; Paz, Fraga et al. 2003; Galm, 
Herman et al. 2006M; Gebhard, Schwarzfischer et al. 2006). Moreover, 
CDKN2A (p16INK4a) gene methylation was detected in JVM-2, HEL as well as 
KG-1a cells and for CDKN2B (p15INK4a), methylation was observed in KBM-5, 
JVM-2 and MOLT-3 cells. TMS1 gene is often found methylated in breast 
cancer cells (Levine, Stimson-Crider et al. 2003). However, methylation-
associated silencing in leukemia and lymphoma cell lines remained so far 
undescribed. Surprisingly, here, TMS1 promoter was hypermethylated or 
partially methylated in all analyzed blood cancer cell lines with the exception 
of THP-1 cells. In accordance with Paz et al., the present study also revealed 
the hypermethylation of MGMT promoter region in RAJI, K-562, KG-1a and 
JURKAT cells, whereas its methylation status in HL-60 was different in both 
studies. Moreover, discordant results were published for the methylation 
status of RARB in HL-60, K-562 and JURKAT cell lines (Paz, Fraga et al. 
2003). The causes for these divergences between both studies are not clear, 
but as it has already been emphasized, region specific differences may be at 
the origin of such discrepancies.  
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Determination of the methylation status of the above mentioned genes 
could provide important information about chemosensitivity, cell motility, 
inflammation, hormone response, cell cycle regulation and apoptosis of 
cancer cells, improving cancer therapy. However, DNA methylation analysis in 
leukemia and lymphoma patient samples was so far done for only several 
genes (Galm, Herman et al. 2006; Boultwood and Wainscoat 2007). 
Therefore, the expansion of DNA methylation analysis to patient samples 
could reveal new path in blood cancer treatment. 
The use of a single gene locus to discriminate malignant from benign 
cells as well as to classify cancer cells has several drawbacks. The sensitivity 
is restricted by the hypermethylation frequency at a specific CpG locus. 
Moreover, as CGi methylation is not specific for blood cancer cells, 
hypermethylation of a specific gene can also occur in non-cancerous tissue or 
in other cancer types. Indeed, methylation analysis of several genes has more 
discriminatory power for detection of a specific cancer. A combinatorial 
approach with several of often but differential hypermethylated genes in 
leukemia cell lines could improve cancer detection and treatment. For 
example, combined detection of GSTP1 and APC hypermethylation in 
prostate cancer achieved a theoretical sensitivity of 98.3% as compared to 
benign prostatic hyperplasia and had a specificity of 100% (Jeronimo, 
Henrique et al. 2004). 
Even if the methylation status of some of the genes reported in this 
study were already published, combined analysis of these genes and blood 
cancer cell lines was never reported. In addition, this study extends the 
knowledge about blood cancer-associated hypermethylation to further target 
genes. As described above, cancer-associated DNA methylation changes 
were mostly analyzed on a gene-by-gene basis, metaphorically speaking, 
from a frog perspective (Schulz and Goering 2011). However, the 
development of new techniques allows today the eagle’s view, an overview of 
the whole methylome. In conclusion, simultaneous methylation analysis of 
selected and highly informative genes or genome-wide methylation patterns 
within the scope of individualized medicine could be used as a molecular 
fingerprint of cancer cells, enabling premalignant cancer detection, prediction 
and prognosis in the same manner as mRNA expression profiling is already 
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applied in molecular cancer diagnosis. Finally, DNA hypermethylation is 
nowadays a promising target for epigenetic drugs (e.g. DAC).  
 
Demethylation efficiency and specificity of 5’-aza-2’-deoxycytidine in 
hematological malignant cells. 
 
Initially synthesized as an anticancer cytotoxic agent in 1968 by Sorm et 
al., the later use of 5’-aza-2’-deoxycytidine (DAC) at low doses revealed its 
differentiation- and DNA demethylation-inducing activities (Piimi 1964; Pískala 
1965; Jones, Taylor et al. 1982). Interestingly, DAC is used as a molecular 
demethylation tool to analyze DAC-mediated induction of gene expression. It 
is known that in cell culture, high doses of DAC trigger cell death, whereas 
low doses lead to loss of DNMT activity and DNA demethylation (Christman 
2002). In addition, multiple clinical trials underlined the promising effect of low-
dose DAC in leukemia, leading to FDA approval for the medication of MDS 
(Kantarjian, O'Brien et al. 2003; Issa, Garcia-Manero et al. 2004; Schmelz, 
Sattler et al. 2005). Even if DAC is routinely used in research and is newly 
used for MDS treatment, statements about DAC-induced molecular and 
cellular effects in hematological malignancies are still vague. Hence, the last 
part of this thesis wanted to elucidate the cellular response as well as the 
demethylation efficiency and specificity of DAC treatment in leukemia cell 
lines at clinical relevant low doses (Aparicio, Eads et al. 2003). 
The present study showed that independently of the tested DAC 
concentrations, 4 days of DAC treatment were not sufficient to induce 
pronounced cell death in K-562 and MEG-01 cells (<10%). In contrast, HEL 
cells were more sensitive to DAC exposure (>40%) than K-562 cells whereas 
MOLT-3 cells were the most sensitive (>60%). Noteworthy, other results from 
our laboratory showed delayed apoptosis in K-562 and MEG-01 cells after 
sustained DAC exposure (data not shown). This study was extended to 
further cell lines, reporting moderate cell death in the DAC-treated RAJI 
Burkitt’s lymphoma and the JVM-2 CLL cell lines. Moreover, the present study 
showed that sustained DAC exposure decreased cell proliferation and 
increased growth inhibition in a time-dependent manner. In addition, DNMT1 
expression and global DNA methylation analysis showed that K-562, JVM-2 
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and MEG-01 genomes were relatively hypomethylated, compared to the 
hypermethylated RAJI and MOLT-3 genomes. In between, HEL genome is 
moderately methylated. Globally, cell death and methylation results indicate a 
direct link between the amount of DNA methylation, the level of DNMT1 
expression and DAC-sensitivity. We assume that cells with high amount of 
methylation and DNMT1 expression are more sensitive to DAC treatment than 
cells with hypomethylated genome. Since DAC induced global demethylation 
and DNMT1 depletion, alterations in DAC metabolism, leading to DAC 
resistance, can be excluded as reasons for differential DAC response of blood 
cancer cell lines (Qin, Jelinek et al. 2009). Since DAC-mediated 
demethylation is related to cell replication, cell proliferation could be a 
decisive factor influencing DAC response. However, all cell lines divide more 
or less at the same rate, leading to a similar demethylation pattern. It is 
conceivable that, in addition to the epigenetic background, genetic differences 
are responsible for the differential response of the analyzed leukemia cell 
lines to DAC treatment.  
It is commonly accepted that DAC is incorporated into the daughter 
stand during replication, subsequently DNMT1 is trapped, ubiquitinylated and 
finally degraded. Goshal et al. reported that DAC exposure (2.5µM) of HELA 
cells led to a entire loss of DNMT1 protein after 24 hours (Ghoshal, Datta et 
al. 2005). Moreover, complete decline of DNMT1 protein expression after 24 
hours of AZA treatment was reported in K-562, HL-60 and HEL cell lines. 
Despite sustained AZA exposure, DNMT1 protein increased again during the 
next 48 hours of treatment (Stresemann, Bokelmann et al. 2008). Moreover, 
another study described complete depletion of DNMT1 protein after 48 hours 
of DAC treatment in KG-1a and THP-1 cell lines at concentrations of 0.1µM 
and 0.3µM, respectively (Hollenbach, Nguyen et al. 2010). However, we 
observed in all analyzed cell lines a partial loss of DNMT1 protein after 72 
hours of DAC treatment. Since DAC and AZA have to be metabolized and 
integrated during replication, the question arises how DAC can induce 
complete removal of DNMT1 after maximal one cell division. Our data show 
moderate DAC-induced depletion of DNMT1, which is in accordance to 
passive loss of DNA methylation. 
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Numerous studies have already discussed the cellular consequences of 
DAC treatment. DNA damage-related and DNA methylation-independent 
activation of CDKN1A (p21) via p53 as well as G1 cycle arrest were reported 
in various DAC-treated AML cell lines (Jiemjit, Fandy et al. 2008). It is 
assumed that in p53-proficient cells, DAC-mediated DNA damages induce cell 
cycle arrest, whereas they lead to cell death in p53-deficient cells (Nieto, 
Samper et al. 2004). On the basis of literature, we found out that K-562 cells 
are p53 negative and HEL cells p53 positive. However, p53 status did not 
correlated with cell survival after DAC exposure (Durland-Busbice and 
Reisman 2002). Alternatively, Tamm et al. have attributed the induction of 
DAC-mediated apoptosis in AML cell lines to the demethylation-associated 
induction of the p53 sequence homolog and apoptosis inducer TP73 (Tamm, 
Wagner et al. 2005). However, the TP73 methylation signature of the blood 
cancer cell lines used in this study did not correlate with DAC-induced cell 
death (e.g. high DAC responsive cell lines are differentially methylated in the 
TP73 locus). Furthermore, it was reported that DAC could induce G2/M cell 
cycle arrest via the p38 MAP kinase pathway (Lavelle, DeSimone et al. 2003). 
As previously described, DAC induces the expression of p53 inducible 
apoptotic proteins Puma and Noxa, leading to the activation of both the 
intrinsic mitochondrial apoptosis pathway and caspase 3 or leading to a 
caspase-independent cell death pathway (Tamm, Wagner et al. 2005; 
Brodska, Otevrelova et al. 2011). In addition, DAC-mediated demethylation 
and induction of other genes, involved in cell death signaling or cell cycle 
regulation are probably at the origin for DAC-induced cell death in our cell 
models. For example, Furukawa et al. described induction of the cell death-
associated APAF-1 gene in DAC-treated acute leukemia cells (Furukawa, 
Sutheesophon et al. 2005). However, methylation profiling of blood cancer cell 
lines showed that APAF-1 is not differentially methylated between DAC-
sensitive and less sensitive cell lines. An alternative model for DAC-mediated 
cancer cell death is related to formation of covalent DNMT-DNA adducts in 
DAC containing DNA, leading to DNA damages and cytotoxicity (Juttermann, 
Li et al. 1994). Noteworthy, it is reported that DAC-induced demethylation and 
gene expression is rather unspecific. Thus, loss of gene regulation and 
simultaneous release of gene expression probably lead to activation of 
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several pathways. Therefore, it is most likely that DAC-induced cell death 
results of a combination of effects reflecting the sum of induced genes. 
The previous part of the study provided insights into DAC-induced 
cellular effects in blood cancer cell population. Noteworthy, results revealed 
that DAC exposure initiates heterogeneously apoptosis and DNA 
demethylation in the same cell population. However, significance of the MSRA 
approach is limited to global methylation and does not allow elucidating the 
causes for heterogeneous demethylation. Therefore, the existing question is: 
Does DAC exposure induce uniform but partial demethylation in the entire cell 
population or does it affect only certain cells and initiate subsequently cell 
death in these unmethylated cell subpopulation? Moreover, it remains to 
determine whether DAC-induced DNA demethylation is gene specific. 
To investigate these issues, RAJI cell line was selected as a suitable 
model based on its relatively high global DNA methylation level and low 
sensibility to DAC-induced cell death. Moreover, GSTP1 gene that is 
hypermethylated in RAJI cells was chosen as reference gene. Since DAC-
treated cells were not synchronized in previous experiments, we assumed 
that cell cycle distribution could be responsible for the differential DAC 
response. Theoretically, cells in G1 phase can integrate DAC during the first 
replication, leading to DNA demethylation from the very beginning of the 
treatment. In contrast, demethylation of cells in G2 is delayed because they 
have first to complete their division before they can subsequently integrate 
DAC. However, results showed that even if doubling time was continuously 
increasing, only an infinitesimal part of the cell population remained undivided 
or was blocked in the first cell division after 3 days of DAC treatment. At that 
time, most of the DAC-treated RAJI cells had divided 3 times. Absence of cell 
proliferation arrest and decreased cell proliferation rate in DAC-treated RAJI 
cells are in contrast to the commonly reported DAC-induced cell cycle arrest 
(Lavelle, DeSimone et al. 2003; Tamm, Wagner et al. 2005; Jiemjit, Fandy et 
al. 2008). Differences in the genetic and epigenetic background of leukemia 
and lymphoma cell lines as well as differences in applied DAC concentrations 
could be at the origin of the differences observed in this study. Moreover, 
combination of cell proliferation assay and GSTP1 immunostaining of DAC-
treated RAJI cells showed that all treated cells were dividing, whereas 
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demethylation-associated induction of GSTP1 expression was detected only 
in a subpopulation. In conclusion, cell proliferation is necessary but not 
sufficient to induce homogeneously demethylation and transcriptional activity. 
It is presumed that DAC does not directly affect cell proliferation and DNA 
demethylation of blood cancer cells, but probably has to be first absorbed and 
metabolized. In line with this assumption, the effect that we observed in this 
study is probably just the beginning of DAC-mediated demethylation. Some 
cells are probably not yet affected by DAC and continue to proliferate, 
whereas another cell subpopulation is demethylated and GSTP1 expression 
concomitantly induced. It is also possible that GSTP1 demethylated cells 
undergo in a next step cell cycle arrest and apoptosis. 
In order to exclude that the heterogeneous demethylation, observed in 
DAC-treated RAJI cells was specificity for the GSTP1 gene locus, further 
genes were included into this study. Deep sequencing results revealed that 
the analyzed genes were differentially demethylated in presence of DAC. For 
example, DCR1 and THBS1 genes were mainly resistant to DAC-induced 
demethylation, in contrast to BCL2L11 and NORE1A genes, which were more 
efficiently demethylated. Moreover, DAC-response was independent of the 
initial gene methylation since partial methylated BCL2L11 and 
hypermethylated GSTP1 promoter regions showed similar demethylation 
efficiency. In addition, deep sequencing results were consistent to GSTP1 
promoter BSP results, showing completely hypermethylated as well as fully 
unmethylated reads, indicating that only a part of cells was demethylated. 
Post-sorting analysis confirmed this statement, showing that GSTP1 promoter 
region was only unmethylated in GSTP1 expressing cells, and accordingly 
GSTP1 was hypermethylated in non-expressing cells. By using a DNA 
methylation reporter gene assay, Si et al. also reported heterogeneous gene 
reactivation by DAC treatment (Si, Boumber et al. 2010). In line with our 
previous hypothesis about delayed and stepwise loss of DNA methylation, we 
assume that heterogeneous re-expression could be explained by the 
existence of a mixed cell population consisting of cells with fully demethylated 
and transcribed DNA and other cells with fully methylated and silenced DNA.  
Finally, the current study showed that GSTP1 methylation was not 
recovered after DAC withdrawal. However, with a similar experimental setup, 
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Qin et al. showed recovery of LINE1 methylation. Indeed, 4-days of DAC 
exposure decreased initial LINE1 methylation to 25% whereas after 10 days 
of DAC withdrawal LINE1 methylation was recovered at 75% of the initial 
density in HL-60 cells (Qin, Youssef et al. 2007). Furthermore, a publication 
about hypermethylation of DAPK1 showed complete recovery of DAPK1 
methylation in RAJI cells after 7 days of DAC exposure (0.3µM) followed by 
11 days in fresh media (Katzenellenbogen, Baylin et al. 1999). Moreover, a 
recent study that used a DNA methylation reporter gene assay to analyze 
evaluation of methylation after DAC exposure showed a time-dependent 
recovery of methylation and reporter gene silencing after DAC withdrawal (Si, 
Boumber et al. 2010). We assume that in the experimental conditions of our 
study, the level of DAC-induced DNA demethylation exceeded a certain 
threshold leading to a decrease of cell proliferation, which is impairing DNA 
remethylation. In addition, it is possible that high quantity of DAC was already 
entered into cells and/or metabolized, sustaining DNMT1 inhibition. Moreover, 
it is possible that lack of recovery is cell line- or gene-specific. In conclusion, 
further experiments are required to understand the gradual loss of DNA 
methylation and explain heterogeneous cell behavior after DAC exposure. 
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7. Conclusions and perspectives 
 
Reversible epigenetic fingerprint is associated to glutathione-S-
transferase P1 gene silencing in human leukemia cell lines. 
 
Results of this thesis part gave new insights into the regulation of 
GSTP1 gene expression by epigenetic mechanisms in leukemia. GSTP1 
promoter hypomethylation and the associated euchromatin structure correlate 
with GSTP1 transcriptional activity (e.g. K-562). In contrast, heterochromatin 
configuration and the hypermethylated state of the GSTP1 promoter region 
lead to expressional silencing (e.g. RAJI, MEG-01). Treatments with the DNA 
hypomethylating agent DAC decrease the hypermethylated state of GSTP1 
promoter, inducing chromatin decondensation of this region and thus restoring 
GSTP1 expression in a subset of GSTP1-negative leukemia cells. 
Furthermore, screening of CLL, AML, ALL and lymphoma patient samples did 
not identify any DNA hypermethylation in the GSTP1 promoter region. This 
epimutation may be CML or Burkitt’s lymphoma specific or the sample 
frequency may be too reduced. Consequently, we will try to further collect and 
enlarge our pool of leukemia patient samples. In conclusion, these data 
demonstrate that cytosine methylation can repress GSTP1 gene expression in 
leukemia and lymphoma cells. Hence, we can consider the investigation of 
GSTP1 methylation marks as a prognostic factor for hematological 
malignancies. Furthermore, these data support the concept of the dominance 
of DNA methylation over HDAC inhibitor-sensitive histone deacetylation in 
silencing genes with a high CpG density in the promoter region.  
In perspective, this study has to be completed with further leukemia and 
lymphoma patient samples to validate GSTP1 as an epigenetic biomarker. 
Moreover, the biological role of GSTP1 epigenetic silencing in early 
carcinogenesis has to be clarified. For this purpose, we suggest to analyze 
the effects of GSTP1 repression in non-cancerous cell lines. Indeed, analysis 
of GSTP1 methylation pattern could allow to anticipate for instance 
chemosensitivity or improve individualized cancer medicine on the field of 
diagnostic, optimized prevention and therapeutic care.  
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Moreover, genome-wide miRNA expression profiling may identify 
miRNAs of importance for GSTP1 gene regulation in hematological 
malignancies. If a potential GSTP1 targeting miRNA is newly identified, the 
study will be completed with an analysis, studying the effect of miRNA 
downregulation or overexpression on GSTP1 expression. 
 
Aberrant epigenetic silencing and reduced expression of prostaglandin-
endoperoxide synthase 2 gene are common events in human 
hematological malignancies. 
 
Results showed that PTGS2 expression is markedly decreased or 
absent in leukemia and lymphoma cell lines. PTGS2 downregulation is closely 
associated with DNA hypermethylation, which can be reversed by DAC to 
increase PTGS2 expression. In patients, PTGS2 promoter methylation is 
identified in numerous blood cancer patients, which significantly contributes to 
PTGS2 downregulation. Noteworthy, PTGS2 downregulation occurs mainly in 
tumors from the lymphoid lineage. In conclusion, PTGS2 promoter 
methylation represents a promising biomarker for diagnosis in hematological 
malignancies. 
In perspective, PGE2 production in DAC-treated cells presenting PTGS2 
demethylation/overexpression will be analyzed in order to determine 
functionality of the DAC-induced protein. In order to evaluate the specificity of 
PTGS2 methylation regarding blood cancer cells, other cancer types will be 
included in this study. To investigate whether DNA methylation is sufficient to 
repress PTGS2 expression, effects of HDACis alone or in combination with a 
canonical inducer of PTGS2 expression such as phorbol myristate acetate 
(PMA) will be analyzed on PTGS2 expression in PTGS2-negative cells. 
Moreover, the biological role of PTGS2 methylation-associated silencing has 
to be clarified. Therefore, PTGS2 knock-out or overexpression in 
undifferentiated blood stem cells or normal non-malignant cells will give new 
insight into the roles of PTGS2 repression in cancer development. In addition, 
we plan to analyze the effects of PTGS2-specific inhibitors on cell 
chemosensitization, which should provide important information for cancer 
treatment and management. Similarly to the experiments carried out on 
  Conclusions and perspectives  
 198 
GSTP1 promoter, chromatin structure will be analyzed in PTGS2 hyper- and 
hypo-methylated blood cancer cell lines.  
To validate PTGS2 as a an epigenetic blood cancer marker, additional 
samples (especially CML, ALL and BL) and further leukemia and lymphoma 
subtypes have to be included in this study. To analyze the evolution of PTGS2 
methylation during cancer progression, samples from different blood cancer 
progression states should be included in the study. Finally, the study should 
be extended to other cancer types (e.g. prostate, lung, breast, colon) in order 
to determine for which cancer types PTGS2 methylation is characteristic. 
 
DNA methylation profiling of leukemia and lymphoma cell lines: 
promising results for blood cancer detection and assessment. 
 
Results of this study revealed high qualitative and quantitative variations 
in the leukemia and lymphoma cell line-specific methylomes.  
In perspective, this study should be extended to further genes by using 
methods investigating the whole methylome (e.g. next generation sequencing) 
instead of MSP analyses, thereby increasing the stringency of the approach. 
In addition, methylation pattern of miRNAs, which are the main players in the 
post-transcriptional regulation of gene expression, has to be included in the 
approach. Further leukemia, lymphoma and myeloma cell lines should be 
included in this study as well as healthy cells as reference. Moreover, this 
candidate gene approach should be applied to a large set of patient samples. 
The present study only served as a starting point, extending our knowledge 
on the field of blood cancer cell lines. However, the use of such a candidate 
gene approach for individualized blood cancer medicine remains a long-term 
objective.  
 
Demethylation efficiency and specificity of 5’-aza-2’-deoxycytidine in 
hematological malignant cells. 
 
The present study pointed out the differential sensitivity of blood cancer 
cell lines to DAC exposure. Furthermore, it was shown that DAC treatment 
leads to heterogeneous induction of DNA demethylation and cell death in a 
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cell population. Moreover, this study showed that cell proliferation is 
necessary to induce DNA demethylation but is not sufficient to cause 
complete loss of methylation in a cell population. However, the precise 
mechanisms and dynamics of DAC about induction of cell death are still not 
well understood. We assume that heterogeneous cell behavior, regarding 
demethylation, gene induction and apoptosis, is due to a gradual impact of 
DAC on the cells. Our model proposes that DAC treatment induces complete 
demethylation in a part of the cell population, whereas the rest of the cells 
remain DAC-unaffected and maintain their cancer-specific methylation 
pattern. Subsequently, methylation poor cells undergo apoptosis, whereas 
methylated cells continue to proliferate. Thus, this study leaves a lot of 
questions unanswered. In consequence, further experiments may be needed 
to verify the above-mentioned presumptions. 
In perspectives, comprehensive analyses of intrinsic and DAC-induced 
expression of various cell cycle and apoptosis regulators, the epigenetic 
pattern of these genes as well as their mutation status have to be included to 
finalize this study and determine the mode of action of DAC in blood cancer 
cell lines. Moreover, kinetic analysis of DAC integration into DNA, possibly by 
HPLC analysis could provide information about DAC-induced demethylation 
dynamics. In order to validate previous demethylation results, deep-
sequencing will be repeated. To investigate whether the heterogeneous 
induction of GSTP1 expression in RAJI cells is caused by complete 
demethylation of certain cells, we will perform post-sorting methylation 
analyses of further genes in DAC-treated RAJI cells. Moreover, the minimum 
degree of hypomethylation required for gene activation is largely unknown. 
GSTP1 expression-based sorting and analysis of both DNA strands by BSP 
or the use of hairpin-bisulfite PCR should elucidate whether DAC-induced 
promoter hemimethylation is sufficient to induce GSTP1 expression. In order 
to reveal a relationship between DAC-mediated demethylation and 
subsequent cell death, induction of membrane proteins by DAC exposure, 
coded by hypermethylated genes (i.e. cadherins or interleukins) will be 
analyzed and used to immunosort cells. In the next step, target membrane 
protein-positive and -negative cells will be separately cultured. Subsequent 
analyses of cell death will provide information about the link between 
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methylation loss and apoptosis. In addition, methylome analysis of both 
fractions can provide information about the quality and quantity of DAC-
mediated demethylation that is needed to induce apoptosis. Alternatively, a 
DNA methylation reporter gene assay (green fluorescent protein (GFP) under 
the control of a methylated cytomegalovirus promoter) could be used to 
analyze DAC-mediated demethylation and induction of expression. Moreover, 
this non-destructive technique allows post-sorting cell culture and subsequent 
cell death assessment. To exclude the presence of different cell-cycle stages 
as a reason for differential demethylation, RAJI cells should be synchronized, 
treated with DAC and demethylation-associated induction of gene expression 
evaluated. Finally, in order to exclude a RAJI cell-specific effect, all 
experiments should be repeated in other leukemia and lymphoma cell lines. 
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Summary 
 
Glutathione S-transferase P (GSTP) 1 and prostaglandin-endoperoxide 
synthase (PTGS) 2 genes are commonly silenced by promoter 
hypermethylation in various cancers. However, these epimutations remain 
poorly investigated in leukemia and lymphoma. We hypothesized that DNA 
methylation-induced GSTP1 and PTGS2 silencing may be involved in 
hematological malignancies. Our results demonstrated that methylation-
associated silencing of GSTP1 and PTGS2 was found in various leukemia 
and lymphoma cell lines. A correlation was found between GSTP1 chromatin 
structure and GSTP1 transcriptional state. Interestingly, PTGS2 
hypermethylation was observed in many samples from patient with 
hematological malignancies presenting reduced PTGS2 expression levels. By 
extending our study to other epigenetically regulated genes, we observed 
differential proliferation, cell death and DNA demethylation responses of blood 
cancer cell lines to the DNA demethylating agent 5-aza-2"-deoxycytidine. In 
conclusion, we identified DNA methylation signatures that could be promising 
clinical biomarkers in hematological malignancies. Finally, our study provides 
critical data for a better understanding of the mechanism of action and effects 
of 5-aza-2"-deoxycytidine that could provide guidance to predict sensitivity and 
response for a therapeutic use of this compound against hematological 
malignancies and potentially other cancers. 
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Zusammenfassung 
 
In Krebszellen liegen die Gene Glutathion-S-transferase P1 (GSTP1) 
und Prostaglandinsynthase-2 (PTGS2) häufig methyliert vor, jedoch wurden 
diese Epimutationen in Blutkrebszellen noch kaum untersucht. Wir 
vermuteten allerdings, dass fehlerhafte Methylierungen eine wichtige Rolle 
beim Ausschalten dieser Gene in Leukämie- und Lymphomzellen spielen 
könnte. Unsere Ergebnisse bestätigten diese Annahme und zeigten, dass die 
Genexpression von GSTP1 und PTGS2 durch die Hypermethylierung der 
DNA unterdrückt wird. Weiterhin konnte ein Zusammenhang zwischen der 
GSTP1 Genexpression und Chromatinstruktur hergestellt werden. 
Interessanterweise konnte die Methylierung des PTGS2 Gens auch in Zellen 
von Blutkrebspatienten nachgewiesen werden. Die Analyse weiterer 
epigenetisch regulierter Gene und die Untersuchung der Zellteilung, des 
Zelltods und der DNA Demethylierung in Blutkrebszellen, welche mit der 
demethylierenden Substanz 5-Aza-2’-Deoxycytidin behandelt wurden, zeigte 
dass jede Zelle unterschiedlich auf den Verlust der Methylierung reagiert. 
Schlussfolgernd sind die Methylierungsmuster der hier beschriebenen Gene 
vielversprechende Blutkrebsmarker. Weiterhin ermöglichen die Ergebnisse 
dieser Studie einen Einblick in die Wirkungsweise von 5-Aza-2’-Deoxycytidin 
in Blutkrebszellen. Diese Erkenntnisse könnten nicht nur eine wichtige Rolle 
für die Diagnose sondern auch für die Behandlung von Blutkrebs oder 
anderen Krebsarten mit dieser demethylierenden Substanz spielen.  
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Appendix 
 
Appendix 1: List of patient samples used for this study.  
Anonymization Age  
(years) 
Organ Diagnosis Origin 
CLL1 57 lymph node CLL Liège 
CLL2 77 lymph node CLL Liège 
CLL3 69 lymph node CLL Liège 
CLL4 60 lymph node CLL Liège 
CLL5 73 lymph node CLL Liège 
CLL6 78 lymph node CLL Liège 
CLL7 69 lymph node CLL Liège 
CLL8 64 lymph node CLL Liège 
CLL9 88 lymph node CLL Liège 
CLL10 83 lymph node CLL Liège 
CLL11 75 lymph node CLL Liège 
CLL12 81 Parotid gland CLL Liège 
CLL13 41 lymph node CLL Liège 
CLL14 31 lymph node CLL Liège 
DLBCL1 68 lymph node DLBCL Liège 
DLBCL2 65 lymph node DLBCL Liège 
DLBCL3 40 lymph node DLBCL Liège 
DLBCL4 71 spleen DLBCL Liège 
DLBCL5 72 lymph node DLBCL Liège 
DLBCL6 42 lymph node DLBCL Liège 
DLBCL7 67 stomach DLBCL Liège 
DLBCL8 74 lymph node DLBCL Liège 
DLBCL9 78 lymph node DLBCL Liège 
DLBCL10 52 lymph node DLBCL Liège 
DLBCL11 46 lymph node DLBCL Liège 
DLBCL12 76 subcutaneous 
tissue 
DLBCL Liège 
FL1 47 lymph node FL Liège 
FL2 55 lymph node FL Liège 
FL3 64 lymph node FL Liège 
FL4 58 retroperitoneum FL Liège 
FL5 65 lymph node FL Liège 
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Anonymization Age  
(years) 
Organ Diagnosis Origin 
FL6 44 lymph node FL Liège 
FL7 65 lymph node FL Liège 
FL8 50 lymph node FL Liège 
FL9 78 lymph node FL Liège 
FL10 66 lymph node FL Liège 
FL11 40 lymph node FL Liège 
FL12 57 lymph node FL Liège 
MCL1 72 lymph node MCL Liège 
MCL2 72 lymph node MCL Liège 
MCL3 50 lymph node MCL Liège 
MCL4 47 lymph node MCL Liège 
MCL5 50 bronchus MCL Liège 
MCL6 77 tonsil MCL Liège 
MCL7 72 eye socket MCL Liège 
MCL8 78 lymph node MCL Liège 
MCL9 80 lymph node MCL Liège 
MCL10 73 lymph node MCL Liège 
MCL11 73 lymph node MCL Liège 
MCL12 53 lymph node MCL Liège 
BL1 64 lymph node BL Liège 
BL2 34 liver BL Liège 
BL3 58 lymph node BL Liège 
LP1 n.a. bone marrow ALL Nancy 
LP2 n.a. n.a. AML Nancy 
LP3 n.a. bone marrow AML Nancy 
LP4 n.a. bone marrow AML Nancy 
LP5 n.a. blood CLL Nancy 
LP6 n.a. n.a. CLL Nancy 
LP7 n.a. n.a. AML Nancy 
LP10 n.a. n.a. CLL Nancy 
LP11 n.a. bone marrow AML Nancy 
LP35 n.a. bone marrow AML Nancy 
LP37 n.a. bone marrow ALL Nancy 
LP39 n.a. bone marrow AML Nancy 
LP40 n.a. n.a. ALL Nancy 
LP41 n.a. bone marrow ALL Nancy 
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Anonymization Age  
(years) 
Organ Diagnosis Origin 
LP43 n.a. n.a. ALL Nancy 
LP46 n.a. n.a. ALL Nancy 
LP48 n.a. n.a. ALL Nancy 
LP50 n.a. bone marrow AML Nancy 
LP54 n.a. n.a. AML Nancy 
601866 n.a. blood CML Marseille 
602393 n.a. blood BL Marseille 
603112 n.a. blood AML Marseille 
701757 n.a. blood AML Marseille 
702082 n.a. blood AML Marseille 
602519 n.a. blood AML Marseille 
700711 n.a. blood AML Marseille 
600389 n.a. blood AML Marseille 
603558 n.a. blood AML Marseille 
800563 n.a. blood AML Marseille 
703142 n.a. blood AML Marseille 
703821 n.a. blood MDS Marseille 
703821 n.a. Bone marrow MDS Marseille 
CHL1 n.a. Blood CML CHL 
Luxembourg 
CHL2 n.a. Blood CML CHL 
Luxembourg 
CHL3 n.a. Blood CML CHL 
Luxembourg 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CLL: chronic lymphocytic 
leukemia, CML: chronic myeloid leukemia, DLBCL: diffuse large B-cell lymphoma, MCL: 
mantle cell lymphoma, FL: follicular lymphoma, BL: Burkitt’s lymphoma, MDS: 
myelodysplastic syndrome, n.a.: information not available. 
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Appendix 2: Genomic DNA from RAJI cells treated for 3 days with 2µM DAC was 
bisulfite converted and regions of interest amplified by PCR. Methylation pattern was 
determined by next generation sequencing on a GS FLX platform. Detailed view on 
the sequence reads of BCL2L11, CALCA, CHFR, DAB2IPA, DAPK1, DCR1, DLC1, 
ESR1, EYA4, HIC1, H19, IGSF4, KLF4, LINE1, MGMT, OSMR1, PTGS2, RARB, 
THBS1, TIMP3 and TP73. Red bars indicate methylated and blue bars unmethylated 
CpGs. 
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Louvain Woluvé, Belgium  
Poster: Reversible epigenetic fingerprint-mediated glutathione-S-
transferase P1 gene silencing in human leukemia cell lines 
12/03/2011-
13/03/2011 
Conference: CLEPSO, Clinical epigenetics international 
meeting, Homburg, Germany 
Poster: Reversible epigenetic fingerprint-mediated glutathione-S-
transferase P1 gene silencing in human leukemia cell lines 
13/09/2011 Conference: Annual Mini-symposium, Ecole doctorale 
thematique en cancerologie expérimentale, Groupe de contact 
FNRS „miRNA and Cancer, Faculté de médecine, Namur, 
Belgium 
Poster: Reversible epigenetic fingerprint-mediated glutathione-S-
transferase P1 gene silencing in human leukemia cell lines 
 
Conference staff: 
 
27/01/2010-
30/01/2010 
Inflammation 2010 conference, Inflammation cell signalling 
mechanisms as therapeutic targets, Kirchberg, Luxembourg  
26/01/2011-
28/01/2011 
Cell-Signalomics 2011 conference, Integrated cellular pathology 
– Systems biology of human disease, Kirchberg, Luxembourg 
 
Internships: 
 
2010 LOUREIRO Camilo Maria Helena, Job discovery, Lycée Esch, 
Luxembourg 
2011 FRENGER Elodie, Etude des altérations du profil de méthylation de 
gènes suppresseurs de tumeur dans les leucémies: le cas des 
leucemies myeloïdes et lymphoblastiques aiguës 
MASTER « ingénierie de la santé et sciences du médicament » 
parcours « Bio-ingénierie et médicaments », Nancy-Université Henri 
Poincaré 
 
 
 
